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ABSTRACT
Adoptive cell therapy (ACT) using T cells engineered to express tumor-specific T
cell receptors (TCR) holds great promise in treating patients with hematological
malignancies and solid tumors. ACT involves the generation of large numbers of tumorspecific T cells in vitro, which later are administered to the patient, aiming to establish
an in vivo response and effective tumor control. Our lab has identified a TCR (TIL 1383I
TCR) specific to the melanoma antigen, tyrosinase, for ACT. In a phase I clinical trial,
patients with metastatic melanoma were treated with a systemic infusion of autologous
T cells transduced to express the TIL 1383I TCR. We observed clinical and biologic
responses following ACT including tumor regression in one of seven patients and the
development of vitiligo, indicative of T cell-mediated killing of melanocytes, in two of
seven patients (one of which was the responder)1. Our findings demonstrate that the
ACT of TCR gene-modified T cells has the potential to eliminate tumors, but the modest
number of patients responding emphasizes the need for improvement.
Extensive investigation into resistance mechanisms has revealed key factors
influencing outcomes to immunotherapy. Tumor cells can downregulate or lose the
expression of the targeted antigen or the corresponding MHC alleles, which can lead to
tumor escape variants that are no longer recognized by the transferred T cells.
Additionally, the tumor microenvironment (TME) can be highly immunosuppressive and
adept at impairing effector T cell responses. T cell-based immunotherapies should
be designed to overcome resistance mechanisms to achieve durable responses.
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A phase I clinical trial that our lab conducted in collaboration with Dr. Keld Kaltoft
evaluated the feasibility and safety of a novel approach by which allogeneic TCR
transduced T cells (C Cure 709) were delivered through direct injection into metastatic
lesions of stage IV melanoma patients2. C Cure 709 is an allogeneic T cell line that was
transduced to express a MART-1-specific TCR (TIL 5). Before intratumoral injection, C
Cure 709 cells were irradiated with 60 Gy, which prevented in vivo proliferation but
maintained effector function for 1-2 days. Significant regression of injected metastases
was reported in four of fifteen patients. Two of fifteen patients had regression of noninjected lesions, and two patients developed vitiligo. One patient that developed vitiligo
also had a local response. Biopsies from both injected and non-injected tumors from
responding patients revealed that C Cure 709 cells were not detected within the tumors,
suggesting the induction of systemic anti-tumor immunity and generation of additional
tumor antigen-specific T cells, with specificities that differed from the original MART-1
target. These results indicated that intratumoral delivery of allogeneic TCR transduced T
cells is safe, feasible, and capable of anti-tumor responses.
In the studies presented in this dissertation, we evaluated the intratumoral
delivery of TIL 1383I TCR transduced T cells in a widely used B16 mouse melanoma
model. To favorably modulate the TME and counteract immune suppression, we
employed an alternative strategy and expressed the TIL 1383I TCR on allogeneic, as
opposed to syngeneic, donor T cells. We rationalized that the allogeneic inflammatory
response would combat the immunosuppressive tumor microenvironment. We
demonstrated that intratumoral treatment with TIL 1383I TCR allogeneic T cells
extended survival and suppressed tumor growth in mice more effectively than treatment

xxv

with TIL 1383I TCR syngeneic T cells. Tumors treated with TIL 1383I TCR allogeneic T
cells exhibited more significant accumulation of mature dendritic cells and crosspresenting dendritic cell subsets, as well as increased T cell activation, in the tumor and
tumor draining lymph nodes. TIL 1383I TCR allogeneic T cell treatment generated
endogenous tumor-specific T cells that prevented the development of distant, untreated
tumors. Furthermore, the addition of immune checkpoint inhibitors promoted tumor
clearance and enhanced protection in mice treated with TIL 1383I TCR allogeneic T
cells. Intratumoral delivery of allogeneic TCR gene-modified T cells can expand the
available tumor antigen targets, without compromising safety, by avoiding systemic
administration. Using allogeneic donor T cells as an “off-the-shelf” approach can
contribute to the accessibility and efficacy of T cell-based immunotherapy.
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CHAPTER ONE:
REVIEW OF LITERATURE
Introduction
Not long ago, surgical resection of tumors and chemotherapy or radiotherapy
were primary options available to treat patients with cancer. The concept of tumor
immunity was established upon the identification of tumor-specific T cells within the
tumors resected from cancer patients. Despite the existence of tumor-specific T cells,
tumors from these patients escaped immune control and failed to regress. The ability to
clone T cell receptor (TCR) genes from T cells reactive against tumor antigens into viral
vectors and redirect the specificity of T cells through transduction, led to the use of TCR
gene-modified T cells for cancer therapy. Adoptive cell transfer (ACT) of autologous
TCR gene-modified T cells targeting tumor antigens is a promising therapeutic strategy
currently in clinical trials to treat patients with advanced malignancies.
While immunotherapies can mediate acute anti-tumor responses that lead to
remission in some patients, long-term and durable responses are rare, especially
among solid cancer types. The immunosuppressive tumor microenvironment,
heterogeneity of solid tumors, and evasion of immune cell detection are some of the
factors that influence the outcome of immunotherapy. Understanding the mechanisms
affecting the generation of anti-tumor responses are critical to enhancing the efficacy of
T cell-based immunotherapies.
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Personalized, rationally-designed combinations of immunotherapies based on
tumor characteristics are likely necessary to overcome various immune resistance
mechanisms and to achieve durable responses in a higher proportion of patients. To
generate the most effective immunotherapies, there should be a tumor-specific
component as well as an adjuvant, or immune-stimulating component. Intratumoral
delivery of TCR gene-modified T cells is a potentially viable, safe, and effective
alternative to the systemic infusion of genetically modified anti-tumor T cells. While this
route eliminates the requirement of T cell trafficking into the tumor, the tumor
microenvironment might still hinder the immune response. Therefore, it is critical to
engineer TCR gene-modified T cells to endure or counteract immunosuppression
following administration.
We have proposed an alternative strategy that utilizes allogeneic, rather than
autologous, donor T cells that are then engineered to express a tumor-specific TCR that
recognizes the melanoma antigen, tyrosinase, in the context of human MHC class I
HLA-A2. As an alternative approach to systemic infusion of tumor antigen-specific T
cells, we proposed to perform intratumoral delivery of TCR-transduced allogeneic T
cells. We hypothesize that this approach will provide additional benefits: direct effector
T cell-tumor interactions and, when combined with the allogeneic response, can induce
local activation of immune cells within the suppressive tumor microenvironment, thus
facilitating activation of antigen presenting cells and cross-priming of CD8+ T cells and
systemic anti-tumor immunity. The goal of this dissertation is to identify the
immunological changes that occur following intratumoral delivery of allogeneic tumorspecific T cells that mediate improved anti-tumor immune responses.
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T Cell-Mediated Immune Responses
T Cell Biology
T cells play a critical role in protecting us against pathogens, recognizing foreign
components, and killing cancer cells. Several immunotherapies designed to treat cancer
employ strategies that improve T cell function or induce tumor-specific T cell responses.
Through a unique T Cell Receptor (TCR), T cells recognize determinant self- and nonself- proteins. The TCR is composed of alpha and beta chain (abTCR) or gamma and
delta chain (gdTCR) heterodimers that bind to antigens (Ags) presented in the context of
Major Histocompatibility Complex (MHC) on the surface of a cell. The focus of this
dissertation will be abTCR T cells.
T cell development. In the bone marrow (BM), the long-term hematopoietic
stem cell (LT-HSC) gives rise to multipotent and lineage-committed hematopoietic
progenitor cells, including common lymphoid progenitors (CLP), common myeloid
progenitors (CMP), and granulocyte-macrophage progenitor (GMP).
T cells are generated in the thymus, which consists of the outer cortex and the
inner medulla, in three major developmental steps: lineage commitment, TCR gene
rearrangement, and selection (Fig 1). The earliest T lineage cell in the thymus is the
early T-cell progenitor (ETP). The phenotype of the cells that seed the thymus remains
controversial, but has been termed lineage negative. A fraction of the DN1 subset
(CD44+CD25-) then moves to the outer regions of the thymic cortex and transition to
DN2 cells by gaining expression of CD253,4. Thymocytes are committed to T cell lineage
during the DN2 to DN3 transition. DN3 (CD44loCD25+CD117lo) thymocytes undergo b
chain rearrangement and selection.
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Figure 1. T Cell Development in the Thymus. The lineage negative ETP enters
the thymus and becomes a DN2 thymocyte by acquiring expression of CD25. DN3
(CD44loCD25+CD117lo) thymocytes undergo b chain rearrangement and selection.
The TCRb chain pairs with the pre-Ta chain, leading to RAG termination and allelic
exclusion. If successful, DN3 become DN4 (CD44-CD25-CD117lo) thymocytes that
proliferate and express CD4 and CD8. CD4+CD8+ DP thymocytes rearrange TCRa
chain alleles until a TCRab heterodimer engages with self-MHC and undergoes
positive selection. Positvely-selected CD4 or CD8 committed T cells encounter
APCs and, based on affinity, become CD8+ or CD4+ (or nTreg cells) SP T cell that
can enter the periphery. Red dashed arrows represent negative selection events
and green arrows represent positive selection events. (HSC: hematopoietic stem
cell; MMP: multipotent progenitors; CLP: common lymphoid progenitor; cTEC:
cortical thymic epithelial cell; DN: double negative; DLL4: delta-like ligand 4; mTEC:
medullary thymic epithelial cells; DC: dendritic cell; SP: single positive
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TCR gene rearrangement requires transient expression of recombinationactivating genes (RAG)5. Once the TCRb chain pairs with the surrogate pre-Ta chain
and CD3 on the cell surface, RAG expression is downregulated and TCR b chain gene
rearrangement is terminated, referred to as allelic exclusion6–8. If TCRb chain gene
rearrangement is successful, DN3 thymocytes become DN4 (CD44-CD25-CD117lo)
thymocytes that undergo proliferation and express CD4 and CD8. Conversely, if b chain
rearrangement on both alleles is unsuccessful, these thymocytes die by apoptosis.
CD4+CD8+ double positive (DP) thymocytes then relocate to the thymic cortex where
rearrangement of TCRa chain alleles occurs. In contrast to b chain selection, both TCR
a chain alleles rearrange until a TCRab heterodimer engages with self-MHC and
undergoes positive selection. Positive selection occurs if a DP TCRab thymocyte has
the adequate affinity and reacts against self-peptide MHC presented by cortical thymic
epithelial cells9. If the affinity is too low and antigen recognition does not occur, DP
TCRab thymocytes undergo death by neglect10. Positively selected DP T cells then
encounter antigen presenting cells (APC) with high expression of self-peptide-MHC
complexes. Initial TCR stimulation partially downregulates CD8 and upregulates the
TCR. If DP T cells bind to thymic APCs with too high affinity, they undergo negative
selection by apoptosis11. Lack of signaling results in MHC class I restriction and
conversely, sustained signaling promotes MHC class II restriction12. Within a few days,
mature, naïve T cells emigrate from the thymus and enter the periphery13.
T cell receptor diversity. TCR gene rearrangement, or somatic diversification,
in the thymus generates TCRs with up to 100 million different specificities14. TCR genes
are encoded from an extensive set of noncontiguous gene segments. The TCRa and
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TCRb chains each contain a variable (V) amino-terminal segment and a constant (C)
segment. The TCRa locus contains V and joining (J) segments (Va and Ja). The TCRb
locus consists of Vb and Jb segments and additional diversity (D) gene segments.
During TCRb gene rearrangement in the thymus, one Db segment and one Jb segment
join, and then randomly combines with one of several Vb genes. During TCRa chain
gene rearrangement, one of several Va genes combines with one of several Ja genes.
Recombination is mediated by heptamer and nonamer recombination signal sequences
(RSS) that flank the gene segments. RSS are recognized by RAG enzymes, which
create double-stranded breaks that are resolved by nonhomologous end joining. TCR
diversification is further achieved through the addition and deletion of a random number
of nucleotides at the V(D)J junction sites, referred to as N-region substitution15.
In addition to the already extensive diversity generated by V(D)J recombination
and N-region substitution, three hypervariable loops that are called complementarity
determining regions (CDR1-3) also contribute to further diversification and antigen
binding16. CDR1 and 2 are found in the V region of the polypeptide chain and mediate
TCR-peptide-MHC interactions. CDR3, which includes the N-region, some of the V, and
the D and J regions, directly contacts the peptide17–19. CDR3, the most variable region,
is used to determine T cell clonotypes20. Advanced technology, such as high-throughput
sequencing, can efficiently permit in-depth measurements of TCR repertoire diversity
from a single sample of blood, thus facilitating the study of TCR diversity in different
contexts21. In summary, the extensive diversity of the TCR, generated by recombination,
random insertions, deletions, and substitutions, is fundamental for adaptive immunity.
T cell signaling and activation. T cell function is controlled through TCR
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activation and signaling. To generate fully functional T cells, three signals must usually
be completed: 1) TCR engagement, 2) co-stimulation and 3) cytokine production.
First, the TCR must bind to cognate antigen presented by MHC proteins on the
surface of an antigen presenting cell (APC). This initial interaction is insufficient for
activation (most of the time) and requires additional help from the co-receptors, CD4
and CD8. CD4 or CD8 binds to MHC class II or MHC class I domains, respectively, to
stabilize the protein complex22,23. Co-receptor-MHC interactions lead to conformational
changes in CD3 (CD3d, CD3e, CD3g) proteins that are proximal to the TCR-peptideMHC complexes. The CD3 and TCRz chain cytoplasmic domains contain
immunoreceptor tyrosine-based activation motifs (ITAMs) composed of two tyrosines
flanking a series of amino acids, including essential leucine and isoleucines with
stereotypic spacing. ITAMs are phosphorylated by leukocyte-specific tyrosine kinase
(Lck), which associates with the cytoplasmic tail of CD4 and CD8 co-receptors, allows
docking of the SH2 domains of the z chain-associated protein 70 (Zap70) kinase24.
Zap70-mediated phosphorylation of adaptor proteins leads to activation of downstream
signaling molecules25. The release of Ca2+ from the endoplasmic reticulum (ER) into the
cytosol activates calcineurin, which dephosphorylates NFAT (nuclear factors of
activated T cells), allowing entry into the nucleus to induce gene transcription.
Collectively, this first signal results in Ca2+ release, cytoskeletal rearrangements, and
the transcription of appropriate T cells genes26.
TCR signaling alone is usually insufficient for full T cell activation and requires
the second signal, co-stimulation27. Co-stimulation can lower the threshold of signal 1
that is needed for activation by amplifying the signal28. Conversely, in the absence of
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co-stimulation following signal 1, T cells can become anergic. For CD4+ T helper cells,
the co-stimulatory molecule CD28 binds to either CD80 (B7.1) or CD86 (B7.2) on the
APC, which stimulates T cell proliferation and generates a clonal population of primed,
antigen-specific T cells. Consequently, the binding of CD28 and CD4 also elicits a
regulatory feedback mechanism to control T cell activation. CD28-CD80 ligation induces
expression of CTLA-4 (CD152) on the T cell surface, which competes with CD28 for
binding CD80, limiting T cell activation29,30. Cytotoxic T cells rely on a slightly different
mechanism for signal 2. Less reliant on CD28, CD8+ T cells require signals from other
co-stimulatory molecules, such as CD70 and 4-1BB (CD137). With regards to tumor
immunity, the absence of CD80/CD86 on cancer cells, required for signal 2 of T cell
activation, can lead to tolerance, or subpar T cell responses28. Therefore, costimulation, the second signal, is important to amplify TCR stimulation, signal 1.
Naïve T cells require a third signal, along with antigen and co-stimulation, to
achieve full activation and prevent death or induce tolerance31. The third signal comes
in the form of cytokines that can dictate function. For example, activated CD8+ T cells
release cytotoxic granules, such as granzyme B and perforin, and produce immuneactivating cytokines32. Naïve CD8+ T cells that have received the first two signals
required for activation, TCR-peptide+MHC engagement and co-stimulation, but had not
received cytokine cues, failed to develop effector function33. Alternatively, CD4+ T cells
differentiate into T helper subsets according to the cytokines produced by antigen
presenting cells encountered after activation (This will be further discussed in the
following section). In conclusion, three signals, TCR-peptide-MHC binding, co-
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stimulation, and cytokine exposure, are required to generate fully functional T cells with
appropriate effector function (Fig 2).
T Helper Cell Subsets and Function
A variety of factors influence the fate of T helper cells, including dose and type of
antigen, APCs, and differential expression of cytokine genes and transcription factors.
Upon activation of naïve CD4+ T cells, extracellular cues initiate the process of
phenotypic polarization of cells. Then, intracellular signaling cascades lead to signals in
the nucleus to generate new gene expression profiles. The first specialized CD4+ T cell
subsets were identified in mice by Mosmann and Coffman in 1986 and classified as T
helper (Th) 1 and Th2 subsets34.
Th1 cells are essential for immunity against intracellular pathogens. Polarization
into Th1 cells occurs in the presence of IL-12, IL-2, and IFN-g, which then activate the
transcription factors, STAT-1, T-bet, and STAT-435. Transcription factor activation
results in T cell production of IL-2, TNF-a, IFN-g, and GM-CSF that further elicit immune
responses. For example, IFN-g production can activate macrophages and increase
expression of MHC class I on APCs and some tumor cells. IFN-g-producing T cells have
been shown to protect against the development of induced and spontaneous cancers in
mouse models36. Th1 subsets can contribute to the induction of anti-tumor immune
responses through the production of Th1 cytokines and chemokines, and the activation
of antigen-specific cytotoxic CD8+ T cells. Th1 cells also produce chemokines such as
monocyte chemotactic protein-1 (MCP-1, also known as CCL2) and macrophage
inflammatory protein-1a (MIP-1a, also known as CCL3), that can promote the
recruitment of natural killer (NK) cells and M1 inflammatory macrophages to the tumor37.
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Figure 2. Effector Functions of CD4+ and CD8+ T Cells Following Activation by
Antigen Presenting Cells. Dendritic cells present endogenous peptides on MHC
class I molecules to CD8+ T cells (left). CD8+ T cells are stimulated to be cytotoxic T
lymphocytes, which can directly kill targets through the release of cytotoxic granules,
such as perforin and granzyme B, and production of cytokines TNF-a and IFN-g.
Dendritic cells present exogenous antigens on MHC class II molecules to CD4+ T
cells. CD4+ T cells are stimulated to become helper T cell subsets based on cytokine
production by dendritic cells. In the presence of IL-12, Th1 subsets are promoted
through induction of the transcription factors T-bet and Stat4. In the presence of IL-4,
Th2 subsets are promoted through the induction of transcription factors GATA-3 and
Stat5. In the presence of IL-6, Th17 subsets are promoted through induction of
transcription factors RORgt and Stat3. In the presence of TGFb, T regulatory subsets
are promoted through the induction of Foxp3 and Stat5.

Th1 cells also produce large quantities of IFN-g, which has a pleiotropic role in antitumor immunity38.
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In tumor models, the adoptive co-transfer of in vitro polarized CD4+ Th1 cells and
CD8+ CTL enhanced B16-OVA tumor regression, compared to CD8+ CTL only, and
resulted in the induction of endogenous immune responses to tumor epitopes other than
OVA39. Additionally, the adoptive transfer of T-bet+ Th1 in vitro-polarized cells into mice
bearing B cell lymphoma resulted in the localization of transferred Th1 cells to the
tumors and inhibition of tumor development and growth40. In summary, Th1 cells are
good candidates to promote anti-tumor responses through the production of cytokines
and chemokines that promote infiltration and activation of innate and adaptive immune
cells.
Th2 subsets orchestrate humoral immunity and mediate responses against
extracellular parasites as well as allergens. Th2 cells differentiate in the presence of IL2 and IL-4, which leads to activation of the transcription factors GATA3 and STAT6. The
effector function of Th2 cells includes production of IL-4, IL-5, IL-6, and IL-13 and
activation of eosinophils and mast cells35. The production of these cytokines also
supports B cell proliferation and differentiation41. The contribution of Th2 cells to antitumor immunity is still somewhat unclear and may be context-dependent. In one mouse
study, B16 tumor cells engineered to express the cytokine IL-4 promoted anti-tumor
responses through the recruitment of eosinophils and macrophages to the tumor42,43.
Furthermore, adoptive transfer of in vitro polarized tumor-specific Th2 cells resulted in
the regression of MHC class II negative mouse myelomas, which was mediated by type
II inflammation and robust infiltration of inflammatory M2-type macrophages at the
tumor site44. Conversely, in a mouse model of breast cancer, IL-4- and IL-13-producing
Th2 CD4+ T cells induced the polarization of M2 macrophages, which promoted relapse
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of tumors following radiotherapy45. In summary, the role of Th2 cells in anti-tumor
immune responses is most likely context- or tumor-dependent.
An additional T cell subset, Th9 cells differentiate in the presence of IL-2, IL-4,
and TGF-b and require the transcription factors STAT6, PU.1, IRF4 and GATA3 to
produce IL-946,47. Th9 cells have a role in the initiation of a broad range of inflammatory
diseases such as allergic inflammation and autoimmune disorders. In tumor immunity,
adoptive transfer of in vitro polarized Th9 cells were highly effective at suppressing B16
tumor growth, even in comparison to Th1 and Th17 cells48. Furthermore, anti-tumor
benefits were abolished in the presence of an IL-9 neutralizing antibody. Additionally, in
the B16 lung metastases model, IL-9-producing tumor-specific Th9 cells induced CCL20
expression in tumor cells, which promoted recruitment of DCs and activation of CD8+
CTL in the tumor draining lymph nodes 49. In contrast, a small frequency of IL-9
transgenic mice has been reported as susceptible to developing thymic T cell
lymphomas, consistent with the role of IL-9 in mediating T cell proliferation and
activation50. IL-9 has been shown to promote the survival and function of human
melanoma tumor infiltrating CD4+CD8+ double-positive T cells51. These findings suggest
that IL-9-producing Th9 cells can promote anti-tumor immunity, but dysregulated IL-9
signaling might lead to T cell lymphomas through aberrant T cell stimulation.
Th17 cells are polarized in the presence of IL-6, IL-21, IL-23, and TGF-b eliciting
a signaling cascade that activates the transcription factors RORgt and STAT3.
Transcription factor activation results in the production of IL-17 and IL-22, which activate
neutrophils and protect the host against extracellular pathogens, such as fungi. In
cancer immunity, Th17 cells have been reported to both promote and inhibit anti-tumor
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responses. The expression of IL-17 in the tumor microenvironment has been reported to
induce angiogenesis and tumor progression through increased tumor-mediated
production of pro-inflammatory cytokines. IL-17A also induces activation of STAT3 in
tumor cells, which has been demonstrated to promote B16 tumor growth52. In a
contrasting example, the adoptive transfer of tumor-specific Th17 cells, polarized in
vitro, supported anti-tumor responses in the B16 mouse melanoma model by recruiting
dendritic cells and priming CD8+ T cells in an IFN-g-dependent manner. Interestingly,
the anti-tumor responses following the adoptive transfer of Th17 cells were more
effective than the adoptive transfer of Th1 cells in this model53. These findings indicate
that Th17 cells have the potential to promote both anti- and pro-tumor responses.
Regulatory T cells (Tregs) are critical for regulating immune responses and
maintaining immune tolerance. In the early 1970s, Gershon and Kondo performed
experiments in which mice were immunized and challenged in the presence and
absence of thymic-derived cells and established two different roles for thymic-derived
cells: immune-activation and immune-dampening54. In 1995, Sakaguchi and colleagues
facilitated the characterization of the immune-suppressing subset through the
identification of CD25, the IL2Ra chain, expressed on CD4+ T cells55. A pivotal moment
in Treg biology was the discovery of the transcription factor Foxp3 in 2001. Mutations in
the FOXP3 gene were linked to severe spontaneous autoimmunity in Scurfy mice56.
Foxp3 is now recognized as the main regulator of the development and function of
natural Tregs (nTregs).
While natural Tregs develop in the thymus, inducible Tregs (iTregs) are
generated when naïve T cells acquire Foxp3 expression and suppressive functions after
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antigen stimulation in the presence of TGF-b or after suboptimal chronic antigen
stimulation57. Several preclinical and clinical studies have illustrated the ability of Tregs
to suppress anti-tumor immunity. Tregs exert immunosuppressive effects through
various mechanisms such as CTLA-4-mediated suppression of APCs, sequestering of
IL-2, and production of immune inhibitory factors58. Tumors can promote the
accumulation of Tregs, as supported by studies detecting intratumoral Treg frequencies
as high as 20-30%, which is associated with a poor prognosis in various types of
cancer59. In one mechanism, melanoma cells can secrete CCL22 that promotes
infiltration of Foxp3+ Tregs60. Additionally, tumor-derived suppressive factors can
convert T effector subsets into Tregs through the induction of Foxp361. Many Tregfocused therapies are under investigation but have been mostly ineffective clinically due
to the difficulty in selectively targeting Tregs or the transient nature of the effects.
Overall, T regulatory cells are critical regulators of immune responses that function to
maintain homeostasis and prevent autoimmunity, but also are potent suppressors of
anti-tumor immune responses. In summary, naïve CD4+ T helper cells have the capacity
to execute an extensive range of immune responses.
Although studies using mouse models have been invaluable to the advancement
of scientific discoveries, they can have limitations. Some difficulties associated with
using mouse models for human disease result from differences in metabolism, anatomy,
and cellular characteristics519. Animals can be essential to transition from bench to
bedside solutions, but it should be noted that animal models only represent part of the
disease. Therefore, it is important to define a certain question to design and conduct an
appropriate experiment using mouse models.
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T Cell Alloresponses
T cells, by way of their TCR, not only recognize antigens presented by self-MHC,
but can also recognize non-self-peptide-MHC complexes as foreign in an allogeneic
response. MHC mismatch is most commonly discussed in transplantation biology,
where the recognition of allogeneic MHC molecules by recipient T cells (allorecognition)
ignites a potent immune cascade ultimately resulting in the rapid elimination of the
foreign donor cells and rejection of the graft. This section will discuss the foundation of
allorecognition, the biology of the allogeneic response, and how allorecognition can be
applied to tumor immunology and immunotherapies.
History. The allogeneic response is one of the oldest known immune reactions,
dating back to 1944 when Medawar was studying allograft rejections62. In the early
1960s, alloreactive cells undergoing DNA synthesis were observed using radioactive
labeling techniques after co-culturing blood samples from two individuals63. Soon after,
human lymphocytes were identified as the alloreactive cells64. Advancements in
understanding the genetic basis of alloreactivity were initiated when Bain and
colleagues observed increased replication of alloreactive cells in co-cultures with blood
samples from unrelated individuals compared to monozygotic twins65. The purpose of
an immune reaction between two individuals of the same species was unclear, and
therefore alloreactivity was initially thought of as biologically irrelevant. However, the
study of alloreactivity paved the way for a series of important discoveries, such as
evaluating the function of histocompatibility proteins 65, identifying a central role for T
cells 66, the phenomenon of graft-versus-host disease (GVHD)67, and the function of
cytotoxic T lymphocytes68.
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Pathways of allorecognition. Despite undergoing an extensive selection
process in the thymus, mature T cells exhibit a high frequency of cross-reactivity, or
alloreactivity, against foreign peptide-MHC molecules to which they have not previously
encountered. CD4+ and CD8+ T cells can respond to foreign donor determinants
through two distinct mechanisms: direct or indirect alloreactivity. In the direct pathway, T
cells recognize allo-MHC complexes present on the surface of APCs in the donor graft;
alternatively, the indirect pathway occurs through recognition of self-restricted
allopeptides, derived from allogeneic peptides or allogeneic MHC molecules, that have
been processed and presented on APCs of the recipient69,70. Distinguishing features of
the two pathways include the breadth of TCR repertoire, the timing of the responses,
and the persistence of alloreactive T cells71.
During direct alloreactivity, T cells that were selected to bind non-self- peptide
and self-MHC cross-react with non-self MHC and peptide complexes69. Direct
allorecognition is the main contributor to cytotoxic T lymphocyte (CTL) responses that
promote GVHD and early allograft rejection events72. Indirect alloreactivity occurs when
donor T cells recognize minor histocompatibility antigens, which are peptides expressed
by host polymorphic genes. Whereas direct allogeneic responses quickly diminish with
the disappearance of donor cells, it is generally thought that the indirect pathway
mediates chronic rejection73. T cells recognizing self-restricted allopeptides display
limited TCR gene usage74. In acute GVHD, in vivo clonal expansion of T cells with
selected TCR usage has been observed and can persist for up to one year75,76.
Alloantigens. Any antigen or group of antigens expressed on donor cells, but
not expressed on cells of the recipient are considered allogeneic non-self77. Allogeneic
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non-self-antigens are mostly MHC protein products, the MHC class I-related chain
(MIC) system, minor histocompatibility proteins, and natural killer cell receptor ligands.
The strongest alloantigens are major histocompatibility complex (MHC) proteins, due to
their highly polymorphic nature, broad expression and capacity to generate expansive
polyclonal T cell responses. These alloantigens can be recognized by T cells either
directly or indirectly. Minor histocompatibility antigens (MiHA) are also highly
polymorphic and expressed on the cell surface in association with MHC proteins. MiHA
alloresponses are generally weaker; however, they are clinically significant especially in
bone marrow transplant recipients. The rejection of grafts based on MHC mismatch
occurs rapidly, whereas MiHAs slowly induce graft rejection.
MiHAs are short peptides with 9-12 amino acids that differ between individuals as
a consequence of single- nucleotide polymorphisms (SNPs) in the coding regions of
genes, gene deletions, frameshift mutations, or insertions78,79. Generation of MiHAs
through the MHC class I antigen presentation pathway involves proteasomal processing
followed by TAP-dependent transport to the ER for binding to MHC class I. Alternatively,
MHC class II-associated MiHAs are non-self- proteins from phagocytosis or
endocytosis. Because of the ubiquitous expression of MiHAs, graft rejection can occur
despite identical MHC proteins80.
Effector response. The T cell-mediated allogeneic response is one of the most
potent immune responses identified. The frequency of T cells that respond to allogeneic
MHC molecules is ³1%, which is 2-3 orders of magnitude higher than the frequency
expected for a foreign non-MHC molecule81. The most well-studied alloresponse is
graft-versus-host disease (GVHD). This section will discuss two alloresponses that are
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currently being investigated. The first alloresponse will be graft-versus-host disease and
the second alloresponse will be graft rejection.
Graft-versus-host disease. Immune cells and molecules mediate the pathology
of GVHD. Acute GVHD is preceded by elevated CD4+ and CD8+ T cells while chronic
GVHD is preceded by thymic damage, generation of aberrant B cells, and dysfunctional
T cell responses82. Prior to transplantation, patients receive a conditioning regimen that
damages host tissue and mucosa leading to microbial products that translocate from the
intestinal lumen into circulation, which stimulate and activate DCs to secrete IL-1 and
TNF-a83. Donor conventional DCs can take up antigens through the indirect pathway
via MHC II to CD4+ T cells84. Alternatively, recipient CCR7+ DCs induced donor T cells
to upregulate chemokine receptors allowing the migration of activated DCs from the
tissue to the draining lymph nodes. Donor T cells first recognize host alloantigens,
followed by production IFN-g, TNF-a, and IL-2, which collectively can mediate robust
proliferation of allo-specific CD8+ T cells and recruit macrophages and CD8+ T cells to
the graft85. Furthermore, CD4+ T cells can stimulate B cells to produce highly specific
alloreactive antibodies. The relationship between Th17 and Treg cells can play a role in
GVHD86. Treg expansion can lessen the severity of GVHD. Conversely, a decrease in
Tregs can result in the increased production of pro-inflammatory cytokines by Th17 and
Th1 cells87. CD8+ T cells also contribute to allogeneic responses by exerting cytolytic
function against the donor cells within the graft.
TNF-a is a key cytokine that plays a role during all stages of GVHD. Blocking
TNF-a diminished GVHD-related damage to the gastrointestinal tract in experimental
allo-HSCT88. Additionally, elevated levels of Th17-related cytokines, such as IL-6, IL-1b,
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IL-17, IL-21, IL-23, and IL-23R, have been observed in patients with GVHD and
associated with the differentiation and expansion of Th17 cells89. Conversely, regulatory
cytokines can suppress GVHD. IL-10, for example, can be produced by both host and
donor B cells. IL-10-/- mice had increased allogeneic T cell responses, enhanced
activation of host DCs in lymphoid tissue, and accelerated GVHD90.
Co-stimulatory molecules, such as the CD80/86-CD28 family, the TNF receptor
family, and adhesion molecules, can also have an important role in the development of
GVHD91. Blocking CD80 and CD86 with monoclonal antibodies lowered the mortality
rate in a mouse model of GVHD by preventing donor CD4 and CD8 T cell expansion92.
Blocking CTLA-4 with a soluble fusion protein also reduced GVHD in mice, but the
effects were not as strong as blocking CD2893. Inducible co-stimulatory (ICOS) is
expressed on CD4 and CD8 T cells and facilitates P13K activation and intracellular
calcium release. ICOS was upregulated on T cells isolated from dogs that were in the
process of developing GVHD94. These studies highlight the therapeutic potential of
modulating cytokines and blocking co-stimulatory molecules in treating GVHD.
Beilhack and colleagues performed an in-depth characterization of the events
mediating GVHD following the transplantation of luciferase-labeled allogeneic
splenocytes95. Using in vivo bioluminescence imaging, they first observed donor CD4+ T
cell proliferation, followed by CD8+ T cell proliferation, in secondary lymphoid organs.
Transplanted T cells then migrated to end-organs, including the intestines by day 5, and
skin and liver acutely within 6 days of transplantation. Robust activation of CD4+ and
CD8+ T cells, characterized by increased expression of CD69 and CD44 by
immunofluorescence, also occurred acutely in secondary lymphoid organs. These
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studies demonstrated the rapid kinetics and magnitude of immune activation generated
during acute alloresponses.
Graft rejection. Acute allograft rejection prevents long-term graft survival,
increases the risk for chronic rejection and decreases the half-life of the allograft by
34%96. The passenger leukocyte theory proposed that graft-derived cells had a role in
the alloresponse97. Specifically, donor dendritic cells are largely responsible for
promoting an acute anti-allograft response. Immature DCs in peripheral tissues can
capture antigens and, upon receiving inflammatory signals- IL-1b, TNF-a, and CD40,
mature and migrate to lymphoid tissue to stimulate naïve T cells98. The activated graftspecific T cells migrate back to the graft and eliminate alloantigen-expressing cells.
Once the donor leukocytes have been eliminated from the graft, the response shifts to
recipient DCs that have infiltrated into the graft and activate T cells via the indirect
pathway99–101. T regulatory (Treg) cells can also influence graft rejection. Recipient and
donor Treg cells have been detected within tolerized allografts102,103. Collectively, these
studies demonstrate that graft rejection is a complex response influenced by both
recipient and donor cells.
Alloresponses in cancer. Donor immune cell reactivity against host tissues and
allograft rejection by the host can have severe consequences, but in some instances,
the allogeneic response can have therapeutic benefits. The induction of mismatched
donor immune cells into an allogeneic recipient with cancer can consist of three distinct
allogeneic responses: 1) recipient T cell reactivity towards the graft (allograft rejection in
immunocompetent hosts) 2) donor T cell reactivity towards normal host tissues (GVHD)
or 3) donor T cell alloreactivity towards tumor (graft-versus-cancer). Allogeneic stem cell
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transplantation has been adopted into a form of immunotherapy, harnessing the graftversus-cancer effect for tumor control in patients with various hematologic
malignancies104. For example, in cases of graft-versus-leukemia (GVL), the engrafting
allogeneic hematopoietic stem cell transplant (HCT) graft includes cytotoxic T cells that
recognize minor histocompatibility antigens (MiHA), polymorphic peptides presented in
the context of (self)-HLA molecules as foreign antigens, thus rejecting and eliminating
residual tumor cells105.
The efficacy and toxicity of allogeneic stem cell transplantation are dependent on
the ability to control the immune reactivity between donor and host by selecting the
degree of MHC incompatibility and the administration of immunosuppressive drugs.
Several studies have demonstrated that the MiHAs that induce GVHD are potential
candidates for a graft-versus-tumor response after allogeneic stem cell
transplantation105–108. Because most MiHAs are a product of donor and recipient SNPs,
it is possible to genotype patients and predict MiHA reactivity prior to transplant109. In
one study, Marijt et al. used in vitro-selected and -expanded MiHA-specific T cells to
treat patients with relapsed leukemia after allogeneic stem cell
transplantation110. They concluded that this approach was feasible and capable of
inducing GVL leading to complete remission in two of eight patients. In summary,
therapeutic decisions should evaluate several MiHAs and select those anticipated to
have the most impact on clinical outcomes.
Allogeneic DCs have also been tested as potential cancer therapeutics.
Intratumoral delivery of allogeneic DCs that were matured in the presence of TLR
ligands and IFN-g has been demonstrated as feasible and capable of inducing T cell-
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mediated responses that might prolong survival of patients with metastatic renal cell
carcinoma111. One possibility is that the allogeneic DCs promoted the production of
immune-potentiating cytokines and activating factors that can activate immune cells
independent of MHC restriction112. The Th1 alloresponse can also contribute to the
generation of anti-tumor immunity113. Additionally, allogeneic DCs might serve as an
“off-the-shelf” immunotherapy, focusing on local bystander immune cell activation and
eliminating the need for personalization. In conclusion, the use of allogeneic immune
cells for cancer immunotherapy is a promising strategy to stimulate recipient immune
responses.
T Cell Cross-Priming
Historical Significance
The presentation of exogenous antigen on MHC class I molecules is termed
cross-presentation and is essential for APCs to induce CD8+ T cell responses. Antigen
cross-presentation was initially described in the context of CD8+ T cell responses to
grafts. In the 1970s, Bevan and colleagues demonstrated that engrafting H-2dxb F1 mice
with splenocytes from H-2b mice generated CD8+ T cells restricted by host MHC class I
H-2d. Evidence of recipient CD8+ T cell activation suggested that the grafted cells
contained minor histocompatibility antigens that were “cross-presented” by recipient
antigen presenting cells that primed CD8+ T cells114,115. This phenomenon was termed
antigen cross-presentation, or T cell cross-priming.
Years later, dendritic cells (DC) were identified as the most potent inducers of
cross-priming among antigen presenting cell subsets116. As professional APCs, DC are
highly efficient at internalizing antigens that undergo further processing for presentation
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on MHC class I or MHC class II complexes117,118. DCs generally reside as immature
APCs within tissues until they capture antigen. Mature DCs upregulate MHC class II,
CCR7 and additional co-stimulatory molecules and traffic to lymph nodes to stimulate
antigen-specific CD4+ and CD8+ T cell responses. During the classical pathway of MHC
class I antigen presentation, endogenously synthesized cellular proteins are
ubiquitinated or trimmed by cytosolic peptidases followed by proteasomal degradation.
Some of the resulting peptides are transported to the ER lumen or further trimmed by
ER-associated proteases and loaded onto MHC class I complexes, which then enter the
secretory pathway for cell surface expression and potential CD8+ T cell engagement119.
In contrast, the MHC class I cross-presentation pathway involves the uptake of
exogenous antigens by DC, which are then processed and presented to CD8+ T cells.
The following sections will discuss the mechanisms of antigen cross-presentation,
specialized DC subsets that excel at antigen cross-presentation, factors that influence
antigen cross-presentation, and the importance of antigen cross-presentation in cancer
immunotherapy.
Cell Biology of Antigen Cross-Presentation
Dendritic cell-mediated MHC class I presentation of exogenous antigens can
occur through two different pathways (Fig 3). The first, and most common, is the
cytosolic pathway, which entails endosomal antigen uptake followed by translocation to
the cytosol of the APC120,121. The second is the vacuolar pathway and involves the
generation of peptides by lysosomal proteases within the phagosome and is less
relevant in vivo122. The following sections will discuss the acquisition of antigen,
intracellular pathways, and immunological outcomes in regards to T cell cross-priming.
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Figure 3. Pathways of Antigen Cross-Presentation by Dendritic Cells. The two
known pathways for antigen cross-presentation are the vacuolar (top purple half) and
cytosolic (blue lower half). In the vacuolar pathway, antigens are degraded by
lysosomal proteases and peptides are loaded onto MHC class I in the phagosome. In
the cytosolic pathway, internalized antigens are transported from the ergosome to the
cytosol where they are degraded by the proteasome. TAP is required for transport
into the ER or back into the ergosome for loading on to MHC class I. The black
arrows indicate the pathways of MHC class I cross-presentation of exogenous
antigens. The green arrows depict the classical MHC class II pathway for
presentation of exogenous antigens, for reference.

Acquisition of antigen. The acquisition of antigen for MHC class I presentation
is a highly complex process that has been extensively studied. The two principal
sources of antigens for MHC class I presentation are derived from intracellular and
extracellular environmental proteins. Intracellularly-derived cytosolic antigens, such as
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viral proteins, are the most common source of peptides presented by MHC class I123.
The classical MHC class I pathway is ubiquitous in cell types expressing MHC class I.
Dendritic cells (DCs), however, have a remarkable ability to cross-present extracellular
antigens for MHC class I presentation. To a lesser extent, B cells and macrophages are
also capable of antigen cross-presentation. The canonical cytosolic pathway entails the
transfer of antigens within the endosome to the cytosol of the DC followed by protein
degradation and transport to the ER lumen120,121. In the ER lumen, MHC class I
molecules are stabilized until a peptide is loaded into the peptide-binding groove of
MHC class I complexes. Then, the peptide-MHC class I complex is transported to the
cell surface. This process requires two components: the proteasome complex to
degrade proteins in the cytosol and the transporter associated with antigen processing
(TAP), which transports processed antigens to the ER121,124,125. The cytosolic pathway is
most commonly used by DCs for antigen cross-presentation.
The second method to achieve antigen cross-presentation is through the
vacuolar pathway. In the vacuolar pathway, endolysosomal proteases (or in some
cases, proteasomes) degrade antigens, and the generated peptides are loaded onto
MHC-I molecules that recycle from the cell membrane126,127. Cathepsin S, a lysosomal
protease, has been reported to have a critical role in the vacuolar pathway122. In
contrast to the cytosolic pathway, the vacuolar pathway is TAP-independent. This
pathway is less common and not well-characterized; therefore, we will focus on the
cytosolic pathway.
In the cytosolic pathway, the proteasome undergoes structural changes upon
IFN-g stimulation or DC maturation that improves the quality and quantity of the
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generated peptides128. It has been postulated that limited degradation of antigen is
associated with more efficient cross-presentation, as rapid antigen degradation would
destroy a vast number of epitopes before they could adequately be processed and
loaded onto MHC class I molecules129. One might imagine that prolonged crosspresentation would be required to cross-prime CD8+ T cells after migrating to the
draining lymph nodes. In agreement with this hypothesis, the endosomes within DCs,
compared to macrophages, have lower levels of proteases and higher pH levels, which
restrict antigen degradation130. In both human and mouse DCs, phagosomes express
NADPH oxidase (NOX)-2 at the phagosomal membrane that produces low levels of
reactive oxygen species (ROS) to limit acidity131,132. The prevention of acidity in
phagosomes and endosomes limits antigen degradation and facilitates crosspresentation. Overall, high pH and low levels of proteases are qualities of endosomal
compartments within DCs that contribute to their superior ability to cross-present
antigens.
Dendritic cell subsets and antigen cross-presentation. While all DC subsets
have similar abilities to uptake soluble and particulate antigens, specific subsets are
more effective at cross-presenting antigens to T cells75–77. Conventional (or myeloid)
and plasmacytoid DCs are two broad subsets capable of antigen cross-presentation;
however, cross-presentation by conventional DCs (cDCs) is more common and
efficient. Human tissues, except for skin, contain low frequencies of cDCs. As a result of
this limitation, most studies investigating cDC cross-presentation have been performed
in mouse studies.
There are two subsets of mouse cDCs, cDC1 and cDC2, found in lymphoid and
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non-lymphoid tissues, respectively. The cDC1 subset is generally the most effective at
antigen cross-presentation in vivo. In mice, cDC1 DCs are composed of CD8a- and
CD8a+ cDC1s, which predominantly reside in lymphoid tissue, and migratory CD103+
cDC1s133. In humans, these subsets correspond to CD1c+ (also known as blood DC
antigen (BDCA)1+) and CD141+ (BDCA3+) DCs, respectively133. Both mice and humans
share similar transcriptional programs and genetic requirements mediating the
development of cDC1 subsets134. Human and mouse cDC1 can be characterized by the
expression of XCR1, which is a chemokine receptor that promotes CD8+ T cell
chemotaxis135. Some of these factors include high levels of TLR3, Clec9A C-type lectin,
interferon regulatory factor 8 (IRF8) and basic leucine zipper transcriptional factor ATFlike 2 (BATF3)136–138.
Cross-presentation is mostly mediated by the (mouse) CD8a+/CD103+ cDC1
subsets in vivo. CD8a+ cDC1 predominantly execute their functions within lymphoid
organs. In contrast, CD103+ cDC1 can acquire antigens in the non-lymphoid tissue
sites. Early studies from the Bevan group observed antigen cross-presentation after
analyzing peptide-MHC-I complexes on sorted populations of splenic DCs following the
in vivo priming of mice with OVA peptide-loaded, b2-microglobulin-deficient
splenocytes. They further reported that CD8a+CD11b- DCs were more efficient
mediators of cross-presentation than CD8a- CD11b+ DCs by comparing their ability to
endocytose fluorescent beads129. In contrast, migratory CD103+ cDC1 can crosspresent soluble and cell-associated antigens in the lung, intestine, and skin139–143. In
summary, CD8a+CD11c+ MHC class II+ DCs and CD103+ CD11c+ MHC class II+ DCs
are the most effective APC subset at cross-presenting tumor-derived antigens in the
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lymphoid organs and non-lymphoid organs, respectively. The role of these cDC1
subsets in the context of cancer immunotherapy will be discussed further in a future
section.
Factors Influencing Cross-Presentation
As mentioned, specific DC subsets are more effective than other antigen
presenting cells at antigen cross-presentation. Other factors that influence crosspresentation are means of antigen internalization, type of antigen, and status of DC
maturation, which will be discussed in this section.
Means of antigen internalization. DCs can internalize antigen through three
different cellular processes: receptor-mediated endocytosis, phagocytosis, and
pinocytosis. However, even though the ability of DCs to phagocytose or pinocytose
soluble antigen is essential, this does not correlate with efficient cross-presentation.
One study reported that antigens internalized by fluid phase pinocytosis or scavenger
receptor-mediated endocytosis were quickly targeted to lysosomes and degraded by
lysosomal proteases, leading to poor cross-presentation144. In contrast, receptormediated endocytosis of the same antigen resulted in targeting to early endosomes
where the antigen was protected from degradation and efficiently cross-presented144.
These findings suggest that the most effective means of antigen internalization is
receptor-mediated endocytosis.
DCs express a variety of receptors that facilitate the cross-presentation of
antigens to T cells. Fc receptors cross-present immune complexes (IC), composed of
immunoglobulin G (IgG) antibodies bound to cognate antigen, to both CD8+ and CD8DCs 145,146. In one study, human BDCA1+ DCs more efficiently cross-presented the NY-
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ESO-1 antigen when delivered as an antigen-antibody IC compared to when the NYESO-1 antigen was administered as a soluble protein147. Additionally, members of the
mannose receptor (MR) family, such as CD205 (DEC-205) and Dectin-1, also mediate
endocytosis of extracellular complexes followed by transport to endosomal pathways for
further processing and antigen presentation144,148. Although all of these receptors play a
role in mediating endocytosis, CD205 is the most effective at directing endocytosed
antigens into MHC class I and MHC class II presentation pathways.
CD205 is an endocytic receptor highly expressed on cortical thymic epithelial
cells and peripheral DC subsets, including the specific cross-presenting CD8+
splenic/lymph node DC subset mentioned above149,150. As a member of the MR family,
CD205 is a type I C-type lectin-like molecule comprised of a single polypeptide chain.
The extracellular region consists of an N-terminal cysteine-rich domain (CyR), a
fibronectin type II domain (FnII) and ten structurally similar C-type lectin domains
(CTLDs)149,151,152. Dendritic cells expressing CD205 (DEC-205) present antigens on
MHC class I to CD8+ lymphocytes and induce a Th1-like response153. This was
demonstrated by Bonifaz and colleagues using anti-CD205 antibodies conjugated to
OVA. They observed stronger CD8+ T cell-mediated immunity when OVA was targeted
to CD205 compared to other forms of antigen delivery148,154. These findings highlight the
therapeutic potential of targeting antigens to CD205+ DCs.
Types of antigens. Several types of antigens are capable of being crosspresented to T cells, including soluble proteins, immune complexes, and microbial
components155,156. Antigens can also be conjugated to either antibodies that bind
specific receptors on DCs or glycans that interact with C-type lectin receptors
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(CLR)157,158. The properties of the cross-presented antigen, such as antigen dose, live
or apoptotic cell-derived, modified self or mutated tumor antigen, and subcellular
location within the tumor cell, can also influence DC cross-priming of T cells159–163.
Different types of antigens are more effectively cross-presented than others.
Tumor antigens can be classified according to the pattern of expression of the parental
gene. Mutated genes can give rise to a modified peptide that can bind HLA class I
molecules, which can then be recognized by self155. Tumors express cancer germline
genes, including those that encode for MAGE-type antigens, that are not expressed on
normal tissue as a result of whole genome demethylation156. Genes that are expressed
in specific tissue can encode for differentiation antigens, which can be expressed on
both normal and tumor tissues. Antigens that are expressed more highly on tumor
tissue compared to normal tissue usually occur due to the overexpression of these
genes due to increased transcription or gene-amplification187. Cross-presentation in vivo
favors cellular antigens that are highly expressed164. Differences in the crosspresentation of apoptotic- versus live cell-derived antigens have been described.
Norbury et al. reported that proteins, instead of proteasomal-derived peptides, represent
the source of cell-associated antigens entering the cross-presentation pathway165.
Furthermore, when comparing cellular and soluble antigens, Li and colleagues
demonstrated cellular OVA is cross-presented 50,000-fold more efficiently than soluble
OVA166. Additionally, stable membrane proteins are more efficiently cross-presented
than soluble, short-lived cytosolic proteins167. Targeting the melanoma antigen MART-1
to the CLR DC-SIGN using antibody- or glycan- conjugated liposomes resulted in
enhanced antigen cross-presentation to MART-1-specific CD8+ T cells168.
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Anatomical location, such as the tissue from which tumor antigens are derived,
can also influence antigen cross-presentation158. DC infiltration of solid tumors is well
documented in both tumor animal models and human studies187. However, it is
unknown what form of tumor antigens is captured by cross-presenting DCs. In one
review, multiple potential mechanisms were described for the transfer of tumor antigens
to DCs521. These mechanisms included phagocytosis of cell-associated tumor antigens,
pinocytosis or endocytosis of soluble tumor antigens, HSP-bound soluble antigens,
“nibbling” of tumor cell membranes, or “cross-dressing”. In summary, these studies
provide evidence that cell-associated proteins, especially those derived from apoptotic
cells, are the predominant source of antigens entering the cross-presentation pathway.
Licensing of dendritic cells. Two different outcomes are possible following DCT cell interactions: T cell activation (priming) or T cell tolerance. The first half of this
section will discuss factors that promote T cell activation. CD8+ T cell activation is a
tightly regulated process in order to limit destruction of normal tissues. As a result,
initiation of T cell cross-priming depends on fully activated and mature DCs to provide
all three signals required for T cell activation169. These appropriately activated DCs are
referred to as “licensed” for T cell cross-priming170. DC licensing can occur through
signals delivered via innate immune receptors and CD4+ T helper cells (classical) or
NKT (alternative) cells.
Innate immune receptors. Efficient T cell cross-priming requires stimulation
through innate immune receptors called pattern recognition receptors (PRRs) on DCs.
PRRs detect highly conserved pathogen-associated molecular patterns (PAMPs) on
microorganisms171. PRRs can also sense damage-associated molecular patterns
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(DAMPs), which are endogenous molecules released from damaged cells. The four
subsets of PRRs identified thus far are Toll-like receptors (TLRs), C-type lectin
receptors (CLRs), retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and NODlike receptors (NLRs)172. Engagement of PRRs validates the type of antigen
encountered and induces DC maturation and migration to lymphoid tissues to crossprime T cells173.
Stimulation through PRRs generally induces expression of genes important for
inflammatory processes, such as pro-inflammatory cytokines, type I interferons (IFNs),
and chemokines171. Inflammatory cytokines critical to DC licensing include IL-1-b, TNFa, and IL-6. Additionally, cross-presenting DCs and cross-primed CD8+ T cells can
produce GM-CSF, which has been demonstrated to enhance antigen crosspresentation by DCs174. Zhan and colleagues observed that GM-CSF transgenic mice
infected with Listeria monocytogenes exhibited an increase in antigen crosspresentation, which occurred by promoting the uptake of antigens by CD8+ DCs and
inducing expression of CD103. In a tumor model, vaccinating B16 tumor-bearing mice
with irradiated, GM-CSF-producing B16 tumor cells elicited robust, specific, and durable
anti-tumor responses175. Type I IFNs, especially IFN-a, are also potent inducers of
antigen cross-presentation by DCs through several mechanisms. Type I IFNs promote
the persistence of antigen by reducing the acidification rate within endosomes.
Additionally, treating human DCs with IFN-a promotes the routing of antigens toward
the MHC class I processing pathway176.
Licensing by CD4+ T helper cells. CD4+ T helper cells can also play a role in
antigen cross-presentation through interacting with DCs. DCs can present the same
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antigen on MHC class II to CD4+ T cells and on MHC class I to CD8+ T cells. CD4+ T
helper (Th) cells serve as a checkpoint to validate the appropriateness of the response
(type of antigen and PRR stimulation). DC-CD4+ Th cell interactions can upregulate the
co-stimulatory marker CD40 on DCs. Upon binding to CD40L, CD40 induces
downstream signals that lead to the production of IL-12 and increases expression of
MHC class I and CD80/CD86 by DCs177. Licensed DCs can now engage the TCR and
CD28 co-stimulatory molecules on CD8+ T cells, thus culminating in efficient crosspriming of T cells178. The absence of CD4+ T cell help during the priming phase results
in CD8+ T cells with defective effector functions and the inability to mount memory
responses179.
Cross-tolerance. In contrast to cross-priming of CD8+ T cells, “steady-state”
DCs can render CD8+ T cells functionally inactive180. This phenomenon termed “crosstolerance” occurs in the absence of an inflammatory stimulus and in the presence of
constitutive exposure to self-antigens181. For example, in the absence of an
inflammatory stimulus, CD8+ T cell tolerance was induced in vivo when CD205-targeted
antigens were delivered to DCs in mice154,182. Cross-tolerance can also result in the
deletion of self-reactive CTL182–185. Elimination of self-reactive CTL can occur when
naïve CD8+ T cells recognize peptide-MHC complexes, but do not engage or express
co-stimulatory molecules182,183. While the induction of peripheral tolerance is critical to
prevent over-stimulation of immune cells and autoimmunity, this can also negatively
impact the ability to generate effective anti-tumor immune responses.
T Cell Cross-Priming in Cancer Immunotherapy
In the 1990s, the Levitsky group provided early evidence that suggested that
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antigen cross-presentation drove anti-tumor immunity186. They sought to determine the
relative role of tumor- versus host-derived APCs to prime CD8+ T cells. Mice were
immunized with MHC class I-expressing or MHC class I-deficient B16 tumors and
subsequently challenged with a lethal dose of live MHC class I+ tumors. Strikingly, they
observed that immunizing mice with MHC class I+ or MHC class I- B16 tumors resulted
in equal protection in vivo, indicating that host APC were capable of eliciting tumorantigen-specific CTL in the absence of MHC class I on tumor cells186.
Generating an effective CD8+ T cell response against cancer antigens, however,
can be challenging to achieve. Cancer cells can engage T cells through TCR-pMHC
interactions, thus inducing signal 1; however, cancer cells have developed mechanisms
to inefficiently induce signal 2, which leads to tolerance. Therefore, T cells must be
activated by mature APCs that have phagocytosed antigens from dying tumor cells.
This has been confirmed through observations that CTL induction in secondary
lymphoid tissues, while enhanced by CD28, was independent of CD80 on tumor
cells187. Therefore, APC cross-priming of CD8+ T cells elicits tumor-specific cytotoxic T
lymphocytes that expand and migrate to the tumor where they can recognize and kill
tumors cells188.
Intratumoral DCs have a critical role in anti-tumor immunity by coordinating T cell
responses against tumor antigens189–193. Clinically, the frequency of tumor-infiltrating
DCs has been reported to correlate with a favorable prognosis in melanoma patients194.
In pre-clinical mouse models, there is mounting evidence that Batf3-lineage DCs are
essential for effective anti-tumor T cell responses192. Murphy and colleagues
demonstrated that mice deficient in Batf3 had reduced tumor-infiltrating CD8+ T cells,
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which produced inadequate tumor-specific CD8+ T cell responses compared to wild type
mice138. It was later demonstrated that Batf3+ DCs within the tumor microenvironment
produced the chemokines CXCL9 and CXCL10, which promote T cell infiltration.
It remains unclear if T cell cross-priming occurs in the tumor microenvironment or
in the tumor-draining lymph nodes. CD103+ cDCs can carry tumor-derived antigens
from the tumor microenvironment to the tumor-draining lymph nodes, but the role of
lymph node-resident DCs in tumor antigen cross-presentation is unknown. It has been
proposed that CD103+ DCs can transfer antigens to other lymph node DC
populations195. There has been some evidence that cross-priming of T cells can occur in
the tumor microenvironment, as in situ priming of naïve T cells has been observed in
mice lacking spleens and lymph nodes196. Therefore, additional studies should be
conducted to further elucidate if the tumor microenvironment is an effective site for T
cell cross-priming.
Unfortunately, the tumor microenvironment can suppress the extent to which
DCs can infiltrate tumors and elicit productive anti-tumor T cell responses. For example,
induction of the tumor cell-intrinsic Wnt/b-catenin pathway inhibits recruitment of Batf3dependent CD103+ DCs into the tumor microenvironment and ultimately prevents CD8+
T cell cross-priming 192,197,198. The Gajewski group demonstrated that melanoma cell
intrinsic b-catenin signaling contributed to the downregulation of CCL4 leading to a
decrease in DC chemoattraction197,199. Furthermore, DCs that have infiltrated tumors
often have functional deficiencies that result in impaired T cell cross-priming or even
facilitate tolerance. DC-intrinsic b-catenin signaling also occurs in tumor-infiltrating DCs
and results in defective cross-presentation and the induction of tolerance, which
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generates Treg cells through TGF-b production. Tumor-infiltrating DCs have low
expression of co-stimulatory molecules and high levels of regulatory molecules200. This
immunosuppressive DC phenotype can be induced by inhibitory factors secreted or
expressed by tumors. For example, in a murine hepatoma model, tumor-derived factors
such as TGF-b and VEGF, converted CD11c+MHC II+CD205+ DCs into tolerogenic cells
that exhibited increased expression of PD-1 and impaired cross-presenting functions201.
In combination with increased PD-L1/L2 expression on tumors, increased PD-1
expression on DCs can impair T cell and myeloid cell responses201. Fortunately,
treatment with anti-PD-1 monoclonal antibodies has been observed to reverse this
immunosuppression.
Tumor-induced suppression also affects infiltrating T cells. The conditions of the
tumor microenvironment can affect the function of tumor-infiltrating immune cells. The
hypoxic environment favors glycolytic metabolism202. A glycolytic shift is characteristic
and a limiting factor of both T cell and DC activation and effector function203. Therefore,
tumor cells and tumor-infiltrating immune cells compete for glucose within the tumor.
The upregulation of T cell Ig and mucin domain 3 (TIM-3) on T cells also promotes the
dampening of immune responses. Therefore, targeting these inhibitory ligands or
receptors have the potential to rescue both DC and T cell effector functions in the tumor
microenvironment. In conclusion, CD8a+, CD103+, and CD205+ DCs are critical subsets
for antigen cross-presentation to CD8+ T cells, a process required to generate antitumor immune responses. These cell types are critical targets when trying to overcome
the tumor-induced immunosuppression that affects the generation of effective antitumor immune responses.
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Immunotherapies to Treat Cancer
Cancer is the second leading cause of death worldwide, with almost 10 million
deaths in 2018169. In some cancer types, spontaneous regression of tumor burden has
implicated the importance of host immunity. Host immune responses, such as T cell
infiltration into tumors, can positively correlate with better outcomes147. Within the last
decade, immunotherapies to treat various malignant cancers have shown promising
results. A vast majority of these immunotherapies are designed to affect T cell
responses. This section will discuss several immunotherapies that are in clinical trials or
have already been FDA approved
Cytokines and Immune Adjuvants
Cytokines act as messengers to induce signaling cascades that lead to rapid
immune responses. Cytokines have broad anti-tumor potential such as activating
numerous types of immune cells and stromal cells in the tumor microenvironment and
facilitating CD8+ T cell recognition of tumors. Because of their immune potentiating
activity, cytokines have been tested in clinical trials for patients with metastatic disease,
with two cytokines receiving FDA approval.
The first FDA-approved cytokine, IL-2, gained approval for the treatment of
metastatic kidney cancer and metastatic melanoma in 1992 and 1998, respectively518.
Out of 409 patients with metastatic melanoma and renal cell carcinoma receiving high
dose IL-2 (720,000 U/kg, 3X/day), thirty-three (8.1%) achieved a complete response,
and 37 (9%) achieved a partial response204. Durable responses observed after
treatment with IL-2 provided evidence that modulating the immune system could induce
anti-tumor responses.
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The second FDA-approved cytokine was IFN-a, a type I IFN that has pleiotropic
effects on multiple cell types, making it an attractive candidate for cancer
immunotherapy520. IFN-a can induce DC maturation, stimulate cytotoxic NK and T cells
responses, mediate tumor cell death and inhibit angiogenesis205. Early phase I-II clinical
trials reported overall response rates of 15-17%, with one-third of patients maintaining
long-term responses206–208. High-dose IFN-a (HDI) has also been tested in the adjuvant
setting for patients with high-risk, resectable melanoma and improved relapse-free
survival209,210. Furthermore, in the neoadjuvant setting, HDI treatment resulted in
objective clinical responses in 55% of patients and complete pathologic responses in
15% of patients211. Currently, IFN-a has been approved to treat hairy cell leukemia212,
follicular non-Hodgkin lymphoma213, melanoma214, and AIDS-related Kaposi
sarcoma215. Some immunological events that have correlated with improved clinical
responses following administration of IFN-a include: modulation of T cell and tumor cell
signaling216,217, tumor infiltration of CD11c+ and CD3+ cells218, the polarization of M1
macrophages219, and acquisition of CD8+ T cell effector phenotypes220.
IL-2 and IFN-a gained FDA approval because of their ability to induce durable
responses, albeit in a small fraction of patients. Major limitations with these therapies
included the low response rates and significant toxicity. In summary, IL-2 and IFN-a
treatment can lead to clinical responses in a small subset of patients; however, there
are several limitations that affect the efficacy of these immunotherapies.
Adjuvants, such as agonists of Toll-like receptors (TLRs) and stimulator of
interferon genes (STING), have been utilized in cancer immunotherapy for their ability to
enhance immune responses. Some adjuvants can induce the production of type I IFN
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and IL-2 and consequently promote DC maturation and robust effector T cell responses.
Activation of TLRs can elicit immune activation and directly lyse tumor cells221. TLR
agonists can induce type I IFN production through the activation of nuclear factor-kB
(NF-kB)222,223. The TLR2/4 agonist, Bacillus Calmette-Guerin (BCG), and TLR7 agonist,
imiquimod, have been approved to treat patients with bladder cancer and breast cancer,
respectively224,225. Additional TLR agonists under pre-clinical and clinical investigation
include Ampligen226 and poly I:C/poly-ICLC227–231, which target TLR3, or R848232–234,
which targets TLR7/8, to treat various malignancies.
Adjuvants that target the STING pathway have also been utilized to promote
robust anti-tumor immune responses and are under clinical development. The STING
pathway is activated by DNA damage to induce anti-tumor immunity and inflammatory
responses235. Induction of the STING pathway can lead to the production of type I IFNs,
dendritic cell activation, T cell infiltration into the tumor microenvironment, and crosspresentation of tumor antigens to CD8+ T cells236,237. Cytoplasmic dsDNA in cancer cells
binds to and activates cGAS, an enzyme that induces production of cyclic GMP-AMP
(cGAMP). cGAMP then binds to and stimulates STING238. Upon STING stimulation,
conformational changes in STING recruit TANK binding kinase 1 (TBK1). TBK1
phosphorylates IRF3 and IRF3 translocates to the nucleus for induction of type I IFN
production239.
Immunotherapies that stimulate innate and adaptive immune cells can promote
robust and durable anti-tumor responses. In one study, the combination of two different
immune modulatory drugs, IL-2/anti-IL-2 mAb complexes to target CD8+ T cells and
poly I:C to target innate immunity, resulted in complete tumor eradication in mice with
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pancreatic tumors240. To further enhance the anti-tumor response, immune-potentiating
adjuvants have been used in combination with tumor cell- or dendritic cell-based
vaccines, which will be discussed in the next section.
Vaccine-Based Immunotherapy
Vaccine-based immunotherapies can have both therapeutic and preventive benefits.
The development of cancer vaccines entails a wide range of targets and vehicles for
delivery. This section will discuss dendritic cell vaccines, tumor cell vaccines, and
immune adjuvants and agonists.
Whole tumor cell vaccines. Vaccinations to treat or prevent cancer first utilized
modified, irradiated whole tumor cells. The advantage of using whole tumor cell
vaccines versus specific protein or peptide tumor antigen is the capacity to induce T
cells with specificities to a broad range of antigens expressed by the tumor. This is
critical especially considering that antigen loss is a prominent tumor escape
mechanism. Furthermore, the immune response following vaccination can be utilized to
identify novel tumor antigens or important immunological biomarkers associated with
tumor control.
The use of irradiated syngeneic or allogeneic tumor cells to protect against
cancer has been demonstrated in animal models and human clinical trials. Autologous
tumor vaccination ensures that a patient is exposed to the same tumor antigens
expressed on their tumor. Although biopsies are feasible, this would be difficult for
inaccessible tumors and could become difficult to obtain sufficient numbers of tumor
cells, especially if multiple rounds of vaccinations are required. Furthermore,
maintaining a personalized tumor vaccine line in vitro would require extensive
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resources241. To circumvent these issues, allogeneic tumor cell vaccines can be used.
This eliminates the personalization barrier, as multiple tumor cell lines can be combined
to increase the diversity and number of available antigenic targets. Although the
development of anti-HLA responses can raise safety questions, some studies have
demonstrated enhanced anti-tumor responses accompanied by the induction of crossprimed T cells following vaccination with allogeneic whole tumor cells242–244.
As emphasized in the above sections, combinatorial strategies have been
promising to treat various cancer types. In the context of tumor cell vaccines, one way
this has been demonstrated is by using allogeneic tumor cells modified to encode
immune-stimulating elements, such as cytokines. A study encompassing both
properties used an allogeneic tumor cell line that secreted GM-CSF to induce CD4+ and
CD8+ T cells to prevent and treat B16-F10 melanoma245. A second study developed a
whole cell B16 melanoma vaccine expressing 4-1BBL and CD80 co-stimulatory
molecules that resulted in regression of live B16 tumors and induced protection against
repeated challenge246. The pre-clinical results demonstrating the efficacy of these
strategies have resulted in tumor vaccines entering Phase I and II trials.
One of the most successful vaccines, GVAX, consists of whole tumor cells
genetically engineered to produce GM-CSF and then irradiated to inhibit cell division175.
GVAX has been utilized in both autologous and allogeneic therapy. Patients with
pancreatic adenocarcinoma that received vaccination with irradiated, allogeneic tumor
cells expressing GM-CSF had prolonged survival accompanied by an expansion of
tumor-specific CD8+ T cells247. Unfortunately, even if engineered tumor vaccines
stimulate robust priming of DCs, the immunosuppressive tumor microenvironment can
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secrete factors, such as TGF-b, that directly inhibit CD8+ T cell responses and indirectly
inhibit DC responses248. In summary, modified whole tumor vaccines, like GVAX, have
shown promising clinical and biologic responses, but additional immune modulation
should be considered to address tumor-induced suppression mechanisms.
Dendritic cell vaccination. Dendritic cell (DC)-based cancer vaccines have
emerged as potential therapeutic and preventive immunotherapies to treat cancer
patients. As described in detail above, DCs have superior abilities to stimulate T cell
responses against self- and non-self- antigens249–251. The identification of optimal
conditions that generate large scale DC cultures in vitro has contributed to the recent
success and progress of DC vaccinations to treat cancer. DCs can be differentiated
from blood monocyte precursors or CD34+ progenitors in cord blood in the presence of
recombinant cytokines such as FLT3-L, IL-4 and GM-CSF252. Early clinical trials testing
the safety and efficacy of DC cancer vaccines entailed treating patients with tumorloaded DCs matured with GM-CSF and IL-4. These studies concluded that DC cancer
vaccines were relatively safe and capable of inducing tumor-specific T cells responses
across multiple tumor types253–259. Achieving complete objective responses can be
difficult, as patients enrolled in these trials already have progressive disease. Results
from these early clinical trials have demonstrated that patients can be successfully
vaccinated, and 5-10% of patients can experience tumor regression.
One consideration when rationally designing DC cancer vaccines is selecting
target antigen(s) that will give optimal responses. The source of antigens has ranged
from syngeneic or allogeneic tumor cells and lysates to MHC-restricted or synthetic
peptides260–262. Some of the first genes encoding tumor antigens recognized by TIL
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were identified within metastatic melanoma lesions resected from patients enrolled in
clinical trials testing high-dose IL-2204. These antigens were mostly categorized as
melanoma/melanocyte differentiation antigens (MDA), and to a lesser extent, mutated
intracellular proteins.
A large portion of DC cancer vaccines utilizes synthetic peptides to generate
tumor-specific CTL263–266. Peptide-based vaccine strategies generally achieve maximal
tumor-specific CD8+ T cell frequencies of between 0 and 0.3% (of all CD8 T cells)267.
There are many strengths to utilizing synthetic peptide approaches for DC vaccination.
First, synthetic peptides are generated through chemical synthesis that results in highly
pure products with defined composition, which can eliminate the potential for biological
contamination. Second, synthetic peptides are relatively stable and can be maintained
in permissive storage conditions, which facilitates cost-effective large-scale
production268. Additionally, synthetic peptides are highly customizable and can include
post-translational modification.
Clinical success in patients receiving DC peptide vaccines has been observed. In
metastatic melanoma patients receiving vaccinations with MAGE-3A1-pulsed DCs,
significant frequencies of MAGE-3A1-specific CD8+ T cells were detected in the
peripheral blood and regressions of individual metastases were evident in about half of
the eleven patients265. Another example illustrating the therapeutic potential of synthetic
peptide DC vaccination was seen in a phase I trial that treated patients with autologous
DCs pulsed with MART-127-35, which is an immunodominant epitope derived from
MART-1/Melan-A (MART-1) protein253,269. Examination of the peripheral blood postvaccination demonstrated an increase in MART-1-reactive T cells measured by
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ELISPOT assays and identified with tetramers. The expansion of MART-1-specific T
cells did not coincide with clinical responses; however, one patient that achieved a
complete response also had evidence of epitope spreading and generated both MHC
class I restricted gp100- and tyrosinase-specific and MHC class II-restricted MART-1specific CD8 and CD4 T cells, respectively253.
Although synthetic peptides are stable in storage, they can become unstable in
vivo. Additional weakness to using synthetic peptides include the requirement of
compatible MHC for identified epitopes and the variation in peptide affinity and
kinetics218. Furthermore, synthetic peptides are generally weakly immunogenic and may
require additional stimulation, such as adjuvants, to induce adequate T cell
responses270. An alternative approach to using synthetic peptides is to express genes
that encode full-length proteins in DCs through genetic modification. By processing fulllength proteins, DCs can present both MHC class I- and MHC class II-restricted
epitopes to elicit tumor-specific T cell responses that are polyclonal in nature271–275.
Additionally, DCs expressing tumor proteins are capable of sustained antigen
processing and presentation compared to DCs pulsed with synthetic peptides276.
Genetic modification of DCs to express target antigens can be achieved using DNA
delivery vehicles, such as viral vectors. This method has been demonstrated to
stimulate tumor antigen-specific T cell responses277–279.
Promising biologic responses have been observed using Adenovirus (AdV)
delivery vectors to express target proteins in DCs. AdV vectors are a useful tool due to
durable transgene expression and minimal induction of neutralizing antibodies. DCs
transduced with AdV have been characterized as more phenotypically mature and
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capable of increased IL-12p70 production280–282. One study investigating T cell
responses following vaccination with DCs transduced with adenovirus to express the
full-length alpha fetoprotein (AFP), a well-characterized hepatocellular carcinoma
antigen, reported increased generation and expansion of T cells with specificities to
both immunodominant and subdominant epitopes compared to T cell responses
following stimulation with AFP protein-stimulated DCs283. Adenovirus has also been
used to deliver full-length MART-1 cDNA to autologous DC284. These findings
demonstrate that AdV-mediated delivery of full-length proteins can be an effective
strategy to induce tumor antigen-specific T cell responses.
Pre-clinical mouse models have been used to study the effect of DC vaccinations
on tumor development. Vaccination with mature DCs loaded with tumor lysates has the
capacity to induce protective T cell responses in mice. For example, using the weakly
immunogenic B16 mouse melanoma model, murine DCs that were pulsed with
apoptotic B16 tumor cells efficiently migrated to the draining lymph nodes and
generated durable CD4+ and CD8+ T cell responses285. Assays commonly used to
measure antigen-specific T cell responses include cytokine-production by ELISPOTs,
identification by flow cytometry using tetramers or dextramers, and intracellular cytokine
secretion. These studies have demonstrated the feasibility and efficacy of DC-based
vaccinations.
DC vaccinations can also be improved by adding cytokines or agonists during in
vitro maturation. By maturing autologous patient-derived DCs in vitro with tumor lysate,
TLR3/7/8 agonists, and an IFN-containing cocktail of IFN-a, IFN-g, IL-1b, and CD40L,
one study found significant production of IL-12-p70 and enhanced antigen-specific CD8+
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T cells responses286. Therefore, licensing DCs prior to vaccination could further improve
the induction of tumor antigen-specific T cells.
Anti-Tumor Monoclonal Antibodies
Monoclonal antibodies (mAbs) have been successful in the treatment of various
cancer types due to low toxicity and long half-life. Since the development of hybridoma
technology, large quantities of mAbs can easily be produced287. A monoclonal antibody
is composed of four polypeptides: two heavy chains and two light chains, which are
further divided into two functionally different domains. The fragment of antigen binding
(Fab) consists of the variable region and dictates antibody specificity. Similar to the
TCR, the variable region harbors three hypervariable complementarity-determining
regions (CDRs). Accordingly, the Fab is located at the antigen binding domains of the
heavy and light chains. The constant domain (Fc) determines antibody function.
Monoclonal antibodies have specificity to one epitope. Upon binding target binding,
antibodies can interfere with signaling pathways within a tumor or directly induce cancer
cell death through antibody-dependent cell-mediated cytotoxicity (ADCC) or
complement-dependent cytotoxicity (CDC) pathways288. In this section, we will focus on
antibodies that target tumor antigens.
The first mechanism by which mAbs exert anti-tumor responses is through the
interruption of tumor-intrinsic signaling pathways. This can occur through targeting
antigens that are growth factors involved in angiogenesis. A few examples of growth
factor targets are CEA, EGFR, and Her-2/neu289–291. These antigens are generally cell
surface receptors and are overexpressed in epithelial cancers. Activation through these
growth receptors leads to robust proliferation and facilitates metastatic disease. MAbs
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can block these growth factor receptors to prevent downstream signaling. Through
inhibiting cell cycle pathways in the tumor, these mAbs induce apoptosis.
Antibody-dependent cell-mediated cytotoxicity (ADCC) is another mechanism by
which mAbs promote anti-tumor responses with the help of additional immune cells.
Macrophages, NK cells, and neutrophils express Fc receptors (FcR) that bind to Fc
regions of a mAb. Upon mAb binding the target tumor antigen, the available Fc domain
interacts with the FcR on effector cells resulting in events that lead to tumor lysis292.
Complement-mediated toxicity is the third mechanism by which mAbs induce
tumor cell killing. Complement is a highly complex network of plasma and membranebound serum proteins that mediate inflammatory and cytolytic immune responses293.
Complement binds to the Fc region of the mAb and induces an extensive pathway that
ends in the opsonization or lysis of the cancer cell. These three mechanisms by which
mAbs mediate indirect or direct killing of tumor cells have resulted in promising clinical
responses in patients.
The first mAb that was clinically tested was Orthoclone OKT (muromonab-CD3)
to prevent kidney transplant rejection294. This mAb was mouse IgG2a and unfortunately
was immunogenic, resulting in human anti-mouse responses in humans and weakly
enabled effector T cell responses295. To circumvent these issues, chimeric and
humanized antibodies were developed. Chimeric mAbs are generally composed of an
antigen recognition domain from mouse genes and constant domains from human
genes. Conversely, humanized mAbs are murine-derived antibodies that have been
genetically engineered with protein sequences that resemble human antibodies. This
eliminated immune responses against the antibodies and facilitated clinical use296.
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Recently, novel approaches have led to the development of smaller antibody molecules,
fusion proteins, and bispecific or conjugated mAbs. Conjugated monoclonal antibodies
are attached to a chemotherapy drug, radioactive isotope or toxin297,298. Two FDA
approved conjugated monoclonal antibodies are Trastuzumab emtansine for certain
types of breast cancer and Brentuximab vedotin for refractory Hodgkin’s lymphoma or
large cell lymphoma299–302. Not only is the cytotoxic function advantageous, but targeted
delivery can limit toxicities. Bispecific antibodies contain two different binding domains,
one that targets the tumor antigen and one that binds to Fc receptors present on
effector cells. Engaging these two targets induces tumor lysis303–305.
Rituximab, a monoclonal antibody that binds to CD20 on the surface of B cells,
was the first to receive FDA approval to treat patients with non-Hodgkin’s lymphoma in
1997306,307. Since then, more than a dozen humanized or chimeric mAbs, such as
Alemtuzumab286, Bevacizumab308, Panitumumab309 and Cetuximab310–312, have been
approved by the FDA to treat patients with various cancer types. However, there are
some disadvantages to using mAbs for cancer immunotherapy. Even though a majority
of mAbs have minimal toxicities, there are some reports of adverse events, such as the
case with gemtuzumab, which was associated with an increase in patient mortality
following treatment313–315. The high cost of mAb administration has also contributed to
the relative lack of commercial success seen with mAb immunotherapy316. Additionally,
mAbs treatment alone is rarely curative for patients with cancer317. To summarize,
although mAbs are relatively safe and can be effective, the high cost of treatment and a
need for greater clinical efficacy can affect the commercial success of mAbs for cancer
therapy.
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Immune Checkpoint Inhibitor Therapy
Activated T cells upregulate immune inhibitory molecules, or checkpoints, to
prevent over-stimulation of T cells. Cancer cells hijack this immune regulatory process
to induce immunosuppression. A huge milestone in the immune-oncology field has been
the development of monoclonal antibodies (mAb) that block immune checkpoint
pathways. The impressive clinical outcomes observed after treating cancer patients with
checkpoint inhibitors have resulted in hundreds of clinical trials and recent FDAapproval of several immune checkpoint inhibitors. Two well-characterized immune
checkpoint pathways, PD-1/PD-L1/2 and CTLA-4, will be discussed in this section.
PD-1-targeted therapies. Programmed death-1 (PD-1 or CD279) is a
transmembrane protein in the CD28 superfamily that is expressed on myeloid cells and
activated lymphocytes. PD-1 has two ligands: PD-L1 (B7-H1) is expressed on a broad
range of tissue and primarily mediates peripheral tolerance. PD-L2 (B7-DC) is
expressed on antigen presenting cells (APC) and controls T cell activation and
tolerance318,319. PD-1 binding to PD-L1 or PD-L2 induces inhibitory signals that result in
immune regulatory events that affect T cell activation, effector T cell responses, T cell
tolerance and T cell exhaustion320–322.
The PD-1-PD-L1/PD-L2 pathway is particularly important in the context of antitumor immunity. PD-1 blockade can not only affect immune responses systemically, but
also locally within the tumor microenvironment. Intratumoral lymphocytes, including
tumor antigen-specific T cells, express high levels of PD-1323,324. As a result of chronic
stimulation by tumor antigens, high levels of PD-1 on T cells coincides with T cell
impaired effector function leading to exhaustion325–328. Additionally, a large frequency of
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tumors expresses PD-L1329. Engagement of PD-L1 on tumors or APCs with PD-1 on T
cells inhibits T cell proliferation, halts cytokine production, and diminishes cytotoxic
activity319. These suppressive effects can be reversed using antibodies blocking PD-1PD-L1 interactions5–7. The development of anti-PD-1 blocking antibodies has been
instrumental in advancing the field of cancer immunotherapy. Clinically, anti-PD-1
therapy has been relatively successful in treating patients with various malignancies,
including melanoma, non-small cell lung cancer, bladder cancer, renal cell carcinoma,
lymphoma, and head and neck cancers330,331.
The promising clinical and biologic responses of patients treated with anti-PD-1
in early trials resulted in the FDA approval of pembrolizumab and nivolumab in 2014
330,332

. Pembrolizumab was first approved to treat patients with advanced or

unresectable melanoma that had failed ipilimumab and a BRAF inhibitor333. Patients
achieved an overall response rate (ORR) of 26% and upon follow-up, a progression-free
survival (PFS) rate of 45% at 6 months334. Nivolumab received FDA approval in 2015 to
treat patients with treatment-refractory clear-cell renal carcinoma (RCC). Patient OS
was extended by 6 months with Nivolumab compared to oral everolimus335. In addition
to solid tumors, Pembrolizimab and Nivolumab have also received FDA approval to
treat relapsed or refractory classical Hodgkin Lymphoma with the latter reaching an
ORR of 87% and 17% complete response336–338. Results from these clinical trials
demonstrate that inhibiting PD-1 can be effective in treating a variety of tumor types.
Various pre-clinical and clinical studies have led to a better understanding of the
mechanisms by which PD-1 inhibition promotes anti-tumor responses. Anti-PD-1 mAb
treatment has been demonstrated to induce activation of CD4+ and CD8+ effector

51
memory T cells and central memory T cells and Th1 cells339. Inhibiting PD-1 can also
impact on T cell metabolism. PD-1 activation induces metabolic reprogramming
characterized by inhibiting glycolysis and increasing fatty acid oxidation340,341. Tumors
have taken advantage of these metabolic changes and out-compete T cells for glucose
intake resulting in dysfunctional effector T cells342–344. More studies are needed to better
understand the modulatory effects of anti-PD-1 mAb therapy.
Inhibitors to PD-L1/L2 have also been tested in clinical trials and Atezolizumab
received FDA approval in 2016 to treat non-small cell lung cancer (NSCLC)345,346. In
these studies, overall survival was positively associated with increased PD-L1
expression on patient tumor cells and immune cells. A second PD-L1 inhibitor,
durvalumab, received FDA approval in 2017 for patients with locally advanced or
metastatic urothelial cancer that had failed chemotherapy347. Durvalumab was granted
FDA breakthrough designation in 2018 as an adjuvant for locally advanced,
unresectable NSCLC348,349. Clinical trials treating patients with anti-PD-L1/L2 mAb show
great promise in treating patients with various cancer types.
Animal models are useful to investigate mechanisms by which the PD-1-PDL1/PD-L2 interactions affect anti-tumor immunity. However, the outcome following PD-1
blockade differs with tumor type. For example, in the weakly immunogenic B16 mouse
melanoma model, anti-PD-1 mAb alone was ineffective to improve survival or control
tumor growth350. Although B16 tumor cells do in fact express PD-L1, Juneja, et al.
reported that PD-L1 expression on tumors was not required to inhibit CD8 T cell
cytotoxic responses. In contrast, PD-L1 expression on host cells was required to inhibit
CD8 T cell responses351. Interestingly, data from the Allison lab have demonstrated that
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significant responses against B16 tumors are only achieved when anti-PD-1 mAb is
combined with GVAX (discussed in the previous section) or anti-CTLA-4 mAb
(discussed in the following section)352.
CTLA-4 targeted therapies. CTLA-4 is rapidly and transiently expressed by
activated T cells and suppresses immune responses by inhibiting IL-2 accumulation and
reducing proliferation 29. CTLA-4 engages with CD80/CD86 on antigen presenting cells
(APCs), subsequently blocking the co-stimulatory molecule CD2830,353. Additionally,
CTLA-4 is constitutively expressed on T regulatory cells (Treg)354. Monoclonal
antibodies (mAb) blocking CTLA-4, such as ipilimumab, have recently demonstrated
clinical success in treating various tumor types. In 2011, the FDA approved ipilimumab
to treat metastatic melanoma patients355. In 2015, ipilimumab was granted FDAapproval after demonstrating improved relapse-free survival and overall survival in
stage III melanoma patients355,356.
Inhibiting CTLA-4 is thought to promote anti-tumor responses through a variety of
mechanisms. Anti-CTLA-4 mAb can disrupt inhibitory signals and stimulate systemic
effector T cells. Additionally, anti-CTLA-4 mAbs can use their binding domain to engage
CTLA-4 on Tregs and the Fc domains can bind to Fc receptors (FcR) on NK cells or
macrophages leading to antibody-dependent cell cytotoxicity357. Treatment with antiCTLA-4 mAb can result in increased CD8+ T cell infiltration of tumors. Furthermore,
some studies have reported an increase in TCR diversity and anti-tumor reactivity358,359.
Anti-CTLA-4 mAb treatment can also mediate changes in peripheral and intratumoral T
regulatory cells, myeloid-derived suppressor cells, and effector T cells330. In some
studies, successful clinical responses following CTLA-4 blockade, as well as anti-PD-1,
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correlated positively with patient tumors that harbored pre-existing CD8+ T cells360,361.
Thus, therapeutic responses to immune checkpoint inhibitors might occur preferentially
in patients with a pre-existing spontaneous anti-tumor T cell response. These studies
demonstrate that, in some cancer settings, anti-CTLA-4 mAb therapy can significantly
improve anti-tumor immune response both locally in the tumor microenvironment as well
as systemically.
Pre-clinical mouse models have also demonstrated the therapeutic effects of
CTLA-4 blockade against various tumors and have been useful to investigate immune
mechanisms and combination strategies. Treatment of mice bearing colon carcinomas
with anti-CTLA-4 mAb leads to tumor regression and protection from re-challenge with
parental tumor lines362. In B16 melanoma, a notoriously aggressive and weakly
immunogenic model, anti-CTLA-4 mAb, in combination with a GM-CSF-producing
vaccine, was able to induce protective systemic anti-tumor T cell responses in a CD8+ T
cell- and NK cell-dependent manner347. In B16 melanoma, inhibiting PD-1 and CTLA-4
pathways significantly increased the ratios of CD8+ T cell: Tregs and CD4+ Teff:Tregs in
the tumor microenvironment352. Dual blockade was also accompanied by an increase in
IFN-g+ and TNFa+ CD8+ T cells in the tumor and draining lymph nodes. Additionally,
vaccination with a GM-CSF-expressing tumor cell line or anti-CTLA-4 mAb treatment
individually resulted in poor responses against established B16-BL6 tumors; however,
combination therapy led to B16 eradication in 80% of mice37. Dual treatment with antiPD-1/PD-L1 and anti-CTLA-4 mAb mediated eradication of B16 in 50% of tumorbearing mice, compared to 10-25% of mice treated with either anti-PD-1 or anti-CTLA-4
mAb monotherapy, respectivey363. Collectively, these studies demonstrate that anti-
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CTLA monotherapy can be successful in a small subset of cases, depending on the
type of malignancies; however anti-CTLA-4 mAb in combination with other checkpoint
inhibitors or vaccination therapies can significantly increase the number of responders.
Immune-related adverse events. Inhibitors to PD-1 and CTLA-4, or other
checkpoint molecules, can cause immune-related adverse events (irAEa) that generally
pertain to the gastrointestinal tract, endocrine glands, skin, liver, and to a lesser extent,
central nervous system, cardiovascular, pulmonary, and hematologic systems364. As a
consequence of mechanistic differences in how PD-1 and CTLA-4 impact T cell
responses, adverse events are usually more frequent and more severe following CTLA4 inhibition compared to PD-1-PD-L1 inhibition365. Severe autoimmunity has been
reported following systemic administration of ipilimumab, particularly when combined
with PD-1/PD-L1 inhibitors366. The first line of treatment for these severe irAEs is usually
corticosteroids or additional immunosuppressive drugs if steroids are ineffective. It is
unclear if the development of autoimmune responses is associated with clinical
response to therapy, as conflicting data have been presented. Specific adverse events
can sometimes indicate therapeutic efficacy. For example, vitiligo, a skin disorder
involving the loss of pigmentation mediated by an immune response to melanocytederived antigens, is commonly observed in melanoma patients following checkpoint
inhibitor therapy and indicative of T cell cross-reactivity against similar antigens shared
by the tumor and normal melanocytes367. In summary, immune checkpoint inhibitor
therapy can be remarkably effective in a proportion of patients with various cancers, but
immune-mediated toxicities can limit their use and are important considerations that
should be carefully assessed prior to and during therapy.
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Oncolytic Virotherapy
Oncolytic viruses (OVs) are a novel class of immunotherapy through which
natural or modified viruses specifically infect and kill tumor cells, but not normal cells368.
OVs can mediate anti-tumor responses utilizing two different mechanisms: directly
killing tumor cells and inducing immune responses. The first takes advantage of the fact
that during progression, tumor cells usually inactivate antiviral pathways, leaving them
susceptible to infection and lysis by viruses. Lysis-induced release of viral particles
propagates infection locally within the tumor microenvironment369,370. Consequently, the
release of tumor antigens in combination with stimulation of innate immunity through the
release of viral particles within the tumor microenvironment facilitates T cell crosspriming. The induction of a polyclonal T cell response serves as the second mechanism
by which OVs enhance anti-tumor immunity.
The most well-characterized oncolytic virus is an attenuated herpes simplex
virus, type I (HSV-1) that expresses human GM-CSF and is designated as tamilogene
laherparepvec (TVEC)285. In clinical trials, impressive durable responses were achieved
in melanoma patients treated with TVEC. TVEC is administered directly into the tumor.
Interestingly, regression of uninjected metastases has been observed after TVEC
treatment, suggesting the induction of endogenous tumor-specific responses. These
impressive outcomes resulted in FDA-approval of TVEC in 2015 for the treatment of
unresectable melanoma. Since then, the efficacy of several other viruses is being
evaluated in clinical trials to treat various types of cancer.
The addition of TVEC can improve the efficacy of other immunotherapies as well.
In one study, patients with unresectable metastatic melanoma receiving TVEC and
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ipilimumab had double the response rates (39%) compared to ipilimumab alone
(18%)371. Improved clinical and biologic responses have also been observed in patients
treated with the combination of TVEC and pembrolizumab372,373. Additionally,
combination treatment facilitated a T cell-inflamed tumor phenotype. Interestingly,
clinical responses did not correlate with pre-existing CD8 T cells in the tumors, generally
seen with checkpoint inhibitors alone. These results demonstrate that combination
treatment can generate anti-tumor responses without the requirement of pre-existing
anti-tumor immunity.
Adoptive Cell Therapy
Early experiments in the 1960s demonstrated that transferring cells from the
draining lymph nodes, but not non-draining lymph nodes nor spleens, of tumor-bearing
mice conferred immunity in secondary hosts374. Almost 20 years later, Berendt and
North described the rejection of established tumors following intravenous adoptive
transfer of T cells from tumor-immunized mice into thymectomized recipients,
concluding that T cells harbored both effector and suppressor functions375. However, to
achieve such robust responses, these experiments required large quantities of donor T
cells from sensitized mice. Eberlein and colleagues addressed this problem by using the
cytokine IL-2 to expand effector T cells in vitro376. Donor splenocytes that were
sensitized with tumor cells and expanded with IL-2 in vitro could eliminate local tumors
and disseminated metastases following intravenous adoptive transfer376. These
therapeutic cells were termed lymphokine-activated killer (LAK) cells. LAK cells, in
combination with recombinant IL-2, mediated the regression of established pulmonary
sarcomas in mice377,378. These promising pre-clinical results in mouse models lead to
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the first phase I clinical trial reported in 1985 in which 25 patients with metastatic cancer
received intravenous infusion of LAK cells and high dose IL-2 leading to partial
regression in almost half of the patients379,380. This process was extremely laborintensive, requiring substantial quantities of LAK cells. Additionally, LAK cells were nonspecifically activated and lacked the necessary tumor-specificity to mediate adequate
responses. This study concluded that LAK cells had the potential to generate anti-tumor
responses, but the laborious process and lack of antigen-specificity demonstrated the
need for an improved strategy.
The problem of tumor-specificity was addressed through the identification of
tumor-infiltrating lymphocytes (TIL), a subpopulation of lymphocytes found within
resected patient tumors204. Following enzymatic digestion of tumors, single cell
suspensions contained a range of 3%-74% lymphocytes that could undergo massive
expansion when maintained in IL-2381. Expanded TIL exhibited reactivity against
autologous tumors, measured by a chromium release assay, but spared normal cells382.
Pre-clinical mouse studies reported that TIL were up to 100 times more effective than
LAK cells, even in the absence of high dose IL-2, at mediating tumor regression in mice
preconditioned with cyclophosphamide383. The first trial treating metastatic melanoma
patients with TIL and IL-2 reported cancer regression in 9/15 patients that had not
received prior treatment and 2/5 patients that had previously failed IL-2 therapy384.
Proceeding trials with larger patient cohorts demonstrated a 31% overall response rate
in patients receiving TIL plus IL-2 and a 35% overall response rate when patients were
preconditioned with cyclophosphamide 36 hours before TIL and IL-2 treatment385.
Importantly, patients that had previously failed on IL-2 were capable of achieving clinical
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and biologic responses following treatment with TIL and IL-2, indicating the improved
benefits when combined with TIL.
In follow-up studies, nonmyeloablative conditioning treatment prior to infusion of
highly tumor-reactive TIL resulted in persistent clonal repopulation of T cells, with the
infused cells dividing in vivo and trafficking to tumor sites386. They not only observed
regression of metastatic melanoma lesions but also reported the development of
autoimmune melanocyte destruction. We now know that TIL composition can be
correlated with cancer prognosis in malignant melanoma, among other tumor types387.
To date, adoptive cell transfer of TIL, in combination with high-dose IL-2 and nonmyeloablative conditioning, has been clinically successful, resulting in a 40-50%
objective response rate in metastatic melanoma patients388,389.
It is now appreciated that, although autoreactive T cells should be deleted
following thymic selection, there is evidence of tumor-specific T cells that can be within
the tumor microenvironment of cancer patients; however, these tumor infiltrating
lymphocytes (TIL) are unable to effectively control tumor burden390,391. Upon further
examination, these TIL are dysfunctional or exhausted due to the suppressive nature of
the tumor microenvironment392. Albeit in low frequencies, these tumor-reactive T cells
can be identified and used to generate large numbers of tumor-specific T cells for
adoptive cellular therapy. The tumor-specific TCRa and b genes can be cloned into a
viral vector. High-titer virus can then be produced upon the transfection of packaging
and producer cell lines. The resulting viral supernatant can then be used to express the
TCR on the surface of activated T cells through viral transduction393. Through this
process, major forms of cellular therapy have risen: TCR gene-modified T cells and
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Chimeric Antigen Receptor (CAR) T cells. Adoptive cell therapy serves as a
personalized strategy to redirect the specificity of patient T cells to recognize and kill
their tumor cells.
CAR T cell therapy. Chimeric antigen receptor (CAR) T cells have been a
breakthrough tool in the field of immune-oncology and cellular therapy, particularly for
hematological malignancies. CAR T cells are composed of an extracellular antigen
recognition domain, a hinge linker, a transmembrane domain, and at least one
cytoplasmic signaling domain (Fig 4). The first description of CARs dates back to 1989
when Eshhar and colleagues generated chimeric TCR genes, which were composed of
the constant domain in order to maintain the intracellular signaling functions of the T
cell, and were fused to the antibody’s variable domains in order to direct specificity394.
The antigen specificity was conferred by the immunoglobulin-derived extracellular
single-chain variable fragment (scFv), which permitted recognition of native cell-surface
antigens, including glycolipids, carbohydrates and proteins, without the need for antigen
processing or MHC restriction. Transfection of the chimeric TCR into cytotoxic T cells
induced antigen-specific killing and IL-2 release in a non-MHC- restricted manner394. In
1993, Eshhar designed what would be referred to as first-generation CAR T cells that
consisted of antibody-derived scFv regions that recognized tumor antigens and were
linked to the intracellular signaling domain of the TCR CD3z chain (Fig 4)395.
Unfortunately, these initial CARs failed to promote T cell proliferation and survival
following constant exposure to antigen failed in vivo and were not clinically effective396.
A huge advance in CAR T cell therapy occurred after the addition of a costimulatory domain was found to improve T cell persistence and effector function.
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Figure 4. Generations of CAR T Cells. First-generation CAR T cells were
composed of a single-chain variable fragment gene that directed antigen specificity
linked to the cytoplasmic signaling domain of CD3z (represented as phosphorylated).
Second-generation CAR T cells included one co-stimulatory domain such as CD28 or
4-1BB. Third-generation CAR T cells incorporated two co-stimulatory domains.
Fourth-generation CAR T cells (or TRUCKs) added a transgene that encoded proinflammatory cytokines or a co-stimulatory molecule. Two examples of smart CARs
are depicted: suicide switch CAR T cells contain an inducible transgene that can
induce apoptotic events. Tandem CAR T cells link two scFv genes to target two
different antigens. (VL: variable light chain; VH: variable heavy chain)

Second generation CARs were designed to include one co-stimulatory domain, such as
CD28 or 4-1BB397. CD28-based signaling domains have been suggested to mediate
constitutive activation and facilitate T cell exhaustion398. In contrast, 4-1BB- based
signaling domains have been shown to reduce exhaustion and promote survival399.
However, both signaling domains are required to achieve the best results. Compared to
first-generation CARs, the addition of a co-stimulatory domain improved proliferation,
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cytokine secretion, and resistance to apoptosis400. The feasibility of second-generation
CAR T cells was confirmed in 2002 upon observation that prostate cancer antigenspecific CAR T cells survived, proliferated, and killed prostate cancer cells401. This led to
pre-clinical mouse studies that demonstrated eradication of leukemia cells in
immunodeficient mice treated with human CD19-specific CAR T cells402.
Early clinical studies treating leukemia patients with CD19 CAR T cells
demonstrated promising results403. Seminal findings from these trials included the ability
of CAR T cells to persist and mediate substantial tumor eradication and the observation
that toxicity due to cytokine storm correlated with tumor burden404.405 These promising
clinical responses paved the way for FDA designation of CAR T cells as a breakthrough
therapy in 2014. Three years later, the FDA finally approved CD19 CAR T cell treatment
for children and young adults with relapsed, refractory ALL. Since then, CD19 CAR T
cell therapy has gained approval in the treatment of certain large B cell lymphomas.
One strategy to enhance the efficacy of second-generation CAR T cells was the
inclusion of two co-stimulatory domains. The so-called third-generation CARs in
development demonstrated even better effector functions and in vivo persistence of
transferred cells400. Additional improvements, resulting in fourth-generation CAR T cells,
have included vector-incorporated transgenes that express pro-inflammatory cytokines
or co-stimulatory molecules406. Furthermore, tandem CAR T cells, which encode two
scFv domains recognizing two different antigens, are another promising strategy to
improve the efficacy of CAR T cells.
CAR T cells can be clinically effective in treating various cancer types. However,
severe toxicities have been reported in patients following treatment. One mediator of

62
toxicity can be on-target/off-tumor recognition by the introduced chimeric antigen
receptor. The first report of on-target/off-tumor toxicity using receptor-modified T cells
was reported in 2006 when patients with metastatic renal cell carcinoma received
autologous CARs targeting carbonic anhydrase IX and developed liver toxicity. Two
patients died as a result of low antigen expression in normal bile duct epithelial
tissue407. Lethal on-target, off-tumor toxicity was reported in one patient treated with
Her-2 CAR T cells. Upon further investigation, low levels of the target antigen were
detected on normal lung epithelial cells408. The outcomes from these studies illustrate
the need to carefully select antigen targets and assess expression on normal tissue to
improve the safety of CAR T cell therapy.
The most common adverse event observed following CAR T cell treatment for
hematologic malignancies is cytokine release syndrome (CRS), which is a multi-faceted
toxicity that encompasses high fever and myalgias to unstable hypertension, multiorgan system toxicity, and respiratory failure409–413. Another primary toxicity
encountered with CAR T cell therapy is neurotoxicity, which in rare cases can be severe
and even fatal414. CRS is thought of as an off-target toxicity due to its antigenindependence415. Additionally, on-target toxicities have been observed following CAR T
cell therapy. Tumor lysis syndrome is another on-target toxicity directly related to tumor
cell destruction416. CAR T cell toxicities are managed with supportive care,
corticosteroids, and tocilizumab, an anti-IL-6 therapy417. Another approach to limit CAR
T cell toxicity is to incorporate suicide genes into the CAR vector418. One example is the
inclusion of an inducible caspase-9 gene that can promote apoptosis of T cells419–421.
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Robust responses in cancer patients receiving CAR T cells can be effective, however,
the lack of regulatory mechanisms can lead to severe, and potentially fatal toxicities.
Another disadvantage to using CAR T cells to treat solid tumors is the limited
breadth of antigen specificity. Under immune-selective pressure, tumor cell variants
emerge that lost the target antigen through genetic mutation or reduced expression,
leading to failed recognition by CAR T cells. The selection for pre-existing alternatively
spliced CD19 isoforms with the compromised CAR T cell epitope is one mechanism by
which tumors escape detection by CAR T cells422. In summary, CAR T cells can be
extremely effective, particularly in hematologic malignancies; however, toxicities and
immune resistance mechanisms are important limitations to their clinical use.
Additionally, CAR T cells are often less effective against solid tumors and can result in
severe toxicities on-target, off-tumor toxicities. Some of these concerns can potentially
be addressed by alternatively using TCR gene-modified T cells, described in the
proceeding section.
TCR gene-modified T cells. Advances in the genetic engineering of T cells have
facilitated the development of large scale, highly functional, tumor-reactive T cells that
can be used to treat patients (Fig 5). In 1990, five patients with metastatic melanoma
were treated with TIL transduced to express a neomycin-resistance gene, with the goal
of monitoring the cells post-infusion 393. To further address the issue of specificity, four
years later, Shilyansky and colleagues identified T cell clonotypes with specificity to
epitopes expressed on shared melanoma tumor-associated antigens423. The following
year, Cole et al. identified and characterized a tumor-derived, antigen-specific TCR,
which was HLA-A2- restricted and recognized the melanoma antigen, MART-1424.
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Tumor-specific
T cell

Clone TCR ⍺ and β
chain genes into a
retroviral vector

Figure 5. Schematic of Adoptive Transfer of TCR Gene-Modified T Cells. Upon
identification of a tumor-specific T cell, the TCR a and b chain genes are cloned into
a retroviral vector. The retroviral vector is used to transfect a virus-producing cell line.
Supernatant containing virus is added to activated T cells isolated from the peripheral
blood of a cancer patient. T cells that express the tumor-specific TCR are purified
and expanded to large quantities. TCR gene-modified T cells are then administered
back to the patient through intravenous infusion.

Another strategy to identify tumor-reactive T cell receptors immunized mice
transgenic for HLA-A2.1 or the chimeric molecule A2.1/Kb with human p53 protein to
generate A2-restricted TCRs with specificity to p53 peptides425. There have been
tremendous advances using adoptive transfer of TCR gene-modified T cells. Upon
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identification of a tumor-reactive TCR and cloning of the alpha and beta chain genes
into a vector, activated patient T cells can be transduced to express the tumor-specific T
cell receptor. TCR gene-modified T cells can be purified and expanded to large
numbers and then infused back into the patient. In sum, the identifying functional tumorspecific TCRs has facilitated the development of new targets for a variety of cancers.
Our laboratory utilizes a TCR (referred to as the TIL 1383I TCR) isolated from a
T cell clone within a population of TIL from a tumor that was resected from a melanoma
patient426. The TIL 1383I TCR has specificity to the melanoma antigen, tyrosinase, and
is restricted by human MHC class I HLA-A2. Our lab has also conducted a phase I
clinical trial in which metastatic melanoma patients received an intravenous (i.v.)
infusion of autologous T cells transduced to express the TIL 1383I TCR. Among three
patients, one had a mixed response and developed vitiligo, and a second had a partial
response by RECIST criteria and then progressed1. After receiving high dose IL-2, this
patient developed vitiligo and entered complete remission. Immunological monitoring
analysis revealed the persistence of transferred TIL 1383I TCR transduced T cells,
which were detectable up to one year post-infusion in the responding patient1. This
study demonstrated that the adoptive transfer of autologous TIL 1383I TCR transduced
T cells can result in clinical and biologic activity without severe toxicity in metastatic
melanoma patients.
Adoptive T cell therapy, while relatively safe compared to other
immunotherapies, can have adverse events. Attempts to improve the function of tumorspecific TCR gene-modified T cells through affinity enhancement strategies have
resulted in unintended toxicities. Such adverse events can occur if a TCR mediates on-
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target/off-tumor or off-target/off-tumor effects. On-target/off-tumor reactivity occurs when
a TCR reacts against the target antigen expressed on normal tissues. In a phase II
clinical trial, patients with metastatic melanoma received infusions of autologous T cells
transduced to express one of two high avidity TCRs recognizing the melanoma antigens
MART-1 or gp100. Compared to a previous trial using a non-affinity enhanced MART-1specific TCR, patients treated with the high-affinity TCRs developed on-target
autoimmunity against normal melanocytes in the eye, inner ear, and skin427. In a
second example, the functional avidity of a TCR recognizing the carcinoembryonic
antigen (CEA) antigen was enhanced through a single amino acid substitution in the
CDR3 region of the a chain. Patients with metastatic colorectal cancer receiving
autologous TCR transduced T cells developed severe inflammatory colitis due to low
levels of CEA present in the colonic epithethium428. Additionally, off-target effects have
been observed in patients receiving an affinity enhanced, MAGE-A3-specific TCR.
Severe cardiac toxicity resulting in two deaths occurred due to TCR cross-reactivity with
an unrelated protein expressed by contracting normal cardiac tissues429. These clinical
trials demonstrate the need for improved methods to define the specificity of engineered
T cells when performing autologous systemic infusion of gene-modified T cells.
Autologous TCR gene-modified T cells are most commonly infused back into the
patient systemically, but intratumoral injections are also a feasible and effective route of
delivery. The unintended toxicities mentioned in the previous paragraph might have
been avoided if the affinity-enhanced TCR gene-modified T cells were delivered
intratumorally, as opposed to systemically. Duval et al. demonstrated the feasibility,
safety, and efficacy of intratumoral injections in a phase I dose-escalation trial using an
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irradiated, MART-1-specific TCR-transduced allogeneic T cell line (C Cure 709) to treat
metastatic melanoma lesions2. This method did not induce any treatment-related graftversus-host disease, which is a well-characterized adverse event of allogeneic
transplantation. Out of fifteen patients, one patient had a partial response,
encompassing metastatic lesions that were injected with T cells and lesions that were
uninjected. Additionally, two patients achieved local regression of injected metastatic
lesions, and two patients developed vitiligo. The authors hypothesized that, in addition
to the direct killing of MART-1+ tumor cells within the injected lesion, intratumoral
delivery of tumor-specific allogeneic T cells could induce epitope spreading through the
combination of released antigens and cytokine production. In some cases, the authors
observed acute symptoms of fever, chills, or injection site reactions that were often
followed by local tumor regression. After observing the lack of symptoms in two patients
after two cycles of treatment using the same lesion, they chose alternative lesions to
inject, which subsequently resulted in the development of injection site reactions and
tumor regression.
A follow-up study attempted to report on longitudinal immune monitoring of
treated patients. They did not detect any of the C Cure 709 cells used for injection within
the peripheral blood. They did not observe any treatment-induced increase in the
frequency of antigen-specific T cells, but they noted a stable frequency of MART-1specific T cells over the course of treatments (63-94% TEM or TEMRA) with new
clonotypes emerging during treatment. Interestingly, although only a few clonotypes
were recurrently detected in consecutive samples, one MART-1-specific T cell clone
disappearing from peripheral blood was later discovered in a metastatic lesion, which
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indicated the generation of tumor-specific T cells that could traffic to distant, uninjected
lesions430. These findings demonstrated that intratumoral delivery of allogeneic, TCR
gene-modified T cells is not only safe and feasible, but also effective, in a small subset
of patients, at generating clinical and biologic responses.
Predictive Biomarkers in Cancer Immunotherapy.
There is a great deal of interest in finding potential predictive biomarkers that
help to identify patients that are likely to respond to a specific immunotherapy regimen.
Increased accessibility to large patient data sets has significantly contributed to this
rapidly evolving area of cancer immunotherapy. While there are several biomarkers
among various tumor types, this section will focus on predictive biomarkers identified in
the peripheral blood, in the immune signature within the tumor microenvironment and
the tumor mutational load/identification of neoantigens.
Cellular analysis from the peripheral blood. The peripheral blood is a highly
accessible source to obtain substantial numbers and subsets of immune cells,
especially in circumstances where tumor lesions are inaccessible, making biopsies
difficult. Therefore, the identification of predictive biomarkers extrapolated from the
peripheral blood would be extremely beneficial. In leukemia and melanoma patients,
some studies have reported biomarkers as general as an increased absolute number of
lymphocytes in the peripheral blood. This increase in lymphocyte number positively
correlated with immunological responses or outcomes to immunotherapy431,432. At the
other end of the spectrum, advanced technologies such as CyTOF-based analysis has
revealed large networks of predictive biomarkers identified from patients before and
after treatment with PD-1 and CTLA-4 inhibitors433. One example was an increase in
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CD4+ and CD8+ memory T cells, which were associated with improved responses to
anti-CTLA-4 mAb. For anti-PD-1 mAb therapy, CD69+ and MIP1b+ NK cells in the
peripheral blood was positively associated with a clinical response433. Obtaining
peripheral blood samples is a relatively safe and easy method to identify potential
biomarkers predictive of clinical or biologic responses.
Results from clinical trials investigating the efficacy of DC-based vaccinations
have contributed to the identification of possible biomarkers predictive of clinical
outcome. The diversity of TCR repertoires has recently been investigated as a
biomarker to monitor immune responses in cancer patients434,435. Several studies have
reported positive clinical outcomes in patients that had evidence of broad CD4+ and
CD8+ T cell responses as a result of epitope spreading253,436,437. The induction of
enhanced anti-tumor immune responses suggests that immunotherapies should be
designed with the goal of inducing in vivo cross-presentation of tumor antigens and
broadening the repertoire of TCRs specific to the tumor for more effective disease
control. In support of this concept, TCR diversity and clonality can correlate with clinical
outcome after various immunotherapy treatments, including adoptive transfer of TIL and
administration of checkpoint inhibitors434,438–442. In summary, the analysis of TCR
repertoires from peripheral blood samples can be a useful predictive biomarker to
assess responses and treatment strategies.
Neoantigens and tumor mutation burden. Tumors with high mutation loads
can often be associated with the increased presentation of tumor neoantigens443.
Tumor-associated neoantigens can arise as a consequence of processed mutant
cancer peptides or aberrant self-antigens, such as EGFR, resulting from oncogenic
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protein overexpression444. Patients bearing tumors with high mutation loads often
achieve better anti-tumor responses445. These improved outcomes have been proposed
to be mediated by T cell responses against neoantigens361,446. Additionally, patients with
tumors established as deficient in mismatch repair (dMMR) or microsatellite instabilityhigh (MSI high) were more likely to respond to anti-PD-1 mAb treatment. The correlation
between dMMR or MSI high tumors and patient response was validated across twelve
different tumor types, resulting in objective radiographic responses in 53% of patients
and complete responses in 21% of patients447,448. Therefore, tumor mutation load can
be a useful predictor of outcome to immunotherapy using anti-PD-1 mAb blockade.
The relationship between neoantigen abundance, mutation load, and T cell
diversity is still unclear. In one study that used whole exome sequencing, transcriptome
profiling, and T cell repertoire analysis, the local tumor mutation burden correlated with
neoantigens and TCR repertoire, but local CD8+ T cell cytotoxicity did not correlate with
neoantigen abundance449. These findings suggest that multiparameter analysis of T cell
diversity, mutation load, neoantigen abundance, and T cell effector function might
potentially be used to predict responses.
Immune profiling the tumor microenvironment. The immune composition of
the tumor microenvironment prior to treatment can influence the response to
immunotherapy. Gene expression analysis of tumors has been used to characterize the
tumor microenvironment (TME). Through gene expression analysis, tumors can be
segregated into: T cell-inflamed, T cell-excluded, and immune desert199,450,451. T cellinflamed tumor signatures are identified by CD8+ T cell infiltration, chemokines that
promote infiltration of T cells, components involved in antigen presentation and
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expression of type I IFN genes164,165. As a result of increased IFN pathway activation,
these intratumoral CD8+ T cells often exhibit a dysfunctional phenotype characterized
by upregulation of immune inhibitory molecules including PD-1, CTLA-4, lymphocyte
activation gene protein 3 (LAG-3), T cell immunoglobulin domain and mucin domain
protein-3 (TIM-3)452,453. T cell-excluded (or non-T cell-inflamed) tumors are devoid of
CD8+ T cells and IFN gene expression. In contrast, immune desert tumors do not show
any evidence of immune cells present454. Evaluation of 30 cancer types within The
Cancer Genome Atlas (TCGA) database has confirmed the presence of these immune
phenotypes, indicating that phenotypic characterization is broadly applicable across
tumors455.
Further data support the utility of characterizing the tumor immune
microenvironment as a means of predicting response to immunotherapy. Successful
clinical responses to anti-PD-1 mAb therapy correlated with patient tumors that
harbored pre-existing CD8+ T cells, and expressed high level of interferon (IFN), IFN-ginducible genes, chemokines, and immune checkpoints, including cytotoxic T
lymphocyte antigen-4 (CTLA-4) and indoleamine 2,3-dioxygenase (IDO)456–459. Another
group reported that increased overall survival (OS) correlated with increased CD4+,
CD8+ T cells, Foxp3+ T cells, CD20+ B cells, NKp46+ cells and activated CD143+ and
CD137+ cells in the tumor tissue460. Multiparameter flow cytometry of tumor samples
from metastatic melanoma patients receiving anti-PD-1 mAb illustrated that high levels
of PD-1 and CTLA-4 on CD8+ T cells were associated with better clinical responses461.
Tumor PD-L1 expression has been one of the most predictive determinants that
correlate with response to anti-PD-1 mAb therapy and is indicative of an active immune
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response in the tumor microenvironment 330. However, PD-L1 expression is highly
variable and heterogeneous leading to some hesitation to rely on quantitative
expression using immunohistochemistry as a reliable means of patient selection for
therapy462. Additionally, the frequency of T regulatory cells, in relation to CD8+ T cells, in
the tumor can also serve as a biomarker. Patient tumors with high Foxp3+: CD8+ T cell
ratios have been demonstrated to correlate with better survival in multiple cancer
types463–467. In summary, immunological changes in the peripheral blood, tumor
microenvironment signatures, and tumor mutational burden can contribute to the
identification and understanding of immune signatures to enhance the efficacy of
immunotherapy.
Concluding Remarks
Cancer immunotherapies have shown great promise in the treatment of various
malignancies. A vast majority of immunotherapies aim to improve T cell function or
induce anti-tumor T cell responses. The ACT of TCR gene-modified T cells has been a
rapidly developing and promising strategy to treat various tumor types. Clinical and
biologic responses have been observed following the ACT of autologous TCR genemodified T cells, but there is still a need to improve the frequency and durability of
responses. In patients receiving monospecific immunotherapy, poor response rates or
high relapse rates are commonly observed. Contributing factors include immune-escape
tumor variants that can arise through target antigen downregulation or MHC allele loss.
Additionally, the tumor microenvironment is highly suppressive, and adept at excluding
effector T cells or inhibiting effector functions. As a result, designing T cell-based
immunotherapies that induce a broad T cell response (epitope spreading) or improve
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the persistence and function of the transferred T cells within the suppressive
microenvironment is critical to improving clinical and biologic responses in cancer
patients.
The experiments described in this dissertation aim to improve the anti-tumor
responses elicited by TCR gene-modified T cells used for immunotherapy. Generally,
autologous patient T cells isolated from the peripheral blood are transduced to express
a tumor antigen-specific TCR followed by enrichment and expansion and then infused
intravenously back into the patient. To facilitate the interaction of transferred TCR genemodified T cells with tumor cells, we proposed to administer transduced T cells directly
into the tumor. We developed an animal model utilizing subcutaneous B16 A2/Kb mouse
melanoma tumors. B16 A2/Kb tumor cells express the tyrosinase antigen in the context
of HLA-A2 (A2), which permits recognition by T cells transduced to express the HLA-A2
(A2)-restricted TIL 1383I TCR.
We concluded that intratumoral delivery of TIL 1383I TCR transduced T cells
prolonged survival and suppressed the growth of B16 A2/Kb tumors. To favorably
modulate the TME and counteract immune suppression, we employed an alternative
strategy and expressed the TIL 1383I TCR on allogeneic, as opposed to syngeneic,
donor T cells. We rationalized that the inflammatory allogeneic response would combat
the immunosuppressive tumor microenvironment. We discovered that anti-tumor
responses were further improved if TIL 1383I TCR T cells were derived from allogeneic,
rather than autologous or syngeneic, donor mice. This mouse model also allowed us to
assess the capacity of TIL 1383I TCR transduced T cell treatment to minimize the risk
of immune escape, which was measured by the detection of B16-reactive endogenous
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T cells. TIL 1383I TCR transduced allogeneic T cells were potent inducers of antigen
cross-presentation that resulted in endogenous T cell-mediated protection against
distant, untreated tumors. In conclusion, we demonstrate that the tumor-specific
reactivity induced by the introduced TCR and alloreactivity mediated by anti-donor graft
responses within the tumor microenvironment synergize to enhance the efficacy of T
cell-based immunotherapy.

CHAPTER TWO
MATERIALS AND METHODS
Cell Lines, Media, and Reagents
T2, RMA/S, EL-4, EL-4 A2 and Phoenix Ecotropic (ECO) cell lines were obtained
from the American Type Culture Collection (Rockford, MD). Human T2 cells are TAP
deficient and therefore cannot load their own peptide onto MHC class I. These T2 cells
were used as stimulator cells for T cell functional assays. The murine T2 equivalent is
the RMA/S cell line. RMA/S cells were used as H-2b-restricted targets to assess cross
priming. T2 and RMA/S cells were maintained in RPMI 1640 supplemented with 10%
FBS (Atlanta Biologicals, Atlanta, GA). Phoenix E cells were maintained in Iscoves
DMEM with 10% FBS.
B16 and B16 A2/Kb melanoma cells were a kind gift from the lab of Dr. Jose
Guevara-Patino at Loyola University of Chicago Health Science campus, Maywood, IL.
EL-4, EL-4 A2, and B16 tumor cells were maintained in DMEM supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, GA, USA), 100 U/mL
penicillin, 100 µg/mL streptomycin (Invitrogen, Grand Island, NY). The same media was
used for B16 A2/Kb tumors with the addition of 1 mg/mL G418 (InvivoGen, San
Diego,CA). One day prior to use in in vitro functional assays, 100 ng/mL mouse
recombinant IFN-g (PeproTech, NJ, USA) was added to B16 A2/Kb cells. All medium
components were obtained from Corning Life Sciences (Corning, NY), unless otherwise
noted.
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Mice
HLA-A2 transgenic, BALB/c, C3H, and NSG A2 mice were obtained from The
Jackson Laboratory and bred in house maintained under specific pathogen-free
conditions. All animal experiments were performed in accordance with the National
Institutes of Health Guidelines and approved by Loyola University Institutional Animal
Care and Use Committee.
Transduction of Mouse T Cells
Three days prior to transduction, Phoenix-E cells were seeded at 4x106 in a 10
cm tissue culture dish (Falcon, Corning, NY) in 10 mL Iscoves DMEM with 10% FBS
and incubated in a humidified chamber at 37°C with 5% CO2. The next day, Phoenix-E
cells were transfected with 18 µg of vector DNA (Aldevron, Fargo, ND), Lipofectamine
2000 (Invitrogen, Grand Island, NY) and OPTI-MEM (Gibco, Waltham, MA) and
incubated overnight. The day after transfection, the Phoenix-E media is replaced with
Iscoves DMEM/10% FBS/ 4mM sodium butyrate and incubated in a humidified chamber
at 37°C with 5% CO2 overnight. Two days prior to transduction, spleens from HLA-A2
transgenic (syngeneic) and BALB/c (allogeneic) mice were harvested and mechanically
disrupted over a 70 µm cell strainer (Falcon, Corning, NY) using the back of a 3 mL
syringe (BD biosciences, San Jose, CA). The red blood cells were lysed with Ack lysis
buffer (Lonza, Alpharetta, GA, USA). After washing and counting, mouse T cells were
enriched using the Pan T Cell Isolation Kit II (Miltenyi Biotec) and activated with antiCD3/anti-CD28 Dynabeads (Gibco). T cells were then seeded in 24 well tissue culture
plates at 1x106/mL in 2 mL per well with IL-2 (20 IU/mL) and IL-15 (50 ng/mL) and
incubated at 37°C with 5% CO2 for 48 hours. On the day of transduction, virus was
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collected and filtered with a 0.45 µm PES syringe (Millipore, Ontario, Canada). T cells
were collected and the anti-CD3/anti-CD28 magnetic activating beads were removed
using a DynaMag. T cells were resuspended in viral supernatant containing 8 µg/mL of
hexadimethrine bromide (polybrene, Sigma) and seeded at 1x106/mL in 24 well tissue
culture plates. Cells were spun at 1000xg for 2 hours at 32°C. Following the spin, plates
were removed and incubated in a humidified chamber for 2-4 hours at 37°C with 5%
CO2. Cells were collected and cultured in mouse media with IL-2 (20 IU/mL) and IL-15
(50 ng/mL) and incubated at 37°C with 5% CO2. Media was refreshed every 2 days.
Transduction efficiency was assessed 48-72 hours later by flow cytometry.
Mouse T cells were maintained in RPMI supplemented with 10% heat-inactivated
fetal bovine serum (Atlanta Biologicals, GA, USA), 10 mM HEPES, 2 mM L-glutamine
(Invitrogen, Grand Island, NY USA), 100 U/mL penicillin, 100 µg/mL streptomycin
(Invitrogen, Grand Island, NY USA), non-essential amino acids (Invitrogen, Grand
Island, NY USA) and 50 µM 2-mercaptoethanol (Sigma), referred to as mouse media.
For maintain mouse T cells in culture, mouse media was supplemented with 20 IU/mL
IL-2 (Novartis Pharmaceuticals Corporation, East Hanover, NJ) and 50 ng/mL IL-15
(Biological Resources Branch, National Cancer Institute, Frederick, MD).
Tumor Challenges and Treatment
B16 and B16 A2/Kb tumor cells were cultured in T-175cm2 flasks (Corning Life
Sciences, Corning, NY) at 37°C with 5% CO2 to reach 80% confluency on the day of
tumor injection. The hind flanks of the mice were shaved at least one day prior to
injection. Mice subcutaneously received 2.5x105 (B16 A2/Kb) or 1x105 (B16) cells in 100
µl PBS in the right flank of 6-12 week old HLA-A2 transgenic mice. Tumor area was
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measured 2-3 times weekly and calculated as the product of two opposing diameters.
Tumor-bearing mice were sacrificed when the tumor area reached >150mm2 or >10%
body weight.
When tumors were clearly palpable, HLA-A2 transgenic mice were randomly
divided into treatment groups (n=4-5/group). Mice under inhalatory isoflurane
anesthesia were intratumorally treated on day 10 post-tumor inoculation with TIL 1383I
TCR transduced allogeneic, TIL 1383I TCR transduced syngeneic, or untransduced
allogeneic T cells in 50 µl PBS. Intratumoral injections were performed using 31G
ultrafine insulin needles. Transduction efficiency was assessed by Vb12 and GFP
expression. For TIL 1383I TCR transduced allogeneic and TIL 1383I TCR transduced
syngeneic treatment, HLA-A2 transgenic mice received approximately 8x106 total T
cells, after adjusting for transduction efficiency. Untransduced allogeneic T cell treatedmice received the same number of total T cell as TIL 1383I TCR transduced allogeneic
T cell-treated mice.
For experiments using checkpoint inhibitors, where indicated, tumor-bearing
HLA-A2 transgenic mice received 200 mg/kg i.p of anti-PD-1 mAb (clone RPM1-14,
BioCellX) or anti-CTLA-4 mAb (clone 9H10, BioCellX) or isotype control administered
intraperitoneally on day 10 post-B16 A2/Kb inoculation. Immune checkpoint inhibitor
treatment continued throughout the experiment and were administered intraperitoneally
every 3-4 days until the completion of the experiment. For experiments testing the TLR3
agonist, HLA-A2 transgenic mice received 50 µg polyinosinic:polycytidylic acid (Poly
I:C) (InVivogen, San Diego, CA) in 50µl PBS by intratumoral injection on day 11 postB16 A2/Kb inoculation .
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Tissue Preparation
Spleens, lymph nodes, and tumors were harvested and maintained in mouse
media (described above). Single cell suspensions of tumors were obtained using the
Miltenyi Biotec (Bergisch Gladbach, Germany) tumor dissociation kit II and collected in
gentleMACS C tubes, then dissociated using gentleMACS Dissociator. Following
dissociation, single cell suspensions of tumors were incubated in a humidified incubator
at 37°C and 5% CO2 for 30 minutes and then passed through a 70 µM cell strainer. For
tumors harvested 2 days post- T cell treatment, cells were washed and stained
immediately. For tumors harvested 7 days post-T cell treatment, cells were layered in a
40%/80% percoll (GE Healthcare) gradient and centrifuged for 25 minutes at 800 x g at
25°C with no brake. Cells at the interphase were collected, washed twice, and
proceeded for staining. Spleens and lymph nodes were mechanically disrupted using
the plunger of a 3 mL syringe over a 70 µm cell strainer. Red blood cells were lysed with
ACK lysis buffer (Lonza, Alpharetta, GA, USA). Cells were then washed twice, counted
and stained with antibodies for flow cytometric analysis, or used for functional assays.
Peptides
Mouse melanoma peptides that were used for in vitro and in vivo functional
assays were synthesized and high-performance liquid chromatography (HPLC) purified
by GenScript (Piscataway, NJ, USA) at >95% purity. Mouse H-2b peptides (gp10025-33
EGSRNQDWL and TRP-2180-188 SVYDFFVWL) were dissolved in 100% dimethyl
sulfoxide (DMSO, Sigma-Aldrich) and stored at a concentration of 5 µg/µL at 80°C.
Peptides were used at a concentration of 10 µg/mL.
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Intracellular Cytokine/Degranulation Bifunctional Assay
To assess in vitro and in vivo cytokine production, we used intracellular cytokine
or degranulation functional assays. CD107a expression was used as a surrogate
marker for lytic function. Peptide-loaded T2 cells, B16, and B16-A2/Kb cells were used
as targets and TIL 1383I TCR transduced mouse T cells were used as effector cells. T2
cells were pulsed with 10µg/mL peptide for 2 hours at 37°C in a 5% CO2 humidified
incubator. After two washes with RPMI, 3 x 105 T cells were co-cultured with 3 x 105
target cells in 96 well U-bottom tissue culture plates at 37°C for 5 hours in the presence
of 250 ng anti-CD107a mAb, 5 ng/mL brefeldin A (BioLegend), and 2 nM monensin
(Biolegend). After 5 hours, the cells were stained with antibodies (described below) for
20 minutes at room temperature. Cells were fixed, permeabilized, and stained with antiIFN-g, anti-GM-CSF, anti-TNF-a , and anti-IL-2 cytokine antibodies (described below)
according to manufacturer’s protocols (Biolegend). Flow cytometry was performed using
a BD LSRII FACSAria and analyzed using FlowJo software.
Antibody Staining and Flow Cytometry
To characterize immune cell populations, we used antibody staining followed by
flow cytometry. Antibodies were used at the concentrations recommended by the
manufacturer. Antibodies were purchased from BioLegend, unless otherwise indicated:
anti- CD3e (clone 145-2C11), CD4 (clone GK1.5), CD8a (clone 53-6.7), CD11c (clone
N418), CD11b (clone M1/70), CD205 (clone NLDC-145), CD80 (clone 16-10A1), CD86
(clone GL-1), CD103 (clone 2E7), I-A/I-E (clone M5/114.15.2), CD62L (clone MEL-14),
CD44 (clone IM7), CD69 (clone H1.2F3), CD25 (clone 3C7), CD152 (clone UC10-4B9),
FOXP3 (clone MF-14), PD-1 (clone 29F.1A12), TIM-3 (clone RMT3-23), PD-L1 (clone
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10F.9G2), PD-L2 (clone TY25), CXCR3 (clone CXCR3-173), CD107a (clone 1D4B),
IFN-g (clone XMG1.2), IL-2 (clone JES6-5H4), TNF-a (clone MP6-XT22), GM-CSF
(clone MP1-22E9), TGF-b/LAP (clone TW7-16B4), IL-10 (clone JES5-16E3), IL-17A
(clone TC11-18H10.1), IL-22 (clone Poly5164), H-2Dd (clone 34-2-12), H-2Db (clone
KH95), human HLA-A2 (clone BB7.2), human TCR VB12 (Beckman Coulter, REF
IM2291 clone). Intracellular IFN-g and IL-2 staining was performed using the
cytofix/cytoperm kit (BD Biosciences) according to manufacturer’s protocol. LIVE/DEAD
Aqua fixable viability dye was purchased from Miltenyi Biotec (Auburn, CA, USA).
Tetramers were provided by the NIH Tetramer Core Facility, Atlanta, GA). CD8
alpha antibody clone KT15 was used when tetramer staining was performed. Cells were
stained in PBS containing 2% bovine serum albumin for 20 minutes at room
temperature. For intracellular markers, cells were fixed and permeabilized using
eBioscience Foxp3/Transcription Factor Staining Buffer set according to manufacturer’s
protocol. Flow cytometry was performed using an LSRFortessa flow cytometer (BD
Biosciences) and data were analyzed with FlowJoX software (Treestar, Ashland, OR).
Detection of IFN-g Secreting Cells by ELISPOT Assays
IFN-g production by tumor-specific T cells isolated from the tumor draining lymph
nodes and spleens of treated mice was measured by IFN-g ELISPOT assays (BD
biosciences). ELISPOT plates (BD component No. 51-2447KC) were coated with 5
µg/mL (final concentration) of purified anti-mouse IFN-g antibody and incubated
overnight at 4°C. After washing the plates, 1-2x105 cells from the tumor draining lymph
nodes or spleens were added and cocultured 1:1 with tumor targets (B16, B16 A2/Kb,
EL4, EL4 A2) or peptide (gp10025-33, TRP-2180-188; 10 µg/mL)-pulsed RMA/S cells for 18
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hours. After extensive washing, 2 µg/mL (final concentration) of biotinylated anti-mouse
IFN-g detection antibody was added for 2 hours. Streptavidin-HRP (1:100) was added
for one hour and spots were developed with 2-Amino-9-ethylcarbazole (AEC) substrate
solution (BD biosciences). Plates were dried in the dark overnight and spots were
enumerated automatically using an ELISOPT plate reader (CTL cellular technology
limited, Immunospot).
In Vivo Cytotoxicity Assay
Target cells were prepared from the spleens of C57Bl/6 mice, as described
above. Splenocytes were pulsed 10 µg/mL TRP-2180-188 or gp10025-33 peptides for 2
hours in a humidified chamber at 37°C with 10 µg/mL TRP-2180-188 or gp10025-33. Target
splenocytes were washed twice with PBS, divided into 3 groups: no peptide, TRP2180188,

or gp10025-33, and labeled with 15 µM, 5 µM, or 0.5 µM CellTraceTM CFSE dye

(Thermofisher, Molecular Probes), respectively. After 10 minutes of incubation at 37°C,
30 mL of complete media was added to quench the CFSE and further incubated for 10
minutes. Cells were washed twice and counted. 3x106 cells from each target group
were combined 1:1:1, centrifuged at 1200 rpm for 5 minutes, and resuspended in 200 µl
of PBS. CFSE-labeled target cells were then retro-orbitally injected into recipient HLAA2 transgenic mice 8 days post-intratumoral treatment when the induction of effector T
cells had been observed. A group of naïve HLA-A2 transgenic mice (n=3, no tumor, no
treatment) injected with CFSE-labeled target cells were used as a control. The following
day, the spleens of recipient HLA-A2 transgenic mice were harvested and analyzed by
flow cytometry. Cells were gated on the CFSE+HLA-A2- population and 50,000 events
were collected. Specific lysis was calculated using the formula:
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Percent specific lysis= [1- (naïve control ratio/experimental mice ratio)] x 100. Results
are presented as % Killing.
Vector Construction
To co-express the TIL 1383I TCR and extracellular LIGHT domain, a DNA gene
block with the sequence of the LIGHT extracellular domain was synthesized from
Genscript (Piscataway, NJ) and ligated into the pCR2.1-TOPO TA vector with EcoRI
(Thermo Scientific, Grand Island, NY), T4 DNA ligase and buffer (New England Biolabs,
Ipswich, MA). Recombinant DNA was transformed into E. coli TOP10 competent cells
(Invitrogen) and plated on LB ampicillin plates (25 g LB agar (Fisher, Hampton, NH) in 1
L deionized water supplemented with 100 µg/mL ampicillin (Sigma-Aldrich) and colonies
were grown in superbroth (32 g Tryptone (Fisher), 20 g yeast extract (Fisher), and 5 g
NaCl (Fisher) in 1 L deionized water) with 100 µg/mL ampicillin (Sigma-Aldrich)).
Plasmid DNA from recombinant clones was extracted using a Miniprep Plasmid
Isolation Kit (Qiagen, Hilden, Germany) according to manufacturer’s protocol and then
screened for LIGHT gene insertion by restriction enzyme digest using EcoRI (Thermo
Scientific, Grand Island, NY).
After running the product on a 1% agarose gel, DNA bands corresponding to the
LIGHT gene product were purified using a Gel purification kit (Qiagen) according to
manufacturer’s protocol. Next, LIGHT DNA was subcloned into the pMIG TIL 1383I TCR
mCherry retroviral vector with compatible EcoRI restriction sites. DNA was ligated into
the vector using T4 DNA ligase and buffer (New England Biolabs, Ipswich, MA), with
vector DNA and insert DNA in a 1:5 ratio and was incubated at 16°C overnight. The
next day, ligation products were transformed into TOP10 competent E.coli and DNA
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was extracted (Qiagen). The DNA was then sequenced (Genewiz, South Plainfield, NJ)
to confirm final product.
Sequence of the LIGHT extracellular domain:
CGAAGGTCTCACGAGGTCAACCCAGCAGCGCATCTCACAGGGGCCAACTCCAGCT
TGACCGGCAGCGGGGGGCCGCTGTTATGGGAGACTCAGCTGGGCCTGGCCTTCC
TGAGGGGCCTCAGCTACCACGATGGGGCCCTTGTGGTCACCAAAGCTGGCTACTA
CTACATCTACTCCAAGGTGCAGCTGGGCGGTGTGGGCTGCCCGCTGGGCCTGGC
CAGCACCATCACCCACGGCCTCTACAAGCGCACACCCCGCTACCCCGAGGAGCT
GGAGCTGTTGGTCAGCCAGCAGTCACCCTGCGGACGGGCCACCAGCAGCTCCCG
GGTCTGGTGGGACAGCAGCTTCCTGGGTGGTGTGGTACACCTGGAGGCTGGGGA
GAAGGTGGTCGTCCGTGTGCTGGATGAACGCCTGGTTCGACTGCGTGATGGTACC
CGGTCTTACTTCGGGGCTTTCATGGTGTGA.
Purified LIGHT recombinant protein was purchased from Sino Biological (Wayne,
Pennsylvania, USA). On day 10 post-B16 A2/Kb tumor inoculation, HLA-A2 transgenic
mice received intratumoral TIL 1383I TCR transduced T cells and recombinant LIGHT
protein in PBS.
Statistical Analysis
All results were analyzed with Prism (GraphPad software, Inc San Diego, CA).
Statistical significance was determined with a regular one-way ANOVA with Tukey
correction. Where indicated, statistical significance was determined using unpaired
student’s t test. Survival and B16 tumor-free graphs were presented using the KaplanMeier plots with significance determined by the log-rank (Mantel-Cox) test. Data
represent means +/- SEM. P<0.05 was considered statistically significant. *P<0.05,
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**P<0.01, ***P<0.001, ****P<0.0001. All experiments were performed at least twice to
ensure consistency.

CHAPTER THREE
INTRATUMORAL DELIVERY OF TIL 1383I TCR TRANSDUCED T CELLS EXTENDS
SURVIVAL AND SUPPRESSES B16 A2/Kb TUMOR GROWTH
TIL 1383I TCR Transduced Mouse T Cells Recognize
B16 A2/Kb Tumors In Vitro
The TCR used in these studies was obtained from a tumor infiltrating lymphocyte
(TIL) clone (1383I) that recognizes the tyrosinase368-376 peptide in an HLA-A2-restricted
manner, referred to as TIL 1383I TCR468. The retroviral vector contains the TIL 1383I
TCR a and b chain genes followed by a green fluorescent protein (GFP) gene, linked by
self-cleaving 2A-like sequences (Fig 6A). Following retroviral transduction, TIL 1383I
TCR+ T cells can be identified through the expression of GFP and an antibody against
the TCR b chain (anti-Vb12) using flow cytometry (Fig 6B). Two days before
transduction, T cells isolated from the spleens of mice were enriched for CD3 using
magnetic labeling and activated with anti-CD3/anti-CD28 beads. This selection method
resulted in ³95% CD3+ T cells (Table 1). We transduced cells by spinoculation and
assessed for TCR expression after 3-4 days. We routinely achieved ³45% CD4+GFP+
Vb12+ and CD8+GFP+ Vb12+ transduced T cells (Table 1). The final population of TIL
1383I TCR transduced T cells usually favored CD8+ T cells (~55%) over CD4+ T cells
(~30%; Table 1). These experiments demonstrated that we could obtain relatively pure
populations of mouse CD3+ T cells, which were ³45% GFP+Vb12+ TCR+ cells.
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Transduced (Td)

VB12

Vβ12

Untransduced (UnTd)

TIL 1383I TCRTransduced (Td)

GFP
GFP
Figure 6. Expression of the TIL 1383I TCR on Mouse T Cells. A) The retroviral
vector containing the TIL 1383I TCR a and b genes linked by a P2A self-cleaving
peptide segment followed by a T2A-linked GFP gene. B) Representative flow
cytometry plots of GFP and Vb12 expression on untransduced (UnTd, left panel) or
TIL 1383I TCR transduced (Td, right panel) T cells. CD3-enriched splenocytes were
activated with anti-CD3/anti-CD28 DynaBeads for 48 hours. Activated T cells were
resuspended in supernatant containing the retrovirus with 8 µg/mL polybrene. T cells
were then transduced by spinoculation for 2 hours at 32°C. T cells were then
resuspended in fresh mouse media with IL-2 (20 IU/mL) and IL-15 (50 ng/mL) and
maintained in a humidified incubator at 37°C. Three to four days post-transduction, T
cells were analyzed for expression of GFP and Vb12 by flow cytometry. Gated on
CD3+ T cells. LTR: long terminal repeat; y: packaging signal; SD: splice donor; SA:
splice acceptor; GFP: green fluorescent protein.
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+

%CD3
%CD4+
%CD4+Vb12+GFP+
%CD8+
%CD8+Vb12+GFP+

Transduced Syngeneic
96 ± 0.96
31 ± 2.7
64 ± 4.7
56 ± 2.92
49 ± 4.25

Transduced Allogeneic
96 ± 1.14
37 ± 3.2
57 ± 4.07
54 ± 3.19
50 ± 3.98

Table 1. Phenotype of TIL 1383I TCR Transduced T Cells. Enrichment of T cells
isolated from the spleens by immunomagnetic separation resulted in ³95% CD3+ T
cells. Three to four days after transduction, T cell were analyzed for expression of
CD3, CD4, CD8, Vb12, and GFP by flow cytometry. Generally, the population of TIL
1383I TCR transduced T cells was comprised of more CD8+ T cells. Numerical
values represent mean ± SEM (n=25). No statistical differences were observed
between syngeneic and allogeneic T cells.

We first assessed the antigen-specific functional phenotypes of TIL 1383I TCR
transduced T cells. T cells isolated from syngeneic HLA-A2 transgenic mice were
transduced to express the TIL 1383I TCR. TIL 1383I TCR transduced syngeneic T cells
were co-cultured with B16 or B16 A2/Kb tumor targets for 5 hours and then analyzed by
flow cytometry for expression of extracellular CD107a, a surrogate marker for cytotoxic
degranulation, and intracellular cytokines: GM-CSF, IL-2, TNF-a, and IFN-g. As
expected, CD8+ (gated on CD3+GFP+) TIL 1383I TCR transduced syngeneic T cells
were highly reactive against B16 A2/Kb tumor cells (Fig 7A, right panel, blue bars), but
not the parental B16 line (Fig 7A, left panel, blue bars).
We observed a substantial frequency of TIL 1383I TCR transduced syngeneic T
cells expressing the lytic marker, CD107a (44.55 ± 5.850%), as well as IFN-g (32.833 ±
2.210%) and TNF-a (38.93 ± 8.392%) cytokines in response to B16 A2/Kb tumors.
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Additionally, TIL 1383I TCR transduced syngeneic T cells expressed IL-2 (12.12 ±
3.471%) and GM-CSF (17.067 ± 3.023%) when co-cultured with B16 A2/Kb (Fig 7A,
right panel, blue bars). TIL 1383I TCR transduced allogeneic T cells had similar
frequencies of CD107a+ cells (gated on CD3+GFP+CD8+) when stimulated with B16
A2/Kb targets (50 ± 1.2%; P=0.4578) and similar frequencies of T cells expressing IFN-g
(26.367 ± 1.489%; P=0.0722), TNF-a (45.033 ± 7.841%; P=0.6234), IL-2 (12.667 ±
1.386%; P=0.8908) and GM-CSF (14.667 ± 1.592%; P=0.5212) (Fig 7B, red bars).
These results demonstrate that expression of the TIL 1383I TCR on CD8+ T cells from
syngeneic or allogeneic donors confers similar functional phenotypes against B16 A2/Kb
tumors and does not elicit tumor-specific responses or alloresponses against B16 in
vitro.
The TIL 1383I TCR is CD8-independent; therefore, transduced CD4+ T cells also
have the capacity to recognize B16 A2/Kb tumors. We examined the functional
phenotype of CD3+CD4+GFP+ T cells in response to tumor targets (Fig 7B, blue bars).
TIL 1383I TCR transduced syngeneic CD4+ T cells stimulated with B16 A2/Kb cells (Fig
7B, right panel, blue bars) resulted in expression of CD107a (34.3% ± 11.9), IFN-g
(10.347% ± 3.713), TNF-a (16.733% ± 4.191), IL-2 (7.320% ± 2.209), and GM-CSF
(7.133% ± 2.313). We also observed comparable functional phenotypes in CD4+ TIL
1383I TCR transduced allogeneic T cells, which expressed CD107a (30.07 ± 3.93%);
P=0.7679), IFN-g (6.613 ± 3.387%; P=0.4988), TNF-a (19.767 ± 7.829%; P=0.7498), IL2+ (7.967 ± 3.353%; P=0.8799), and GM-CSF (5.317 ± 2.618%; P=0.6305) cells (Fig
7D, red bars). As expected, TIL 1383I TCR transduced syngeneic CD4+ T cells did not
recognize B16 tumors, which lack HLA-A2 (Fig 7B, left panel, blue bars). These results
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indicated that CD4+ T cells expressing the TIL 1383I TCR are highly functional against
B16 A2/Kb, but not B16 tumors.
In addition to examining reactivity against whole B16 and B16 A2/Kb tumor cells,
we also tested the capacity of TIL 1383I TCR transduced syngeneic T cells and TIL
1383I TCR transduced allogeneic T cells to recognize the tyrosinase368-376 peptide
presented by T2 antigen presenting cells (APCs). We also tested recognition against an
irrelevant negative control peptide, gp100209-217. As expected, significant frequencies of
TIL 1383I TCR transduced syngeneic CD8+ T cells expressed CD107a+ (65.25% ±
0.650), IFN-g (49.2% ± 5.092), TNF-a (59.067% ± 5.843), IL-2 (25.067% ± 3.227), and
GM-CSF (29.533% ± 7.835) after stimulation with tyrosinase368-376 -pulsed T2 cells (Fig
8A, right panel, blue bars). In contrast, TIL 1383I TCR transduced syngeneic CD8+ T
cells did not recognize the negative control gp100209-217 peptide (Fig 8A, left panel, blue
bars), confirming antigen specificity.
We observed similar results when investigating the ability of TIL 1383I TCR
transduced allogeneic T cells to recognize tyrosinase368-376 peptide-pulsed T2 cells.
CD8+ TIL 1383I TCR transduced allogeneic T cells were also highly reactive against
tyrosinase368-376 peptide-pulsed T2 cells, and similar frequencies of CD107a+ (75% ±
7.2), IFN-g+ (41.4% ± 9.3), TNF-a+ (62.3% ± 11.9), IL-2+ (25% ± 6.1), an GM-CSF+
(26.2% ± 11.2) cells were observed compared to TIL 1383I TCR transduced syngeneic
T cells (Fig 8B, red bars). Additionally, TIL 1383I TCR transduced syngeneic CD4+ T
cells were highly reactive when co-cultured with tyrosinase368-376 peptide-pulsed T2 APC
cells, and expressed CD107a+ (29.7 ± 17.2%), IFN-g (10.4 ± 3.01%), TNF-a (45.7 ±
5.0%), IL-2 (25.6 ± 8.4%), and GM-CSF (9.9 ± 4.8%) (Fig 8B, right panel, blue bars).
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Figure 7. TIL 1383I TCR Transduced T Cells Recognize B16 A2/Kb Tumors. B16 or
B16 A2/Kb tumors were co-cultured 1:1 with 300,000 TIL 1383I TCR transduced
mouse T cells derived from the spleens of syngeneic HLA-A2 transgenic mice (blue
bars) or allogeneic BALB/c mice (red bars) for 5 hours. Cells were collected and
examined for expression of CD3, CD4, CD8, GFP, CD107a, IFN-g, TNF-a, IL-2, and
GM-CSF by flow cytometry. 50,000 CD3+ events were recorded. A) Reactivity of
CD3+CD8+GFP+ T cells in response to B16 (left panel) or B16 A2/Kb (right panel)
tumors. B) Reactivity of CD3+CD4+GFP+ T cells in response to B16 (left panel) or B16
A2/Kb (right panel) tumors. No statistically significant differences in functional markers
were observed between syngeneic and allogeneic donor T cells using the student’s t
test.
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Figure 8. TIL 1383I TCR Transduced T Cells Recognize Tyrosinase368-376
Peptide. T2 cells were pulsed with 10 ug/mL peptide for 2 hours in a humidified
incubator at 37°C and then cocultured 1:1 with 300,000 TIL 1383I TCR transduced
mouse T cells that were derived from the spleens of syngeneic HLA-A2 transgenic
mice (blue bars) or allogeneic BALB/c mice (red bars). After 5 hours, co-cultures
were analyzed for expression of CD3, CD4, CD8, GFP, CD107a, IFN-g, TNF-a, IL-2,
and GM-CSF by flow cytometry. 50,000 CD3+ events were recorded. A) Reactivity of
CD3+CD8+GFP+ T cells in response to gp100209-217-pulsed (left panel) or
tyrosinase368-376-pulsed (right panel) T2 cells. B) Reactivity of CD3+ CD4+ GFP+ in
response to gp100209-217-pulsed (left panel) or tyrosinase368-376-pulsed (right panel)
T2 cells. No statistically significant differences in functional markers were observed
between syngeneic and allogeneic T cells using the student’s t test.
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We confirmed antigen-specificity by the lack of reactivity of T cells isolated from
the tumor draining lymph nodes of treated mice against the gp100209-217 peptide (Fig 8B,
left panel, blue bars). TIL 1383I TCR transduced allogeneic CD4+ T cells were also
highly reactive to the tyrosinase368-376 peptide, but not statistically different from TIL
1383I TCR transduced syngeneic T cells. TIL 1383I TCR transduced allogeneic CD4+ T
cells expressed CD107a (30.05% ± 16.65), IFN-g (4.973% ± 0.713), TNF-a (39% ±
8.358), IL-2 (24.1% ± 6.974), and GM-CSF (4.417% ± 1.016) cells (Fig 8D, red bars).
Neither TIL 1383I TCR transduced allogeneic nor syngeneic CD4+ or CD8+ T cells were
reactive against gp100209-217- pulsed T2 cells (Fig 8A and C, red and blue bars). These
in vitro results indicated that both TIL 1383I TCR transduced syngeneic and allogeneic
T cells were equally polyfunctional against B16 A2/Kb tumors in vitro. In general,
stimulating TIL 1383I TCR transduced T cells with tyrosinase368-376-pulsed T2 cells
resulted in a higher frequency of functional T cells compared to stimulation with B16
A2/Kb tumors. The increased antigen-specific reactivity observed with T2 cells can likely
be attributed to their TAP deficiency, which prevents the presentation of endogenously
synthesized antigens and permits saturation with peptides loaded exogenously. Results
from these in vitro experiments demonstrated that TIL 1383I TCR transduced syngeneic
T cells were polyfunctional, producing IL-2, GM-CSF, IFN-g, and TNF-a and exhibiting
cytolytic activity (CD107a+) when stimulated with B16 A2/Kb tumors, but not B16 tumors.
Intratumoral Treatment with TIL 1383I TCR Transduced Allogeneic T Cells
Improves Survival and Suppresses B16 A2/Kb Tumor Growth in Mice
Previous pre-clinical mouse studies demonstrated that i.v. infusion of TIL 1383I
TCR transduced HLA-A2 transgenic T cells, in combination with tyrosinase368-376
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peptide-loaded dendritic cells (DCs) and high dose IL-2, prevented growth of
established subcutaneous B16 A2/Kb tumors in syngeneic HLA-A2 transgenic mice469.
In patients with metastatic melanoma, i.v. infusion of TIL 1383I TCR transduced T cells
has resulted in clinical and biological responses, exhibited by tumor regression and
vitiligo, respectively; however, this route of delivery imposes additional barriers that
could limit therapeutic efficacy470. Factors such as instability and inefficient trafficking in
vivo can restrict the ability of transferred T cells to persist long enough to reach primary
or metastatic lesions471–474. These are critical barriers, as the persistence of transferred
tumor-specific T cells has been documented to correlate with clinical or biologic
responses in some patients386,475. Furthermore, tumor cells exhibit a highly
immunosuppressive microenvironment that can prevent the transferred T cells from
accumulating effectively in the tumor and executing effector functions476–479. As a result,
we aimed to directly modulate the tumor microenvironment in order to improve the
chances of effector-tumor cell interactions.
We attempted to eliminate the requirement for transferred T cells to traffic to and
infiltrate tumors utilizing an alternative strategy by which TIL 1383I TCR transduced T
cells are delivered intratumorally, as opposed to systemically (Fig 9). This method not
only bypasses the requirement of the transferred T cells to traffic to the tumor but also
facilitates immediate and direct tumor cell interactions. TIL 1383I TCR transduced T
cells exhibited cytolytic activity (CD107a+) and produced IFN-g and TNF-a; therefore,
we anticipated that TIL 1383I TCR transduced T cells would induce tumor-specific killing
and cytokine production, leading to the regression of B16 A2/Kb tumors in vivo.
Furthermore, we hypothesized that if the TIL 1383I TCR were expressed on T cells
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derived from MHC-mismatched allogeneic donors, as opposed to syngeneic donors,
then the endogenous T cells present in the recipient would mount an alloresponse
against the donor T cells and promote potent immune cell activation within the tumor,
thus converting an immunosuppressive microenvironment into an immune-active
microenvironment.
Substituting allogeneic donor T cells for syngeneic donor T cells can lead to two
potential alloresponses within the tumor microenvironment. First, recipient endogenous
T cells could recognize allogeneic MHC molecules expressed on the donor T cells and
mount an anti-donor cell alloresponse locally in the injected tumor. Second, the
endogenous TCR expressed on the transferred donor T cells could recognize recipient
MHC molecules and mount an anti-recipient cell alloresponse within the tumor. In either
scenario, the potent immune activation and cytokine production induced by alloreactivity
between MHC-mismatched donor T cells and recipient cells could alter the tumor
immune microenvironment. The human HLA-A2-restricted TIL 1383I TCR could
potentially mediate a xenogeneic response against mouse H-2b MHC-expressing cells.
We found this unlikely since xenoresponses are much weaker than alloresponses and
are not mounted as rapidly480. We hypothesized that the cytokine profiles induced by
the allogeneic response would promote the maturation and licensing of intratumoral
dendritic cells (DCs). Concurrently, TIL 1383I TCR-mediated tumor-specific killing can
induce the release of tumor antigens, and these exogenous tumor antigens can be
phagocytosed by DCs that are present in the tumor (Fig 9). The mature, licensed DCs
that have captured exogenous tumor antigens can then traffic to the tumor draining
lymph node and, cross-present tumor-derived antigens and prime endogenous T cells.
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Figure 9. Proposed Model to Enhance the Efficacy of Adoptive Transfer of TCR
Gene-Modified T Cells for Cancer Immunotherapy. Intratumoral delivery of
allogeneic T cells transduced to express a tumor-specific TCR can lead to tumor
killing and cytokine production, mediated by the tumor-specific TCR, and additional
immune stimulation, mediated by alloreactivity. Within the tumor, cytokine-stimulated
mature DCs can 1. internalize released tumor antigens, 2. traffic to tumor draining
lymph nodes, and cross-present tumor antigens to endogenous T cells. 3. Systemic
tumor-specific T cells with specificities to additional tumor antigens can induce further
therapeutic or protective immune responses.
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Figure 10. Experimental Design to Determine If Intratumoral Treatment with TIL
1383I TCR Transduced T Cells Induces Regression of B16 A2/Kb Tumors. HLAA2 transgenic recipient mice were subcutaneously inoculated with 2.5 x 105 B16
A2/Kb tumor cells. Ten days later, B16 A2/Kb tumors were intratumorally injected with
1) TIL 1383I TCR transduced syngeneic T cells 2) TIL 1383I TCR transduced
allogeneic T cells 3) untransduced allogeneic T cells or 4) PBS/untreated. Survival
and tumor area were monitored. Mice were sacrificed when tumors reached >150
mm2 or >10% body weight.

T cell cross-priming, which is the generation of systemic, endogenous T cells
with specificities to additional melanoma antigens (different than the initial target,
tyrosinase and termed epitope spreading) could provide therapeutic responses against
primary tumor lesions and protective responses against distant, untreated tumor
lesions. In summary, the tumor-specificity and alloreactivity of TIL 1383I TCR
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transduced allogeneic T cells can improve the efficacy of adoptive cell transfer using
TCR gene-modified T cells for cancer immunotherapy.
We compared the effect of intratumoral delivery of TIL 1383I TCR transduced
syngeneic T cells to TIL 1383I TCR transduced allogeneic T cells against B16 A2/Kb
tumors in vivo (Fig 10). HLA-A2 transgenic mice were used as recipients to receive
2.5x105 B16 A2/Kb tumor cells subcutaneous. After ten days, when tumors reached
approximately 4 mm in one diameter, mice were intratumorally treated with a single
dose of TIL 1383I TCR transduced syngeneic or allogeneic (GFP+VB12+) T cells, or
untransduced (GFP-VB12-) allogeneic T cells or saline/PBS, as negative controls.
We monitored the survival of mice and measured tumor growth every 2-3 days following
intratumoral T cell treatment. B16 A2/Kb tumor-bearing mice intratumorally injected with
saline succumbed to tumor burden within three weeks post-treatment (Fig 11, black line;
median survival: 13 days). Tumor-bearing mice treated with untransduced allogeneic T
cells also succumbed to tumor burden within three weeks after T cell treatment (Fig 11,
green line; median survival: 15 days), indicating that the allogeneic response alone did
not improve survival compared to saline-treated mice (ns, P=0.1830). In contrast,
intratumoral injection of TIL1383I TCR transduced syngeneic T cells significantly
extended survival compared to treatment with PBS (P<0.0001) or untransduced
allogeneic T cells (P=0.0005; Fig 11, blue line; median survival: 21 days). Strikingly,
mice intratumorally treated with TIL 1383I TCR transduced allogeneic T cells (red line)
exhibited the best survival outcomes among treatment group (median survival: 28 days;
Fig 11). TIL 1383I TCR transduced allogeneic T cells significantly extended survival
compared to treatment with TIL 1383I TCR transduced syngeneic T cells (P=0.0005),
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untransduced allogeneic T cells (P<0.0001), and PBS (P<0.0001). These results
demonstrated that the TIL 1383I TCR was required to prolong survival compared to
PBS and untransduced allogeneic T cell treatment, and the allogeneic response
synergized with the tumor-specific T cell response to improve the survival of mice
treated with TIL 1383I TCR transduced allogeneic T cells compared to mice treated with
TIL 1383I TCR transduced syngeneic T cells.
We also compared B16 A2/Kb tumor progression in individual mice. B16 A2/K2
tumors at the time of treatment are 15-20 mm2, however because B16 A2/K2 is such an
aggressive tumor model, we did not frequently observe complete regression. We
therefore wanted to demonstrate the ability of intratumoral TIL 1383I TCR transduced T
cells to control tumor burden. In order to visualize the ability to control tumor growth, we
chose to draw a line at the tumor area measurement 50 mm2. We felt this was an
intermediate-size tumor which could represent treatment-induced control of B16 A2/Kb
tumor growth, visualized by mice that maintained tumor areas below the dotted line.
B16 A2/Kb tumors treated with PBS or untransduced allogeneic T cells grew rapidly (Fig
12, black and green lines, respectively). Mice bearing B16 A2/Kb tumors that were
treated with TIL 1383I TCR transduced syngeneic (blue) T cells exhibited delayed tumor
growth compared to tumors treated with PBS (black) or untransduced allogeneic T cells
(green). The most effective control of B16 A2/Kb tumor growth occurred after
intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells (red). We
consistently observed improved survival and tumor control in mice treated with TIL
1383I TCR transduced allogeneic compared to syngeneic T cells over four independent
experiments (Fig 12, solid, dashed, dotted, and dashed-dotted lines).
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Figure 11. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Extends
Survival of B16 A2/Kb Tumor-Bearing Mice. HLA-A2 transgenic mice received
2.5x105 B16 A2/Kb cells subcutaneously and 10 days later received an intratumoral
injection with TIL 1383I TCR transduced syngeneic T cells (blue), TIL 1383I TCR
transduced allogeneic T cells (red), untransduced allogeneic T cells (green) or saline
(black). A) Survival of tumor-bearing mice following intratumoral treatment. Mice were
sacrificed when tumors reached >150 mm2 or >10% body weight. Data represent a
compilation of 4 independent experiments, 4-5 mice/group B) Statistical analysis was
performed using the Log Rank (Mantel-Cox) test (***P<0.001, ****P<0.0001).
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Figure 12. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Suppresses
B16 A2/Kb Tumor Growth. B16 A2/Kb tumor-bearing HLA-A2 transgenic mice were
intratumorally treated on day 10 and tumor area was measured using a digital caliper
2-3 times weekly and calculated as the product of opposing diameters. Solid, dotted,
dashed, and dash/dot lines represent individual mice from 4 independent
experiments with 4-5 mice/group. Dotted line at 50 mm2 serves as a reference for the
capacity TIL 1383I TCR transduced T cells to control tumor burden. Mice were
sacrificed when tumors reached >150 mm2 or >10% body weight. Data represent a
compilation of 4 independent experiments, 4-5 mice/group
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Figure 13. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Delays
Progression of B16 A2/Kb Tumors. A) Average B16 A2/Kb tumor growth obtained
from individual mice shown in Figure 11. Data represent 4 independent experiments
(4-5 mice/group) B) Linear regression analysis of data represented in A. C) Graphical
analysis comparing the slope between treatment groups. Data points represent the
mean slope ± SEM D) Statistical analysis performed using one-way ANOVA with
Tukey’s correction [*P<0.05, **P<0.01, ****P<0.0001].
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These results indicated that TIL1383I TCR transduced allogeneic T cells enhanced the
anti-tumor responses in comparison to TIL 1383I TCR transduced syngeneic T cell
treatment.
We wanted to use a second approach to re-evaluate the comparison of B16
A2/Kb tumor growth curves more qualitatively to effectively illustrate the ability of TIL
1383I TCR transduced T cells to control tumor burden compared to the control
treatment groups. For this approach, we averaged the B16 A2/Kb tumor growth curves
from the individual mice seen in Figure 12 and performed linear regression analysis.
This method allowed us to obtain the slope of B16 A2/Kb tumor growth following
intratumoral T cell treatment (Fig 13A and B). We then compared the slopes of B16
A2/Kb tumor growth among the different T cell treatment groups (Fig 13C and D).
B16 A2/Kb tumors from PBS-treated mice rapidly progressed over three weeks and,
consequently, resulted in the highest slope (7.063 ± 0.4290).The slope of B16 A2/Kb
tumor growth following intratumoral treatment with untransduced allogeneic T cells was
slightly, but not significantly, lower (5.890 ± 0.3920) than PBS treatment (P=0.0648; Fig
13C and D). Treatment with TIL 1383I TCR transduced syngeneic T cells significantly
delayed progression of B16 A2/Kb tumors (4.457 ± 0.2643) compared to treatment with
untransduced allogeneic T cells (P=0.0152) and PBS (P<0.0001). Injection with TIL
1383I TCR transduced allogeneic T cells resulted in the best inhibition of tumor growth,
demonstrated by the lowest slope (2.784 ± 0.1537), in comparison to TIL 1383I TCR
transduced syngeneic T cells (P=0.0033), untransduced allogeneic T cells (P<0.0001),
and PBS (P<0.0001). These results indicated that comparing the slope of B16 A2/Kb
tumor growth after intratumoral treatment represented an additional method to evaluate
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the effects of T cell treatment on tumor progression. Furthermore, survival outcomes
and tumor suppression were significantly enhanced with TIL 1383I TCR transduced
allogeneic T cells compared to TIL 1383I TCR transduced syngeneic T cells.
Improved Anti-Tumor Responses Following TIL 1383I TCR Transduced Allogeneic
T Cell Treatment Requires an Intact Recipient Immune System
Intratumoral delivery of allogeneic TIL 1383I TCR modified T cells provided an
improvement in anti-tumor immunity in vivo. One possibility is that TIL 1383I TCR
transduced allogeneic T cells induced alloresponses against B16 A2/Kb tumor cells,
resulting in more robust cytokine production within the tumor. However, our in vitro
functional assays argue against this hypothesis (Fig 7 and Fig 8). Syngeneic and
allogeneic donor T cells expressing the TIL 1383I TCR displayed similar polyfunctional
phenotypes when stimulated with B16 A2/Kb tumor cells in vitro, but it is possible that
there were differences in other cytokines not tested in the in vitro assay. However, TIL
1383I TCR transduced allogeneic T cells were more effective than TIL 1383I TCR
transduced syngeneic T cells at suppressing the growth of B16 A2/Kb tumors. In the in
vivo tumor setting, there is the potential to mount two types of immune responses: the
first can occur upon TIL 1383I TCR-mediated recognition of B16 A2/Kb tumors, resulting
in polyfunctional T cell responses. Second, allogeneic donor T cells can initiate a local
inflammatory alloresponse. TIL 1383I TCR transduced syngeneic and allogeneic T cells
share the same TCR and are capable of inducing tumor antigen-specific responses, but
only the latter provides the additional host anti-donor alloresponse.
To determine if the synergy of alloresponses and tumor-specific responses
contributed to the extended survival and delayed tumor growth observed in mice treated
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with TIL 1383I TCR transduced allogeneic T cells, we eliminated the potential for host
anti-donor alloresponses using immunodeficient recipient mice. The immunodeficient
NSG A2 mouse strain is on an HLA-A2 and non-obese diabetic (NOD) background that
results in defective macrophages, DCs, and natural killer (NK) cells 481 Additionally,
NSG A2 mice have impaired development of mature lymphocytes, as a result of a
homozygous severe combined immunodeficiency (SCID) mutation, and mpaired
cytokine signaling and NK cell development due to the IL2rgnull mutation482. Without
functional lymphocytes and myeloid-lineage cells, NSG A2 recipients are incapable of
mounting alloresponses.
We compared survival of mice and B16 A2/Kb tumor growth following treatment
with TIL 1383I TCR transduced syngeneic and allogeneic T cells. Strikingly, we
observed identical survival outcomes of NSG A2 mice treated with TIL 1383I TCR
transduced allogeneic T cells (Fig 14, red line) compared to TIL 1383I TCR transduced
syngeneic T cells (dotted blue line, P=0.7261; Fig 14). Furthermore, both TIL 1383I TCR
transduced syngeneic and TIL 1383I TCR transduced allogeneic T cell treatment
significantly extended survival compared to untransduced allogeneic T cell treatment
(P<0.0001 and P=0.0001, respectively) and PBS (P<0.0001). We also observed equal
capacities of TIL 1383I TCR transduced syngeneic and allogeneic T cells to control B16
A2/Kb tumor growth (P=0.9676; Fig 15). These results suggest that in the absence of
recipient immunity, treatment with TIL 1383I TCR transduced allogeneic T cells no
longer provide an advantage over TIL 1383I TCR transduced syngeneic T cells.
The contribution of the alloresponse was further probed through linear regression
analysis of B16 A2/Kb tumor growth following intratumoral T cell treatment (Fig 16A). In
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NSG A2 recipient mice, the slope of B16 A2/Kb growth following intratumoral treatment
with TIL 1383I TCR transduced allogeneic T cells (slope: 1.866) was no longer
significantly lower than the slope of B16 A2/Kb tumor growth following intratumoral
treatment with TIL 1383I TCR transduced syngeneic T cells (slope: 2.205, P=0.2327;
Fig 16B). These results suggest that the recipient-mediated alloresponse contributes to
anti-tumor responses exhibited by prolonged survival and delayed tumor progression.
During an alloreactive response, host CD4+ and CD8+ T cells can initiate an
inflammatory allogeneic immune response that ultimately leads to host T cell-mediated
graft rejection77. Consistent with graft rejection, we were unable to detect TIL 1383I TCR
transduced allogeneic T cells, which were identified by the expression of GFP using
flow cytometry, in the tumors of intratumorally T cell-treated immunocompetent HLA-A2
transgenic recipient mice by seven days post-T cell treatment (Fig 17).Therefore, we
predicted that the TIL 1383I TCR transduced allogeneic donor T cells would not be
eliminated in the immunocompromised NSG A2 recipient mice, which do not have the
capacity to mount effective alloresponses against introduced allogeneic donor T cells.
We detected TIL 1383I TCR transduced syngeneic T cells and TIL 1383I TCR
transduced allogeneic T cells in the tumors of NSG A2 recipient mice up to 22 days
post-T cell treatment (Fig 18). Taken together, these data support our hypothesis that
the recipient anti-donor T cell immune alloresponse, which could occur through
recognition of foreign allogeneic donor T cells, improves upon the efficacy of
intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells compared to
TIL 1383I TCR transduced syngeneic T cells.
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Figure 14. TIL 1383I TCR Transduced Allogeneic T Cell-Treated NSG A2 Mice
Have Similar Survival Outcomes Compared to TIL 1383I TCR Transduced
Syngeneic Mice. NSG A2 mice received 2.5x105 B16 A2/Kb cells subcutaneously
and ten days later were treated with A) saline (black), untransduced allogeneic T
cells (green), TIL 1383I TCR transduced syngeneic T cells (dotted blue), or TIL 1383I
TCR transduced allogeneic T cells (red). Mice were sacrificed 22 days post-T cell
treatment for further analysis or when tumors reached >150 mm2 or >10% of body
weight. Graph represents 2 independent experiments with 5-6 mice per group. B)
Statistical analysis performed using the Log Rank (Mantel-Cox) test (***P<0.001,
****P<0.0001)
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Figure 15. TIL 1383I TCR Transduced Syngeneic and Allogeneic T Cells Have
Equal Capacities to Suppress B16 A2/Kb Tumors in NSG A2 Recipient Mice
NSG A2 mice received 2.5x105 B16 A2/Kb cells subcutaneously and ten days later
were treated with saline (black), untransduced allogeneic T cells (green), TIL 1383I
TCR transduced syngeneic T cells (blue), TIL 1383I TCR transduced allogeneic T
cells (red). Mice were sacrificed 22 days post-T cell treatment for further analysis or
when tumors reached >150 mm2 or >10% of body weight. Solid and dotted lines
represent individual mice from 2 independent experiments with 5-6 mice/group.
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Figure 16. Linear Regression Analysis of B16 A2/Kb Tumor Growth in NSG A2
Mice After TIL 1383I TCR Transduced T Cell Treatment. A-B) Linear regression
analysis of B16 A2/Kb tumor growth group averages from mice shown in Figure 15.
C) Comparison of the slope among treatment groups. Graph represents two
independent experiments with 5-6 mice/group. Data points represent the mean slope
± SEM. D) Statistical analysis performed using one-way ANOVA with Tukey’s
correction [****P<0.0001].
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Figure 17. TIL 1383I TCR Transduced T Cells are Undetectable in the Tumors
from Immunocompetent HLA-A2 Transgenic Recipient Mice. B16 A2/Kb tumors
were isolated seven days post-intratumoral T cell treatment and examined for the
presence of cells expressing CD3, CD8, and Vb12 by flow cytometry. Representative
flow cytometry plots are shown. Cells are gated on live CD3+ cells.
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Figure 18. TIL 1383I TCR Transduced T Cells Persist in the Tumors from
Immunodeficient NSG A2 Recipient Mice. NSG A2 recipient mice were inoculated
with 2.5x105 B16 A2/Kb tumor cells and ten days later, received intratumoral
treatment with A) TIL 1383I TCR transduced syngeneic T cells (left panel gated on
CD3+ CD4+ cells, right panel gated on CD3+ CD8+ cells ) or B) TIL 1383I TCR
transduced allogeneic T cells (left panel gated on CD3+ CD4+ cells, right panel gated
on CD3+ CD8+ cells ). Twenty-two days post-T cell treatment, B16 A2/Kb tumors were
isolated and cells were examined for expression of CD3, CD4, CD8, H-2d and Vb12
by flow cytometry. Representative flow cytometry plots are shown.
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Summary
The transplantable B16 melanoma model is one of the most commonly used
mouse models in immuno-oncology and has greatly contributed to the identification and
manipulation of actionable immune checkpoints that can be targeted therapeutically.
Additionally, B16 has been used to evaluate the efficacy and mechanism of action of
combination treatment strategies. B16 is a notoriously aggressive and weakly
immunogenic tumor model, characterized by low MHC class I expression and minimal
responsiveness to intravenous adoptive transfer of CTL for treatment of subcutaneously
implanted tumors454. While these features are limitations in modeling human melanoma,
B16 is a stringent test for the feasibility and efficacy of immunotherapeutic strategies.
We observed a significant extension of survival in B16 A2/Kb tumor-bearing mice
treated with TIL 1383I TCR transduced syngeneic T cells by intratumoral delivery
compared to untreated mice or untransduced allogeneic T cell-treated mice.
Survival was further improved after intratumoral delivery of TIL 1383I TCR
transduced allogeneic T cells. B16 A2/Kb tumors treated with TIL 1383I TCR transduced
allogeneic T cells also displayed a significant reduction in growth compared to tumors
treated with TIL 1383I TCR transduced syngeneic T cells. B16 A2/Kb tumors treated
with untransduced allogeneic T cells did not exhibit any delay in tumor progression
compared to untreated tumors, indicating that the TIL 1383I tumor-specific TCR was
required for B16 A2/Kb tumor suppression and that the alloresponse alone was
insufficient for tumor control. Furthermore, intact recipient immune systems were
required to mediate the enhanced anti-tumor responses observed with TIL 1383I TCR
transduced allogeneic T cells.
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Following intratumoral delivery of TIL 1383I TCR transduced allogeneic T cells,
B16 A2/Kb tumors regressed within 1-3 days, sometimes accompanied by peri-tumor
inflammation. We observed complete tumor regression in approximately 20% of mice
treated with TIL 1383I TCR transduced allogeneic T cells compared to <10% of mice
treated with TIL 1383I TCR transduced syngeneic T cells. After intratumoral treatment,
individual B16 A2/Kb tumors varied in size and morphology (Fig 19) as a result of either
tumor regression or progression, as treatment resulted in tumor necrosis and ulceration.
Therefore, we performed only one intratumoral injection for the purposes of
reproducibility and consistency in measuring tumor development. In summary,
intratumoral injection of TIL 1383I TCR transduced allogeneic T cells significantly
extends survival and suppresses tumor growth in B16 A2/Kb tumor-bearing mice.
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Figure 19. Representative Pictures of Treated B16 A2/Kb Tumors Seven Days
Post-T Cell Treatment. B16 A2/Kb tumor-bearing mice were treated with A) PBS B)
untransduced allogeneic T cells C) TIL 1383I TCR transduced syngeneic T cells or D)
TIL 1383I TCR transduced allogeneic T cells. Pictures were taken at seven days
post-T cell treatment.

CHAPTER FOUR
INTRATUMORAL DELIVERY OF TIL 1383I TCR TRANSDUCED ALLOGENEIC T
CELLS STIMULATES DENDRITIC CELL RESPONSES
Characterization of Dendritic Cells in the Tumor Microenvironment
From the experiments performed in Chapter Three, we concluded that
intratumoral treatment with TIL 1383I TCR transduced allogeneic T cell treatment
extended survival and delayed tumor progression in B16 A2/Kb tumor-bearing HLA-A2
transgenic immunocompetent mice. Based on the NSG A2 data, the improved antitumor responses induced by TIL 1383I TCR transduced allogeneic, compared to
syngeneic, T cells required functional myeloid- and lymphoid-lineage cells in the treated
recipient. Additionally, TIL 1383I TCR transduced T cell recognition of B16 A2/Kb tumor
targets in vitro resulted in robust cytokine production and surface expression of
CD107a, indicative of cytolytic activity. The in vitro cytokine response was dominated by
TNF-a and IFN-g, which are two cytokines reported to stimulate dendritic cells
(DCs)483,484. Therefore, we next investigated whether intratumoral treatment with TIL
1383I TCR transduced T cells altered DC frequencies, co-stimulatory molecule
expression, or DC subsets in the tumor. We observed similar frequencies of CD11c+
MHCII+ conventional DCs (cDCs) in the tumors isolated from untreated mice (9.48 ±
1.01%) and mice treated with untransduced allogeneic T cells (10.27 ± 1.09%), TIL
1383I TCR transduced syngeneic T cells (9.2 ± 1.06%), and TIL 1383I TCR transduced
allogeneic T cells (9.83 ± 1.27%) two days post-intratumoral T cell treatment (Fig 20).
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Figure 20. CD11c+MHCII+ Dendritic Cells in the Tumor Microenvironment
Two Days Post-T Cell Treatment. Two days following intratumoral T cell
treatment, B16 A2/Kb tumors were harvested and cells were analyzed for the presence
of CD11c+MHCII+ DCs by flow cytometry. A) Representative flow cytometry plots
of CD11c+ and MHCII+ cells from B16 A2/Kb tumors. Cells were gated on single,
live cells. B) Percentage of CD11c+MHCII+ dendritic cells in the tumor
microenvironment. Symbols (Circles, squares, and triangles) represent individual mice
from 3 independent experiments (n=4-5 mice/group). No statistical significance was
detected by one-way ANOVA.

However, we observed a significant increase in the frequency of CD11c+ MHC II+ DCs
expressing the co-stimulatory molecule, CD80, in B16 A2/Kb tumors treated with TIL
1383I TCR transduced syngeneic T cells compared to tumors from untreated mice
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(P=0.0003; Fig 21A and C). Interestingly, B16 A2/Kb tumors from mice treated with
untransduced allogeneic T cells and TIL 1383I TCR transduced allogeneic T cells had
the highest increase in CD80+ DCs (P<0.0001) compared to tumors isolated from
untreated mice. Additionally, the cell surface levels of CD80, as assessed by mean
fluorescence intensity (MFI), were significantly higher on DCs isolated from tumors
treated with TIL 1383I TCR transduced allogeneic T cells (P<0.0001) and untransduced
allogeneic T cells (P<0.00010) compared to DCs from untreated tumors (Fig 22),
supporting enhanced DC activation. DCs from TIL 1383I TCR transduced syngeneic T
cell-treated tumors also had significantly higher surface expression of CD80 compared
to untreated mice (P=0.0008). Interestingly, we observed a large frequency of CD11c
negative MHC class II positive in the T cell-treated tumors, which might indicate the
presence of macrophages, but would have to be tested further. This suggested that
both the tumor-specific response and the allogeneic response promoted the activation
of intratumoral CD11c+MHC II+ antigen presenting cells, while the tumor-specific TCR
was required for the suppression of tumor growth.
We next wanted to determine if TIL 1383I TCR transduced allogeneic T cell
treatment promoted the induction of specialized antigen cross-presenting DC subsets.
CD103+ DCs, or Batf3-lineage DCs, are critical for recruiting effector T cells to the tumor
microenvironment as well as cross-presenting skin-derived antigens in the draining
lymph node485. The frequency of CD103+ DCs was significantly increased in the tumors
that were intratumorally treated with TIL 1383I TCR transduced allogeneic T cells (9.43±
1.37%) compared to the TIL 1383I TCR transduced syngeneic T cell-treated (4.9 ±
0.66%, P=0.0152) tumors or untreated tumors (5.14 ± 1.03%; P= 0.021; Fig 23).
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Figure 21. Expression of Co-Stimulatory Molecules on CD11c+ MHC II+ Dendritic
Cells in the Tumor Two Days Post-T Cell Treatment. B16 A2/Kb tumors were
harvested two days post-T cell treatment and cells were analyzed for expression of
CD11c, MHC class II, CD80 and CD86 by flow cytometry. Cells were gated on live,
CD11c+MHCII+ cells. Symbols (circles, squares, and triangles) represent individual
mice from three independent experiments. Graph shows mean ± SEM; statistical
analysis by one-way ANOVA with Tukey’s correction (***P<0.001, ****P<0.0001)
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Figure 22. Surface Expression of Co-Stimulatory Molecules on CD11c+ MHC II+
Dendritic Cells in the Tumor Two Days Post-T Cell Treatment. B16 A2/Kb tumors
were harvested two days post-T cell treatment and cells were analyzed for
expression of CD11c, MHC class II, CD80 and CD86 by flow cytometry. Cells were
gated on live, CD11c+MHCII+ cells. Results from one representative experiment are
shown, out of three experiments with similar results. Graph shows mean ± SEM;
statistical analysis by 2way ANOVA with Tukey’s correction (*P<0.05, ***P<0.001,
****P<0.0001)
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Figure 23. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Increases the
Frequency of CD103+Dendritic Cells in the Tumor Two Days Post-T Cell
Treatment. B16 A2/Kb tumors were harvested two days post-T cell treatment and
cells were analyzed for expression of CD103 by flow cytometry. Cells were gated on
live, CD11c+MHCII+CD11b-. Symbols (circles and squares) represent individual mice
from two independent experiments. Graph shows mean ± SEM; statistical analysis
by one-way ANOVA with Tukey’s correction (*P<0.05)
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These results suggested that intratumoral treatment with TIL 1383I TCR transduced
allogeneic T cells promoted the accumulation of migratory CD103+ DCs in the tumor
microenvironment two days post-T cell treatment.
Within the tumor, we observed a large portion of CD11c+MHCII+ DCs expressing
the endocytic receptor, CD205, which facilitates antigen cross-presentation (Fig 24)150.
We detected the highest frequency of CD205+ CD11c+MHCII+ DCs in tumors from mice
treated with TIL 1383I TCR transduced allogeneic T cells (67.37 ± 2.38%) in
comparison to mice treated with untransduced allogeneic T cells (60.32 ± 2.56%,
P=0.1744) and TIL 1383I TCR transduced syngeneic T cells (55.29 ± 2.51%,
P=0.0062). Untreated tumors had significantly lower frequencies of CD205+
CD11c+MHCII+ DCs (42.73 ± 3.21%) compared to untransduced allogeneic T cells (P=
0.0001), TIL 1383I TCR transduced syngeneic T cells (P= 0.0085), and TIL 1383I TCR
transduced allogeneic T cells (P<0.0001). These results indicated that intratumoral
treatment with TIL 1383I TCR transduced allogeneic T cells increased the frequency of
intratumoral CD205+ DCs and CD103+ DCs, two subsets that excel in antigen crosspresentation.
Characterization of Dendritic Cells in the Tumor Draining Lymph Nodes
The induction of tumor antigen-specific T cell responses requires that DCs that
have acquired tumor antigens then traffic to the tumor draining lymph nodes where they
can present antigen in the context of MHC class I, engage co-stimulatory molecules,
and cross-prime CD8+ T cells. Therefore, we next examined the tumor draining lymph
nodes two days post-intratumoral T cell treatment for the presence of activated DCs, as
well as the specialized antigen cross-presenting DC subsets observed in the tumor.
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Figure 24. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Increases the
Frequency of CD205+ CD11c+ MHC II+ Dendritic Cells in the Tumor Two Days
Post-T Cell Treatment. B16 A2/Kb tumors were harvested two days post-T cell
treatment and cells were analyzed for expression of CD205. Cells were gated on live,
CD11c+MHCII+ cells. Symbols (circles, squares, and triangles) represent individual
mice from three independent experiments. Graph shows mean ± SEM; statistical
analysis by one-way ANOVA with Tukey’s correction (**P<0.01, ***P<0.001,
****P<0.0001).
Two days following intratumoral T cell treatment, we isolated the tumor draining lymph
to determine if intratumoral treatment with TIL 1383I TCR transduced T cell resulted in
the migration of DCs from the tumor environment to the tumor draining lymph nodes.
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Indeed, there was a significant increase in the frequency of CD11c+ MHC II+
conventional DCs (cDCs) in the tumor draining lymph nodes of TIL 1383I TCR
transduced allogeneic T cell-treated mice compared to mice treated with TIL 1383I TCR
transduced syngeneic T cells (P= 0.005) and untreated mice (P<0.0001; Fig 25B-C).
There was also a significant increase in the frequency of CD11c+ MHC II+ DCs in the
tumor draining lymph nodes of mice treated with untransduced allogeneic T cells
compared to untreated mice (P=0.0204). These data suggested that both the anti-tumor
and alloresponses promoted DC accumulation in the tumor draining lymph nodes early
after T cell treatment.
We also observed an increased frequency of CD86-expressing CD11c+ MHC II+
DCs in the tumor draining lymph nodes of mice following intratumoral treatment with TIL
1383I TCR transduced allogeneic T cells compared to intratumoral treatment with TIL
1383I TCR transduced syngeneic T cells (P= 0.0036) and no treatment (P= 0.0133; Fig
26A). The number of cDCs expressing the co-stimulatory molecules CD80 or CD86 in
the tumor draining lymph nodes were significantly greater in the TIL 1383I TCR
transduced allogeneic T cell-treated mice compared to the tumor draining lymph nodes
of mice that were treated with TIL 1383I TCR transduced syngeneic T cells (P<0.001),
untransduced allogeneic T cells (P=0.0001), and untreated mice (P<0.0001; Fig 26B).
Moreover, the surface level of CD80 on CD11c+ MHC II+ DCs was generally highest in
TIL 1383I TCR transduced allogeneic T cell treated mice (Fig 27). Collectively, these
results indicated that intratumoral treatment with TIL 1383I TCR transduced allogeneic
T cells promoted the accumulation of CD11c+ MHC II+ DCs expressing high levels of costimulatory molecules in the tumor draining lymph nodes.
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Figure 25. TIL 1383I TCR Transduced Allogeneic T Cells Induce the
Accumulation of CD11c+ MHCII+ Dendritic Cells in the Tumor Draining Lymph
Nodes Two Days Post-T Cell Treatment. Mice were intratumorally treated on day
10 and two days later the tumor draining lymph nodes were harvested and analyzed
for expression of CD11c, MHC class II, CD80, and CD86 by flow cytometry. A)
Representative flow cytometry plots of CD11c+MHCII+ DCs. B) Absolute number of
cells isolated from the tumor draining lymph node. C) Frequency and D) Absolute
number of CD11c+ MHC II+ DCs. Cells were gated on live, singlet cells. Squares and
circles represent individual mice from 2 independent experiments. Graph shows
mean ± SEM; statistical analysis by one-way ANOVA with Tukey’s correction
(*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001)
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Figure 26. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Leads to an
Increased Frequency and Total Number of CD80+ and CD86+ Dendritic Cells in
the Tumor Draining Lymph Nodes Two Days Post-T Cell Treatment. Tumor
draining lymph nodes were isolated from B16 A2/Kb tumor-bearing mice two days
post-T cell treatment and cells were examined for expression of CD11c, MHC II,
CD80 and CD86 by flow cytometry. A) Frequency and B) Total number of CD80 and
CD86-expressing DCs. Cells were gated on live, CD11c+MHCII+ cells. Symbols
(circles and squares) represent individual mice from two independent experiments.
Graph shows mean ± SEM; statistical analysis performed using 2way ANOVA with
Tukey’s correction (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001)
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Figure 27. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Leads to
Increased Surface Levels of the Co-Stimulatory Molecule CD80 on Dendritic
Cells in the Tumor Draining Lymph Nodes Two Days Post-T Cell Treatment.
Tumor draining lymph nodes were isolated from B16 A2/Kb tumor-bearing mice two
days post-T cell treatment and cells were analyzed for expression of CD11c, MHC II,
CD80, and CD86. Cells were gated on live, CD11c+MHCII+ cells. Symbols represent
individual mice from one representative experiment with 4-5 mice/group. Graph
shows mean ± SEM; statistical analysis performed using 2way ANOVA with Tukey’s
correction (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001)

We further examined the tumor draining lymph nodes for evidence of crosspresenting DC subsets. The frequency and number of CD103+ cDCs were significantly
increased in the tumor draining lymph nodes isolated from mice treated with TIL 1383I
TCR transduced allogeneic T cells compared to TIL 1383I TCR transduced syngeneic T
cells (P=0.0312; Fig 28). Treatment with TIL 1383I TCR transduced allogeneic T cells
also promoted an increase in the frequency and the number of lymphoid-resident CD8a
cDCs compared to TIL 1383I TCR transduced syngeneic T cell treatment (P=0.0105)
and untreated mice (P=0.0091; Fig 29). Furthermore, the frequency and number of
CD205-expressing cDCs were increased in the tumor draining lymph nodes following
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intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells compared to
TIL 1383I TCR transduced syngeneic T cells (P=0.0220) and no treatment (P=0.0003;
Fig 30). The differences in DC responses in the tumor draining lymph nodes were most
pronounced at two days post-T cell treatment, whereas pilot experiments suggested a
waning in response at day 3 and day 5 post-T cell treatment (Appendix Fig 100-102).
Together, these results support our findings that intratumoral injection with TIL 1383I
TCR transduced allogeneic T cells promotes the maturation of DCs and accumulation of
cross-presenting DC subsets in the tumor draining lymph nodes two days post-T cell
treatment.
Summary
In this section, we examined the dendritic cell populations in the tumors and
tumor draining lymph nodes of B16 A2/Kb tumor-bearing mice treated with TIL 1383I
TCR transduced T cells. In the tumor, the frequency of CD11c+MHC II+ cDCs was
similar among untreated and T cell-treated tumors; however, the CD11c+ MHC II+ DCs
from tumors treated with allogeneic T cells exhibited increased surface levels of the costimulatory molecule CD80. We also observed an increased frequency of CD103+ and
CD205+ DCs, two highly specialized subsets of cross-presenting DCs, in the tumors of
mice treated with TIL 1383I TCR transduced allogeneic T cells. In accord with findings
in the tumor, the tumor draining lymph nodes following T cell treatment showed a
greater accumulation of CD11c+MHC II+ DCs, particularly the cross-priming CD103+ DC,
CD8a+ DC, and CD205+ DC subsets. The increased DC responses observed following
TIL 1383I TCR transduced allogeneic T cell treatment led us to examine whether T cell
activation was also enhanced in the tumor and tumor draining lymph nodes.
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Figure 28. Treatment with TIL 1383I TCR Transduced Allogeneic T Cells
Increases CD103+ Dendritic Cells in the Tumor Draining Lymph Nodes Two
Days Post-T Cell Treatment. Two days post-T cell treatment, the tumor draining
lymph nodes of B16 A2/Kb tumor-bearing mice were isolated and cells were
examined for the expression of CD11c, CD11b, MHC II, and CD103 by flow
cytometry. A) Representative flow cytometry plots of CD103+CD11b- DCs B)
Percentage of CD103+CD11b- DCs (gated on live CD11c+MHCII+ cells) C) Total
number of CD103+CD11b- DCs. Symbols (circles and squares) represent individual
mice from two independent experiments with 4-5 mice/group. Graph shows mean ±
SEM; statistical analysis by one-way ANOVA with Tukey’s correction (*P<0.05,
***P<0.001).
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Figure 29. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Promotes the
Accumulation of CD8a+ Dendritic Cells in the Tumor Draining Lymph Nodes
Two Days Post-T Cell Treatment. Two days post-T cell treatment, the tumor
draining lymph nodes of B16 A2/Kb tumor-bearing mice were isolated and cells were
examined for the presence of CD11c, CD11b, MHC II, and CD8a by flow cytometry
A) Representative flow cytometry plots of CD8a+CD11b- DCs B) Percentage of
CD8a+ CD11b- DCs (gated on CD11c+MHCII+ cells) C) Total number of CD8a+CD11bDCs. Symbols (circles and squares) represent individual mice from two independent
experiments with 4-5 mice/group. Graph shows mean ± SEM; statistical analysis
performed using one-way ANOVA with Tukey’s correction (*P<0.05, **P<0.01).
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Figure 30. Treatment with TIL 1383I TCR Transduced Allogeneic T Cells
Increases CD205+ Dendritic Cells in the Tumor Draining Lymph Nodes Two
Days Post-T Cell Treatment. Two days post-T cell treatment, the tumor draining
lymph nodes of B16 A2/Kb tumor-bearing mice were isolated and cells were
examined for the expression of CD11c, CD11b, MHC II, and CD205 by flow
cytometry A) Representative flow cytometry plots of CD205+ DCs B) Percentage of
CD205+ MHCII+ DCs (gated on CD11c+MHCII+ cells) C) Total number of CD205+
DCs. Circles and squares represent individual mice from two independent
experiments with 4-5 mice/group. Graph shows mean ± SEM; statistical analysis by
one-way ANOVA with Tukey’s correction (*P<0.05, ***P<0.001, ****P<0.0001).

CHAPTER FIVE
TIL 1383I TCR TRANSDUCED ALLOGENEIC T CELL TREATMENT ENHANCES
ACTIVATION OF T CELLS
Characterization of T Cells in the Tumor Microenvironment
Intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells
promoted dendritic cell (DC) responses in the tumor and tumor draining lymph nodes of
B16 A2/Kb tumor-bearing mice. We, therefore, examined the tumor microenvironment to
determine if intratumoral treatment with TIL 1383I TCR transduced T cells impacted on
the T cell response. Consistent with intratumoral delivery of T cells, all T cell treatment
groups had a significant increase in the frequency of CD3+ T cells compared to
untreated tumors (P<0.01, Fig 31) two days post-T cell treatment. The T cell infiltrates
were predominantly CD8+ T cells in the untransduced allogeneic T cell- and TIL 1383I
TCR transduced syngeneic T cell- and TIL 1383I TCR transduced allogeneic T celltreated tumors (P<0.0001, Fig 32). Thus, as expected, the tumors of mice treated with
untransduced allogeneic T cells and TIL 1383I TCR transduced syngeneic and TIL
1383I TCR transduced allogeneic T cells resulted in a greater accumulation of CD8+ T
cells in B16 A2/Kb tumors.
We examined whether the combination of tumor-reactivity and alloreactivity
promoted enhanced T cell activation compared to tumor-reactivity and alloreactivity
alone. We examined B16 A2/Kb tumors for the presence of CD4+ and CD8+ T cells
within the tumor for the expression of the activation markers CD25, CD44, and CD69.
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Figure 31. Frequency of CD3+ T Cells in the Tumor Microenvironment Two Days
Post-T Cell Treatment. Two days post-T cell treatment, tumors were isolated and
cells were analyzed for expression of CD3 by flow cytometry. A) Representative flow
cytometry plots of CD3+ T cells B) Frequency of CD3+ T cells. Gated on single, live
cells. Circles and squares represent individual mice from two independent
experiments with 4-5 mice per group. Graph shows mean ± SEM; statistical analysis
by one-way ANOVA with Tukey’s correction (**P<0.01).
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Figure 32. Frequency of CD4+ and CD8+ T Cells in the Tumor Microenvironment
Two Days Post-T Cell Treatment. Two days post-T cell treatment, tumors were
isolated and analyzed for expression of CD3, CD4, and CD8 by flow cytometry. A)
Representative flow cytometry plots of CD4+ and CD8+ T cells B) Frequency of CD4+
and CD8+ T cells. Gated on live, CD3+ T cells. Circles and squares represent
individual mice from two independent experiments, with 4-5 mice per group. Graph
shows mean ± SEM; statistical analysis was performed using one-way ANOVA with
Tukey’s correction (****P<0.0001).
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Two days post-T cell treatment, the frequency of CD25+ CD4+ T cells in the tumors of
TIL 1383I TCR transduced syngeneic T cells and untransduced allogeneic T cells were
significantly increased compared to untreated tumors (P<0.01, Fig 33A-B). TIL 1383I
TCR transduced allogeneic T cell treatment resulted in the most significant increase of
CD25+CD4+ T cells compared to untreated mice (P<0.001, Fig 33A-B). However, we did
not notice any significant differences in the frequency of CD44+ CD4+ T cells between
treatment groups (Fig 34). The proportion of CD69+ CD4+ T cells were increased in the
untransduced allogeneic T cell-treated tumors compared to untreated mice (P= 0.0272;
Fig 35). The surface levels of CD25, CD44, and CD69 were equivalent between
treatment groups (Fig 33-35). These results suggest that while the tumor-specific
response mediated by intratumoral delivery of transduced T cells promotes moderate
CD4+ T cell activation, the allogeneic response seems to have more of an impact on
CD4+ T cell activation.
We also examined the activation status of CD8+ T cells in the tumor
microenvironment two days post-intratumoral T cell treatment. TIL 1383I TCR
transduced syngeneic T cell treatment resulted in a significant increase in the frequency
of CD25-expressing CD8+ T cells compared to untreated mice (P<0.0001) or
untransduced allogeneic T cell-treated mice. (P<0.001, Fig 36A-B). TIL 1383I TCR
transduced allogeneic T cell-treatment resulted in even higher frequencies of CD25+
CD8+ T cells compared to treatment with TIL 1383I TCR transduced syngeneic T cells,
untransduced allogeneic T cells, and no treatment (P<0.0001). TIL 1383I TCR
transduced allogeneic T cell treatment also promoted increased CD44-expressing CD8+
T cells in the tumor compared to untransduced allogeneic T cells (P=0.007; Fig 37A-B).
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Figure 33. Frequency and Surface Expression of CD25 on CD4+ T Cells in the
Tumor Microenvironment Two Days Post-T Cell Treatment. Two days post-T cell
treatment, B16 A2/Kb tumors were isolated from mice and cells were analyzed for
expression of CD3, CD4, and CD25 by flow cytometry. A) Representative histograms
B) Frequency of CD25+ T cells. Symbols (circles and squares) represent individual
mice from two independent experiments C) CD25 MFI. Circles represent individual
mice from one of two independent experiments. Cells were gated on live, CD3+ CD4+
T cells. Graph shows mean ± SEM; statistical analysis by one-way ANOVA with
Tukey’s correction (**P<0.01, ***P<0.001).
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Figure 34. Frequency and Surface Expression of CD44 on CD4+ T Cells in the
Tumor Microenvironment Two Days Post-T Cell Treatment. Two days post-T cell
treatment, B16 A2/Kb tumors were isolated from mice and cells were analyzed for
expression of CD3, CD4, and CD44 by flow cytometry. A) Representative histograms
B) Frequency of CD44+ T cells. Symbols (circles and squares) represent individual
mice from two independent experiments. C) CD44 MFI. Circles represent individual
mice from one of two independent experiments. Cells are gated on live, CD3+ CD4+ T
cells. shows mean ± SEM; No differences in statistical analysis were observed using
one-way ANOVA with Tukey’s correction.
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Figure 35. Frequency and Surface Expression of CD69 on CD4+ T Cells in the
Tumor Microenvironment Two Days Post-T Cell Treatment. Two days post-T cell
treatment, B16 A2/Kb tumors were isolated from mice and cells were analyzed for
expression of CD3, CD4, and CD69 by flow cytometry. A) Representative histograms
B) Frequency of CD69+ T cells. Symbols (circles and squares) represent individual
mice from two independent experiments C) CD69 MFI. Circles represent individual
mice from one of two independent experiments. Cells were gated on live, CD3+ CD4+
T cells. Graph shows mean ± SEM; statistical analysis by one-way ANOVA with
Tukey’s correction (*P<0.05).
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TIL 1383I TCR transduced syngeneic T cell promoted CD44+CD8+ T cell accumulation
compared to untransduced allogeneic T cell treatment (P=0.0069; Fig 37A-B),
suggesting that the accumulation of CD44+CD8+ T cells is promoted by the tumorspecific response, rather than the alloresponse. The frequency of intratumoral
CD69+CD8+ T cell was also increased in all T cell-treated groups compared to untreated
mice (P<0.0001, Fig 38A-B). In addition to the increased frequency of activated CD8+ T
cells present in the tumor of TIL 1383I TCR transduced T cell treatment, the cell surface
expression of the activation markers tended to be higher as well (Fig 36C-38C). These
results demonstrate that both the TIL 1383I TCR-directed response and the
alloresponse can promote T cell activation within the tumor.
Allogeneic responses are mostly T cell-mediated, with indirect allorecognition
characterized by IL-2-producing CD4+ T cells and direct allorecognition characterized by
TNF-a- and IFN-g-producing CD8+ T cells77. In Chapter Four, we observed an increase
in mature DCs in the tumor after treatment with TIL 1383I TCR transduced allogeneic T
cells. We therefore performed one pilot experiment to examine the tumor for T cells
producing cytokines that are involved in the allogeneic responses and that stimulate DC
maturation. Two days post-T cell treatment, B16 A2/Kb tumors were isolated from mice
to assess CD4+ and CD8+ T cells for expression of IL-2, TNF-a or IFN-g to determine if
TIL 1383I TCR transduced allogeneic T cell treatment altered the T cell cytokine
response compared to TIL 1383I TCR transduced syngeneic T cell treatment. As
expected, only the tumors that were treated with TIL 1383I TCR transduced T cells
contained CD4+GFP+ and CD8+GFP+ T cells (Fig 39). We observed minimal production
of IL-2 from CD4+ and CD8+ T cells within the tumors of T cell-treated mice (Fig 39).
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Figure 36. Frequency and Surface Expression of CD25 on CD8+ T Cells in the
Tumor Microenvironment Two Days Post-T Cell Treatment. Two days post-T cell
treatment, B16 A2/Kb tumors were isolated from mice and cells were analyzed for
expression of CD3, CD8, and CD25 by flow cytometry. A) Representative histograms
B) Frequency of CD25+ T cells. Symbols (circles and squares) represent individual
mice from two independent experiments. C) CD25 MFI. Circles represent individual
mice from one of two independent experiments. Cells were gated on live, CD3+ CD8+
T cells. Graph shows mean ± SEM; statistical analysis by one-way ANOVA with
Tukey’s correction (**P<0.01, ***P<0.001, ****P<0.0001).
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Figure 37. Frequency and Surface Expression of CD44 on CD8+ T Cells in the
Tumor Microenvironment Two Days Post-T Cell Treatment. Two days post-T cell
treatment, B16 A2/Kb tumors were isolated from mice and cells were analyzed for
expression of CD3, CD8 and CD44 by flow cytometry. A) Representative histograms
B) Frequency of CD44+ T cells. Symbols (circles and squares) represent individual
mice from two independent experiments. C) CD44 MFI. Circles represent individual
mice from one of two independent experiments. Cells were gated on live, CD3+ CD8+
T cells. Graph shows mean ± SEM; statistical analysis by one-way ANOVA with
Tukey’s correction (**P<0.01, ***P<0.001).
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Figure 38. Frequency and Surface Expression of CD69 on CD8+ T Cells in the
Tumor Microenvironment Two Days Post-T Cell Treatment. Two days post-T
cell treatment, B16 A2/Kb tumors were isolated from mice and cells were analyzed
for expression of CD3, CD8, and CD69 by flow cytometry. A) Representative
histograms B) Frequency of CD69+ T cells. Symbols (circles and squares)
represent individual mice from two independent experiments. C) CD69 MFI. Circles
represent individual mice from one of two independent experiments. Cells were
gated on live, CD3+ CD8+ T cells. Graph shows mean ± SEM; statistical analysis
performed using one-way ANOVA with Tukey’s correction (***P<0.001,
****P<0.0001).
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We did observe a small frequency of IFN-g+CD3+CD8+ T cells (~3%) in the tumors
treated with TIL 1383I TCR transduced allogeneic T cells. More than half of IFN-g+ cells
were detected in the TIL 1383I TCR transduced T cell population (from the GFP+; Fig
40). Interestingly, we only detected a small percentage of IFN-g+CD3+CD8+ T cells
within the GFP+ population present in the TIL 1383I TCR transduced syngeneic T celltreated tumors. GFP expression allows for the detection of TIL 1383I TCR transduced T
cells, but the lack of GFP can include injected T cells that were untransduced or
endogenous T cells.
In a small-scale follow-up experiment, we used a combination of PE-conjugated,
anti-H-2d and anti-Vb12 antibodies, which would further allow for the separation of the
endogenous T cells from the total transferred allogeneic T cell population. We also
examined TNF-a production from T cells within the tumors of treated mice. Overall, we
observed more IFN-g+ T cells in the tumors of all T cell-treated mice compared to the
previous pilot experiment shown in Fig 41. Seven days post-intratumoral T cell
treatment, CD4+ and CD8+ T cells from untransduced allogeneic and TIL 1383I TCR
transduced syngeneic T cell-treated tumors had similar TNF-a expression, ranging from
4-8% of T cells (Fig 42). However, the tumors treated with TIL 1383I TCR transduced
allogeneic T cells contained approximately 14.8% CD4+ TNF-a+ T cells and 12.5%
CD8+ TNF-a+ T cells (Fig 42). These results suggested that treatment with
untransduced allogeneic T cells and TIL 1383I TCR transduced syngeneic T cells
induce low levels of cytokine production on their own, but TIL 1383I TCR transduced
allogeneic T cells induce the most robust cytokine responses by CD8+ T cells within the
tumor microenvironment.
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Figure 39. Production of IL-2 from CD3+ T Cells in the Tumor Microenvironment
Two Days Post-T Cell Treatment. Two days post-T cell treatment, B16 A2/Kb tumors
were isolated from mice and pooled. Cells were examined for expression of CD3,
CD4, CD8, GFP, and IL-2 by flow cytometry. A) CD3+CD4+ T cells B) CD3+CD8+ T
cells. Cells were gated on live, singlet, CD3+ cells. Flow plots represent one pilot
experiment with 5 mice/group.
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Figure 40. Intratumoral TIL 1383I TCR Transduced Allogeneic T Cells Produce
IFN-g. Two days post-T cell treatment, B16 A2/Kb tumors were isolated from mice and
pooled. Cells were examined for expression of CD3, CD4, CD8, GFP and IFN-g by
flow cytometry. A) CD3+CD4+ T cells B) CD3+CD8+ T cells. Cells were gated on live,
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Figure 41. Intratumoral TIL 1383I TCR Transduced Allogeneic T Cells Produce
IFN-g .Two days post-T cell treatment, B16 A2/Kb tumors were isolated from mice and
pooled. Cells were examined for expression of CD3, CD4, CD8, Vb12, H-2d, and
IFN-g by flow cytometry. A) CD3+CD4+ T cells B) CD3+CD8+ T cells. Cells were gated
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146

A) CD3+ CD4+

Vb12 and H-2d

PBS-treated
tumor

UnTd Allo T celltreated tumor

Td Syn T celltreated tumor

Td Allo T celltreated tumor

B) CD3+ CD8+

TNF-a
Figure 42. Intratumoral TIL 1383I TCR Transduced Allogeneic T Cells Produce
TNF-a. Two days post-T cell treatment, B16 A2/Kb tumors were isolated and pooled.
Cells were examined for expression of CD3, CD4, CD8, Vb12, H-2d, and TNF-a by
flow cytometry. A) CD3+CD4+ T cells B) CD3+CD8+ T cells. Cells were gated on live,
singlet, CD3+ cells. Flow plots represent one pilot experiment with 5 mice/group.

The ability to comprehensively compare cytokine production from T cells among
treatment groups and between endogenous and transferred T cells is limited by the
ability to distinguish the untransduced transferred syngeneic T cells from the recipient
HLA-A2 transgenic T cells. In spite of these limitations, results from these small-scale
experiments suggested that the combined alloreactivity and tumor-specificity of TIL
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1383I TCR transduced allogeneic T cells induce increased in vivo cytokine production
within the tumors compared to the cytokine responses induced by alloreactivity
(untransduced allogeneic T cells) or tumor-specificity (TIL 1383I TCR transduced
syngeneic T cells) alone.
Characterization of T Cells in the Tumor and Tumor Draining Lymph Nodes Seven
Days Post-T Cell Treatment
Examining the phenotype of the T cell present in the tumor microenvironment two
days post-T cell treatment had some limitations to distinguishing endogenous and
transferred T cells. Therefore, we also looked at the tumor seven days post-T cell
treatment when transferred T cells were undetectable and the endogenous T cells could
be assessed. We did not observe differences in the frequency and activation of
endogenous intratumoral CD4+ T cells among treatment groups (Fig 43 and Fig 44).
The tumors treated with untransduced allogeneic T cells and TIL 1383I TCR transduced
allogeneic T cells had the greatest frequency of CD8+ T cells (Fig 43). Interestingly, TIL
1383I transduced syngeneic T cell-treated tumors did not have an increase in CD8+ T
cell infiltration but did have increased frequencies of CD69+ CD8+ T cells (Fig 43 and
Fig 45).
The increase in T cell activation led us to ask if there was also an increase in the
frequency of regulatory T cells (Tregs) following treatment with TIL 1383I TCR
transduced T cells. Surprisingly, seven days post-T cell treatment, the tumors from TIL
1383I TCR transduced syngeneic T cell-treated mice had the highest frequency of
Foxp3+CD25+ Tregs compared to tumors treated with TIL 1383I TCR transduced
allogeneic T cells (P=0.0108) and untransduced allogeneic T cells (P=0.0302; Fig 46A)
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Figure 43. Frequency of CD4+ and CD8+ T Cells in the Tumor Seven Days Post-T
Cell Treatment. Seven days post-T cell treatment, B16 A2/Kb tumors were isolated
from mice and cells were analyzed for expression of CD3, CD4 and CD8 by flow
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independent experiments. Cells were gated on live cells. Graph shows mean ± SEM;
statistical analysis performed using one-way ANOVA with Tukey’s correction
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Figure 44. Frequency of Activated CD4+ T Cells in the Tumor Seven Days PostT Cell Treatment. Seven days post-T cell treatment, B16 A2/Kb tumors were isolated
from mice and cells were analyzed for expression of CD3, CD4, CD25, CD44, and
CD69 by flow cytometry. Symbols (circles and squares) represent individual mice
from two independent experiments. Cells were gated on live, CD3+CD4+ T cells.
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Figure 46. Regulatory T cells in the Tumor Microenvironment Seven Days PostT Cell Treatment. Seven days post-T cell treatment, B16 A2/Kb tumors were isolated
from mice and cells were analyzed for expression of CD3, CD4, CD25, and Foxp3 by
flow cytometry. A) Frequency of Foxp3+CD25+ T cells, gated on CD3+CD4+ cells B)
Ratio of CD8+ T cells: Tregs. Symbols (circles and squares) represent individual mice
from two independent experiments. Cells were gated on live, CD3+ CD8+ T cells.
Graph shows mean ± SEM; statistical analysis performed using one-way ANOVA
with Tukey’s correction (**P<0.01, ***P<0.001, ****P<0.0001).
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Furthermore, the tumors treated with TIL 1383I TCR transduced allogeneic T cells had
the highest CD8+ T cells: Treg ratio compared to tumors treate TIL 1383I TCR
transduced syngeneic T cells (P=0.0048) and PBS (P=0.0038), suggesting enhanced
cytotoxic T cell infiltration (Fig 46B).The robust activation of dendritic cells in the tumor
and the tumor draining lymph nodes after treatment with TIL 1383I TCR transduced
allogeneic T cells (Fig 21-30) suggested the potential to induce anti-tumor T cell
immune responses. We next examined the T cells present in the tumor draining lymph
nodes seven days following intratumoral T cell treatment, usually when peak T cell
responses occur. We did not detect differences in frequency or number of CD4+ and
CD8+ T cells in the tumor draining lymph nodes in any of the treatment groups (Fig 47).
We further investigated the presence of CD4+ and CD8+ T cells in the tumor
draining lymph nodes seven days post-T cell treatment and assessed expression of the
T cell activation molecules, CD44 and CD69. We did not observe a significant
difference in the frequency or number of CD44+ or CD69+ CD4+ T cells among T cell
treatment groups (Fig 48). However, the frequency of CD44+ CD8+ T cells was
significantly higher in the tumor draining lymph nodes isolated from TIL 1383I TCR
transduced allogeneic T cell-treated mice compared to the tumor draining lymph nodes
isolated from mice treated with PBS (P<0.0001) and untransduced allogeneic T cells
(P=0.0469; Fig 49A). Furthermore, the tumor draining lymph nodes isolated from TIL
1383I TCR transduced syngeneic T cell-treated mice also had significantly increased
CD44+CD8+ T cells compared to PBS treatment (P=0.0045; Fig 49A). The tumor
draining lymph nodes of untransduced allogeneic T cell-treated mice also had increased
frequencies of CD44+CD8+ T cells compared to PBS-treated mice (P=0.042). We
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additionally assessed CD69 expression on T cells isolated from the tumor draining
lymph nodes of mice seven days post-intratumoral T cell treatment. We observed an
increased frequency of CD69+ CD8+ T cells following treatment with TIL 1383I TCR
transduced allogeneic T cell treatment compared to PBS (P=0.002) and TIL 1383I TCR
transduced syngeneic T cell treatment (P=0.0178; Fig 46B). Untransduced allogeneic T
cell treatment promoted CD69+ CD8+ T cells compared to PBS treatment (P=0.0171).
These results indicated that intratumoral treatment with TIL 1383I TCR transduced
allogeneic T cells promoted the activation of endogenous CD8+ T cells in the tumor
draining lymph nodes.
CXCR3 is highly expressed on activated and memory T cells486. We observed
increased CXCR3+CD4+ T cells in the tumor draining lymph nodes from mice treated
with TIL 1383I TCR transduced allogeneic T cells compared to the other T cell
treatment groups (Fig 50). Additionally, CXCR3+CD8+ T cells were present at an
increased frequency in the tumor draining lymph nodes of TIL 1383I TCR transduced
allogeneic T cell-treated mice compared to the tumor draining lymph nodes of PBStreated mice. These results suggested that TIL 1383I TCR transduced allogeneic T cell
intratumoral treatment promotes the activation of endogenous CD8+ T cells in the tumor
draining lymph nodes of tumor-bearing mice seven days post-T cell treatment.
TIL 1383I TCR Transduced Allogeneic T Cell Treatment Generates Endogenous
Tumor-Specific T Cells
Intratumoral delivery of TIL 1383I TCR transduced allogeneic T cells promoted
the expression of DC maturation markers CD80 and CD86 and T cell activation
molecules in the tumor microenvironment two days post-intratumoral T cell treatment.
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Figure 47. Frequency and Number of CD4+ and CD8+ T Cells in the Tumor
Draining Lymph Nodes Seven Days Post-T Cell Treatment. Seven days post-T
cell treatment, tumor draining lymph nodes from B16 A2/Kb tumor-bearing mice were
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cytometry. A) Frequency and B) Total number of CD4+ and CD8+ T cells. Cells were
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Figure 48. Activated CD4+ T Cells in the Tumor Draining Lymph Nodes Seven
Days Post-T Cell Treatment. Seven days post-T cell treatment, tumor draining
lymph nodes were isolated from B16 A2/Kb tumor-bearing mice and cells were
examined for expression of CD3, CD4, CD44, and CD69 by flow cytometry. A)
Frequency (left panel) and number (right panel) of CD44+CD4+ T cells. B) Frequency
(left panel) and number (right panel) of CD69+CD4+ T cells. Cells were gated on
single, live, CD3+ T cells. Symbols (circles and squares) represent individual mice
from two independent experiments with 4-5 mice/group. Graph shows mean ± SEM;
No statistically significant differences were observed using one-way ANOVA with
Tukey’s correction.
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Figure 49. Treatment with TIL 1383I TCR Transduced Allogeneic T Cells
Increases the Frequency and Number of Activated CD8+ T Cells in the Tumor
Draining Lymph Nodes Seven Days Post-T Cell Treatment. Seven days post-T
cell treatment, tumor draining lymph nodes were isolated from B16 A2/Kb tumorbearing mice and cells were examined for expression of CD3, CD4, CD8, CD44, and
CD69 by flow cytometry. A) Frequency (left panel) and number (right panel) of
CD44+CD8+ T cells. B) Frequency (left panel) and number (right panel) of
CD69+CD8+ T cells. Cells were gated on single, live, CD3+ T cells. Symbols (circles
and squares) represent individual mice from two independent experiments with 4-5
mice/group. Graph shows mean ± SEM; statistical analysis using one-way ANOVA
with Tukey’s correction (*P<0.05, **P<0.01, ****P<0.0001).
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Figure 50. Treatment with TIL 1383I TCR Transduced Allogeneic T Cells Leads
to CXCR3+ T Cells in the Tumor Draining Lymph Nodes Seven Days Post-T Cell
Treatment. Seven days post-T cell treatment, tumor draining lymph nodes were
isolated from B16 A2/Kb tumor-bearing mice and cells were examined for expression
of CD3, CD4, CD8 and CXCR3 by flow cytometry. A) Frequency (left panel) and
number (right panel) of CXCR3+CD4+ T cells. B) Frequency (left panel) and number
(right panel) of CXCR3+CD8+ T cells. Cells were gated on single, live, CD3+ T cells.
Symbols (circles and squares) represent individual mice from two independent
experiments with 4-5 mice/group. Graph shows mean ± SEM; statistical analysis by
one-way ANOVA with Tukey’s correction (*P<0.05, **P<0.01, ***P<0.001,
****P<0.0001).
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We also observed increased frequencies of CD205+ and CD103+ cross-presenting DC
subsets in the tumors treated with TIL 1383I TCR transduced T cells (Fig 23-24).
Furthermore, we detected CD8a+ DC, CD205+ DC, and CD103+ DC cross-presenting
subsets at an increased frequency and number in the tumor draining lymph nodes of
mice treated with TIL 1383I TCR transduced allogeneic T cells (Fig 28-30). The
accumulation of cross-presenting DCs and activated T cells in the tumor draining lymph
nodes suggested that TIL 1383I TCR transduced allogeneic T cell treatment could
promote antigen cross-presentation by DCs to induce endogenous tumor-specific T cell
responses. We used two established methods to detect antigen-specific T cell
responses in vitro and in vivo. We first performed in vitro IFN-g ELISPOT assays to
determine if we could identify B16-reactive cells in treated mice. The second method, an
in vivo CTL assay, determined if antigen-specific T cells were capable of lysing
appropriate targets.
Detection of Tumor-Specific Cells by IFN-g ELISPOT Assay
Ten days after intratumoral T cell treatment, we harvested the tumor draining
lymph nodes from B16 A2/Kb tumor-bearing mice and co-cultured cells with B16 and
B16 A2/Kb tumor targets for 18 hours. HLA-A2 transgenic mice can mount MHC class I
HLA-A2- or H-2b- restricted T cell responses. Because TIL 1383I TCR transduced T
cells used for treatment are HLA A2-restricted, we tested T cell reactivity against B16
and B16 A2/Kb tumor targets, as the presence of H-2b-restricted, B16-reactive cells
would provide evidence that T cell cross-priming has occurred. The tumor draining
lymph nodes from mice treated with TIL 1383I TCR transduced allogeneic T cells had
significantly higher frequencies of B16-reactive, IFN-g-producing cells (mean number of
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spots: 105 ± 29.8) compared to tumor draining lymph nodes isolated from TIL 1383I
TCR transduced syngeneic T cell (27.62 ± 9.53; P=0.0013)- and untransduced
allogeneic T cell (39.87 ± 20.7; P= 0.0099)- treated mice (Fig 51). The tumor draining
lymph nodes from mice treated with TIL 1383I TCR transduced allogeneic T cells also
had a significant frequency of B16 A2/Kb-reactive, IFN-g-producing cells compared to
TIL 1383I TCR transduced syngeneic T cells (P=0.0308) and untransduced allogeneic T
cells (P=0.0099).
To confirm that the observed reactivity of the endogenous immune response was
melanoma antigen-specific, we also compared IFN-g-production from host cells cocultured with the melanoma antigen-negative targets, EL4 and EL4 A2/Kb. The tumor
draining lymph nodes isolated from TIL 1383I TCR transduced allogeneic T cell treated
mice had a substantial increase in cells reactive against B16 tumor targets compared to
EL4 (P<0.0001) and against B16 A2/Kb compared to EL4 A2/Kb (P<0.0001; Fig 51). In
contrast, the tumor draining lymph nodes from TIL 1383I TCR transduced syngeneic T
cell- or untransduced allogeneic T cell-treated mice failed to exhibit B16 or B16 A2/Kb
responses above the levels of EL4 and EL4 A2/Kb. These results indicated that
intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells induced
endogenous tumor-specific H-2b- and human HLA-A2-restricted cells.
We also measured reactivity of cells from the tumor draining lymph nodes
against H-2Kb-restricted TRP-2180-188 and H-2Db-restricted gp10025-33- peptide-pulsed
RMA/S cells (H-2b). We chose TRP-2180-188 and gp10025-33 peptides because they are
two melanocyte antigens restricted by H-2b, which would suggest the induction of crossprimed T cells. Additionally, TRP-2 and gp100 are highly expressed on B16 tumors.
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Figure 51. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Induces
Tumor-Specific IFN-g+ Cells in the Tumor Draining Lymph Nodes. Ten days postT cell treatment, tumor draining lymph nodes were isolated from mice. 100,000
effector cells and 100,000 target cells were co-cultured for 18 hours. Spots were
automatically enumerated using an ELISPOT plate reader. Data represent the
average of duplicates from individual mice. Symbols (squares and closed and open
circles) represent the individual mice from 3 independent experiments. Graph shows
mean ± SEM; Statistical analysis using one-way ANOVA with Tukey correction [*
P<0.05, **P<0.01]
To determine if we could detect peptide-specific responses, we co-cultured cells
isolated from the tumor draining lymph nodes of treated mice with gp10025-33-and TRP2180-188-pulsed RMA/S antigen presenting cells (H-2b). We detected a significant
frequency of gp10025-33-reactive cells from the tumor draining lymph nodes of mice
intratumorally treated with TIL 1383I TCR transduced allogeneic T cells (mean number
of spots: 144.167 ± 31.5) compared to treatment with TIL 1383I TCR transduced
syngeneic T cells (48.93 ±16.56; P= 0.0034) and compared to treatment with
untransduced allogeneic T cells (36.7 ± 21.45; P=0.0011, Fig 52). We also observed a
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trending increase in TRP-2180-188-specific cells in the tumor draining lymph nodes of TIL
1383I TCR transduced allogeneic T cell treated-mice (mean number of spots: 82 ± 23.6)
compared to TIL 1383I TCR transduced syngeneic T cell- (39.654 ±17.34; ns,
P=0.3052) or untransduced allogeneic T cell- (39.71 ± 22.12; ns, P=0.3217) treated
mice (Fig 52). These results indicated that treatment with TIL 1383I TCR transduced
allogeneic T cells induced H-2b and HLA-A2-restricted tumor antigen-specific
responses.
We further increased the ability to detect IFN-g- producing cells by re-stimulating
splenocytes from mice intratumorally treated with TIL 1383I TCR transduced T cells with
irradiated B16 A2/Kb tumors for five days prior to ELISPOT co-cultures. Re-stimulation
of splenocytes yielded higher frequencies of B16 and B16 A2/Kb tumor-reactive cells,
but we generally observed higher non-specific background reactivity as well
(Supplemental Fig 102 and 103) These results demonstrated that IFN-g- producing cells
can be detected in the tumor draining lymph nodes of mice treated with TIL 1383I TCR
transduced allogeneic T cells, both with and without re-stimulation.
We wanted to determine if T cell cross-priming correlated with control B16 A2/Kb
tumor progression. We retrospectively compared the final B16 A2/Kb tumor area (at day
10 post-T cell treatment when tumor-bearing mice were sacrificed) to the number of
IFN-g spots produced in response to B16 and B16 A2/Kb tumors and TRP-2 and gp100loaded RMA/S (Fig 53). There appeared to be a trend between the IFN-g- producing
cells in the tumor draining lymph nodes and the tumor area at the time of analysis,
suggesting that the induction of T cell cross priming might correlate with regression of
B16 A2/Kb tumors
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Figure 52. TIL 1383I TCR Transduced Allogeneic T Cell Treatment Induces
gp100-Specific IFN-g+ Cells in the Tumor Draining Lymph Nodes. Ten days postT cell treatment, tumor draining lymph nodes were isolated from mice. RMA/S cells
were pulsed with 10 µg/mL peptide for 2 hours. 100,000 effector cells and 100,000
target cells were co-cultured for 18 hours. Spots were automatically enumerated
using an ELISPOT plate reader. Squares and open and closed circles represent
individual mice from 3 independent experiments. Graph shows mean ± SEM;
Statistical analysis using one- way ANOVA with Tukey correction [**P<0.01]
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IFN-g+ Tumor-Specific Cells. The number of IFN-g+ spots after co-culturing recipient
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Figure 54. TIL 1383I TCR Transduced T Cells Are Not Detectable in the Spleens
or Tumor Draining Lymph Nodes. Mice were inoculated with 2.5x105 B16 A2/Kb
tumor cells and nine days post-T cell treatment, A) tumor draining lymph nodes and
B) spleens were isolated and cells were examined for the presence of CD3, CD4,
CD8, Vb12, and GFP by flow cytometry.

We simultaneously examined the spleens and tumor draining lymph nodes of T
cell-treated mice for GFP+ or Vb12+ T cells by flow cytometry to confirm that the tumor
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specific response was truly recipient-mediated. We were unable to detect any
GFP+ or VB12+ expression above the background of mice treated with untransduced
allogeneic T cells or PBS (Fig 54). This demonstrated that intratumoral treatment with
TIL 1383I TCR transduced allogeneic T cells induced cross-priming of recipient cells
that produced IFN-g in response to B16 and B16 A2/Kb tumors, and gp10025-33- and
TRP-2180-188- pulsed RMA/S cells.
Detection of Cytolytic Activity by In Vivo CTL Assay
Results from the ELISPOT assays suggested that tumor antigen-specific cells
were functional in vitro; however, it was still unknown if treatment-induced, endogenous
cells were functionally capable of inducing tumor antigen-specific killing in vivo. To
determine if endogenous cells generated after intratumoral treatment with TIL 1383I
TCR transduced T cells could effectively eliminate TRP-2180-188 and gp10025-33 peptideloaded target cells, we utilized a well-established in vivo cytotoxicity assay (Fig 55).
C57Bl/6 (H-2b) splenocytes were used as antigen presenting cells and were pulsed with
TRP-2180-188 and gp10025-33 peptides and labeled with 5 µM (CFSEmid) and 10 µM
(CFSEhi) CFSE, respectively. We labeled a group of unpulsed splenocytes with 0.5µM
(CFSElow) CFSE as a negative control. We retro-orbitally transferred an equal ratio of
CFSE-labeled splenocytes into recipient mice that had been treated with TIL 1383I TCR
transduced syngeneic T cells, TIL 1383I TCR transduced allogeneic T cells or
untransduced allogeneic T cells eight days prior. The following day, we harvested the
spleens and assessed the ratios of HLA-2-CFSE+ cells by flow cytometry (Fig 55).
We detected relatively similar ratios of gp100-pulsed CFSEhi cells, TRP-2-pulsed
CFSEmid cells, and unpulsed CFSElow cells in untreated mice and untransduced

166
allogeneic T cell-treated mice, indicating that neither group generated functional, tumorspecific T cells (Fig 56B and C). TIL 1383I TCR transduced syngeneic T cell treatment
resulted in a moderate induction of cytotoxic gp10025-33-specific T cells (Fig 56C).
Interestingly, we did not detect TRP-2180-188-specific killing above background (Fig 56B).
In contrast, TIL 1383I TCR transduced allogeneic T cell treatment promoted the
induction of cytotoxic T cells specific to both gp10025-33 and TRP2180-188-peptides (Fig
56B and C). Intratumoral TIL 1383I TCR transduced allogeneic T cell treatment induced
a significant frequency of TRP2180-188 -specific CTL compared to untreated mice
(P=0.0059) and TIL 1383I TCR transduced syngeneic T cell-treated mice (P= 0.0390;
Fig 56B).
Treatment with TIL 1383I TCR transduced allogeneic T cell mediated significant
gp10025-33-specific lysis compared to untransduced allogeneic T cell treatment
(P=0.0045) and untreated mice (P=0.0047; Fig 56C). These results were consistent with
ELISPOT data demonstrating the ability of TIL 1383I TCR transduced allogeneic T cells
to induce gp10025-33 and TRP-2180-188- specific responses, with a more dominant
response against gp10025-33. It is possible that differences in antigen composition could
affect the ability to be cross-presented by DCs. We will explore this idea further in the
discussion. Overall, these data confirm our findings that TIL 1383I TCR transduced
allogeneic T cell treatment is inducing endogenous tumor-specific cells capable of
producing cytokines and killing tumor antigen-loaded targets in vitro and in vivo.
We observed a small percentage of untreated or untransduced allogeneic T celltreated mice that generated cytolytic T cells against gp10025-33-or TRP-2180-188-pulsed
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target cells. We postulate that these responses result from acute inflammation induced
by the implantable B16 melanoma. The tumor inoculation itself results in a low
percentage of dying B16 cells which could stimulate endogenous tumor-specific T cells.
These results provided evidence that cross-primed tumor antigen-specific T cells
generated after treatment with TIL 1383I TCR transduced allogeneic T cells eliminated
gp10025-33 and TRP-2180-188 peptide-pulsed cells.
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Figure 55. In Vivo CTL Assay Experimental Design. Eight days post-T cell
treatment, mice received transfers of 3x106 gp100 [10µM], 3x106 TRP-2 [5µM], and
3x106 unpulsed [0.5µM] CFSE-labeled C57Bl/6 splenocytes. The following day,
spleens were collected and 100,000 total HLA-A2-CFSE+ cells were collected using
flow cytometry.
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Figure 56. TIL 1383I TCR Transduced Allogeneic T Cells Induce TRP-2- and
gp100- Specific CTL. Eight days post-T cell treatment, B16 A2/Kb tumor-bearing
mice received 3x106 gp100 [10µM], 3x106 TRP-2 [5µM], and 3x106 unpulsed [0.5µM]
CFSE-labeled C57Bl/6 splenocytes i.v. The following day, spleens were isolated from
T cell-treated, tumor-bearing HLA-A2 transgenic mice and 100,000 total HLA-A2CFSE+ cells were collected. A) Representative histograms of collected CFSE labeled
cells. B) Specific killing of TRP2-pulsed splenocytes C) Specific killing of gp100pulsed splenocytes. Symbols (Open and closed circles and diamonds) represents
individual mice from 3 independent experiments. Graph shows mean ± SEM;
Statistical analysis performed using one-way ANOVA with Tukey correction [*P<0.05,
**P<0.01]

CHAPTER SIX
INTRATUMORAL TREATMENT WITH TIL 1383I TCR TRANSDUCED
ALLOGENEIC T CELLS PREVENTS DEVELOPMENT OF
DISTANT, UNTREATED B16 TUMORS
Intratumoral Treatment with TIL 1383I TCR Transduced Allogeneic T Cells
Prevents Development of Untreated, Contralateral B16 Tumors
The previous experiments demonstrated that intratumoral treatment with TIL
1383I TCR transduced allogeneic T cells induced cross priming of endogenous tumor
antigen-specific T cells. Cross-primed T cells produced IFN-g and eliminated tumor
antigen-loaded targets in vitro and in vivo. Generally, cytotoxic T cells are more reactive
against peptide-pulsed targets compared to tumors, most likely due to peptidesaturating conditions that result in the supraphysiologic expression of antigen compared
to the expression of antigens normal presented on tumor cells. Therefore, we
determined if intratumoral treatment with TIL 1383I TCR transduced T cells induced
host cells capable of recognizing and eliminating B16 tumor targets. If TIL 1383I TCR
transduced allogeneic T cell treatment induced systemic cross-primed T cells capable of
recognizing B16 tumor cells, then we would expect these endogenous T cells to prevent
the development of B16 tumors that were inoculated on the contralateral flank of mice
with pre-existing treated B16 A2/Kb tumors. To test this hypothesis, we first treated B16
A2/Kb tumor-bearing mice with TIL 1383I TCR transduced T cells and seven days later
inoculated the same mice on the contralateral flank with 1 x105 B16 tumor cells (Fig 57).
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Figure 57. Experimental Design to Determine if Intratumoral Treatment with TIL
1383I TCR Transduced Allogeneic T Cells Induces Endogenous T Cells Capable
of Preventing Development of Distant, Contralateral B16 Tumors. Primary B16
A2/Kb tumors, implanted on the right flank of mice, were treated with TIL 1383I TCR
transduced T cells. Seven or four days later, mice were inoculated with 1 x105 B16
tumor cells on the left, contralateral flank. Mice were monitored for survival and
development of B16 tumors.
Mice were monitored for the development of contralateral B16 tumors and survival.
B16-inoculated mice without primary B16 A2/Kb tumors all developed B16
tumors within seven days of challenge (Fig 58, purple line). Treating B16 A2/Kb primary
tumors with saline (black line) or untransduced allogeneic T cells (green line) failed to
induce protection and all mice developed B16 tumors within 7-11 days following B16
inoculation (P=0.8037, Fig 58). TIL 1383I TCR transduced syngeneic T cell treatment
(blue line) prevented the development of B16 in approximately 20% of mice (P=0.0027
vs. PBS; P=0.0021 vs untransduced allogeneic T cells, Fig 58). However, treating
primary B16 A2/Kb tumors with TIL 1383I TCR transduced allogeneic T cells (red line)
resulted in protection against B16 tumor development in approximately 50% of TIL
1383I TCR transduced allogeneic T cell-treated mice (P=0.0049 vs. TIL 1383I TCR
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transduced syngeneic T cells and P<0.0001 vs. PBS and untransduced allogeneic T
cell-treated mice). This supported our previous findings that TIL 1383I TCR transduced
allogeneic T cell treatment promoted the induction of T cell cross-priming to promote
systemic, anti-tumor T cell responses to protect against distant, untreated tumors.
Interestingly, we also observed the development of vitiligo in one mouse that
received intratumoral treatment of the primary B16 A2/Kb tumor with TIL 1383I TCR
transduced allogeneic T cells and was protected from developing the B16 tumor on the
contralateral flank (Fig 59). The vitiligo developed at the site of the primary tumor. In
some melanoma patients receiving immunotherapy, the development of vitiligo can
indicate an active T cell response directed against melanoma differentiation antigens
and can occasionally correlate positively with the induction of a clinical responses1.
For example, in our phase I clinical trial treating metastatic melanoma patients with
autologous TIL 1383I TCR transduced T cells, one of the patients achieving a complete
response also developed widespread vitiligo. Together, these observations supported
our hypothesis that intratumoral treatment of primary B16 A2/Kb tumors with TIL 1383I
TCR transduced allogeneic T cells induces systemic endogenous, tumor-specific T cells
with the capacity to prevent the development of B16 tumors inoculated on the
contralateral flank.
Intratumoral treatment of B16 A2/Kb tumor-bearing mice with TIL 1383I TCR
transduced allogeneic T cells considerably extended survival (median survival: 26 days)
compared to intratumoral treatment with TIL 1383I TCR transduced syngeneic T cells
(median survival: 21 days; P= 0.001), untransduced allogeneic T cells (median survival:
15.5 days; P<0.0001) and PBS (median survival: 14 days; P<0.0001, Fig 60).
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Figure 58. TIL 1383I TCR Transduced Allogeneic T Cell Treatment of
Primary B16 A2/Kb Primary Tumors Prevents Development of B16 Tumors
Inoculated on the Contralateral Flank. Primary B16 A2/Kb tumors, implanted on the
right flank of mice, were treated with TIL 1383I TCR transduced T cells. Seven days
later, mice were inoculated with 1.0 x105 B16 tumor cells on the left, contralateral
flank. Mice were monitored for the development of B16 tumors. A) Percentage of B16
tumor-free mice. B) Statistical analysis using the Log Rank test (*P<0.05,
***P<0.001) Data compiled from four independent experiments with 4-5 mice/group.
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Figure 59. Development of Vitiligo in a Mouse with a TIL 1383I TCR Transduced
Allogeneic T Cell-Treated Primary B16 A2/Kb Tumor That Was Protected from
B16 Tumor Development. Primary B16 A2/Kb tumors, implanted on the right flank of
mice, were treated with TIL 1383I TCR transduced T cells. Seven days later mice
were inoculated with 1 x105 B16 tumor cells on the left, contralateral flank. Mice were
monitored for development of B16 tumors

Generally, mice succumbed to B16 A2/Kb tumor burden, and not secondary B16
tumors. In some cases, B16 A2/Kb tumor-bearing mice treated with PBS or
untransduced allogeneic T cells succumbed to primary B16 A2/Kb tumors before we
could visualize B16 development. To attempt to address this issue, we performed a
small-scale pilot experiment and shortened the time frame between B16 A2/Kb
intratumoral treatment and B16 tumor challenge. Instead of challenging with B16 seven
days after intratumoral treatment, we challenged with B16 four days after intratumoral
treatment with the anticipation that untreated and untransduced allogeneic T cell-treated
mice would survive long enough post-B16 A2/Kb inoculation to detect the development
of B16 tumors (Fig 57).
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Figure 60. Treatment of Primary B16 A2/Kb Tumors with TIL 1383I TCR
Transduced T Cells Improves Survival Following Challenge with B16 on the
Contralateral Flank. Primary B16 A2/Kb tumors, implanted on the right flank of mice,
were treated with TIL 1383I TCR transduced T cells. Seven days later mice were
inoculated with 1.0 x105 B16 tumor cells on the left, contralateral flank. Mice were
monitored for survival and sacrificed when one tumor or the sum of both tumors
reached >150 mm2 or >10% body weight. Data compiled from four independent
experiments with 4-5 mice/group. Statistical analysis using the Log Rank test
(***P<0.001, ****P<0.0001)
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We still observed differences among T cell treatment groups in the ability to
generate anti-B16 responses; however, we did not see complete protection in mice
treated with TIL 1383I TCR transduced syngeneic or allogeneic T cells (Fig 61).
Because all mice development B16 tumors, we could not compare the percentage of
B16 tumor-free mice; therefore, we compared the median time for B16 tumors to
develop. The median time for B16 tumors to develop in 50% of mice (B1650) was 10
days for TIL 1383I TCR transduced syngeneic T cell-treated mice and 12 days for TIL
1383I TCR transduced allogeneic T cell-treated mice (P=0.5509). The B1650 for TIL
1383I TCR transduced syngeneic T cell-treated mice was not significantly different from
untransduced allogeneic T cell-treated mice (B1650: 7 days, P= 0.1546) or untreated
mice (B1650: 5 days, P= 0.0605; Fig 61). However, the B1650 for TIL 1383I TCR
transduced allogeneic T cell-treated mice was significantly shorter compared to
untransduced allogeneic T cell-treated mice (P= 0.018) and untreated mice (P= 0.0071).
The results from this pilot experiment suggested that endogenous T cells induced by
TIL 1383I TCR transduced allogeneic T cell treatment might delay the progression of
four-day-old B16 tumors, but this experiment would need to be repeated.
One possible explanation for the lack of complete protection against the
development of B16 tumors on the contralateral flank is that the absence of crossprimed T cells at the time of B16 challenge permitted three days of B16 tumor formation
before the induction of cross-primed T cells observed seven days post-T cell treatment.
These results indicated that treatment with TIL 1383I TCR transduced allogeneic T cells
is more effective than TIL 1383I TCR transduced T cells in the induction of systemic,
endogenous tumor-specific T cells capable of preventing B16 tumor development.
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Figure 61. TIL 1383I TCR Transduced T Cell Treatment of Primary B16 A2/Kb
Tumors Delays the Development of B16 Tumors Inoculated on the
Contralateral Flank. Primary B16 A2/Kb tumors, implanted on the right flank of
mice, were treated with TIL 1383I TCR transduced T cells and four days later were
inoculated with 1.0 x105 B16 tumor cells on the left, contralateral flank. Mice were
monitored for the development of B16 tumors. Mice were sacrificed when one
tumor or the sum of two tumors reached >150 mm2 or >10% body weight. B)
Statistical analysis performed using the Log Rank test (*P<0.05, **P<0.01). Data
represent one pilot experiment with 5-7 mice/group
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Figure 62. TIL 1383I TCR Transduced T Cell Treatment of Primary B16 A2/Kb
Tumors Improves Survival Following Challenge with B16 Tumors on the
Contralateral Flank. Primary B16 A2/Kb tumors, implanted on the right flank of mice,
were treated with TIL 1383I TCR transduced T cells and four days later were
inoculated with 1.0 x105 B16 tumor cells on the left, contralateral flank. Mice were
monitored for survival. Mice were sacrificed when one tumor or the sum of both
tumors reached >150 mm2 or >10% body weight. Data represent one pilot
experiment with 5-7 mice/group. Statistical analysis using the Log Rank test (*P<0.05,
**P<0.01, ***P<0.001)
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Intratumoral treatment with TIL 1383I TCR transduced T cells improved the
survival of mice despite B16 challenge prior to induction of T cell cross-priming (Fig 62).
TIL 1383I TCR transduced syngeneic T cells (median survival: 22 days) significantly
prolonged survival compared to untransduced allogeneic T cell-treated mice (median
survival: 18 days, P= 0.0366) and untreated mice (median survival: 17 days, P=
0.0248). Furthermore, TIL 1383I TCR transduced allogeneic T cell-treated mice had the
best overall survival (median survival: 26 days) in comparison to mice treated with TIL
1383I TCR transduced syngeneic (P=0.0064) and untransduced allogeneic (P=0.0003)
T cells, or untreated mice (P=0.0003). Together these data indicated that TIL 1383I
TCR transduced T cell treatment can induce endogenous T cell cross-priming that can
prevent or delay the development of B16 tumors inoculated on the contralateral flank,
depending on when cross-priming occurs. Additionally, expressing the tumor-specific
TCR on allogeneic donor T cells is more effective than expressing the tumor-specific
TCR on syngeneic donor T cells.
Adoptive Transfer of Splenocytes from Mice Treated with TIL 1383I TCR
Transduced Allogeneic T Cells Suppresses Growth of Established B16 Tumors
We next tested if adoptively transferring splenocytes from TIL 1383I TCR
transduced mice into a second group of untreated mice bearing established B16 tumors
could impact on tumor progression (Fig 63). B16 A2/Kb tumor-bearing mice were first
treated with TIL 1383I TCR transduced T cells or controls. Seven days later, spleens
were harvested and adoptively transferred into a second group of mice with 7 day old
established, palpable B16 tumors. B16 tumors grew rapidly in mice that did not receive
T cells or mice treated with untransduced allogeneic T cells (Fig 64A and B).

180

Figure 63. Experimental Design to Determine If the Transfer of T Cells from TIL
1383I TCR Transduced Allogeneic T Cell-Treated Mice Can Reject Established
B16 Tumors. Seven days after treatment of B16 A2/Kb tumors with TIL 1383I TCR
transduced T cells, spleens were isolated and 1 x 106 splenocytes were adoptively
transferred i.v, into mice bearing established 7- day old B16 tumors. Mice were
monitored for survival and B16 tumor growth.

Unexpectedly, splenocytes transferred from mice treated with TIL 1383I TCR
transduced syngeneic T cells did not have a therapeutic effect on B16 tumors (Fig
64C).In contrast, we observed substantial attenuation of B16 tumor growth in mice that
received splenocytes isolated from mice bearing B16 A2/Kb tumors that were treated
with TIL 1383I TCR transduced allogeneic T cells (Fig 64D). Linear regression analysis
of B16 tumor growth demonstrated that adoptive transfer of TIL1383I TCR transduced
allogeneic T cells significantly impaired B16 tumor progression compared to TIL1383I
TCR transduced syngeneic T cells (P=0.0028, Fig 65). In a follow-up experiment, the
transfer of splenocytes from mice treated from TIL 1383I TCR transduced allogeneic T
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cells also similarly delayed the progression of established B16 tumors (Fig 73-74).
These results suggested that TIL 1383I TCR transduced allogeneic T cells could induce
cross-primed T cells capable of transferring anti-tumor immunity to naïve mice with
established B16 tumors.
B16 tumor-bearing mice that received splenocytes isolated from mice treated
with TIL 1383I TCR transduced syngeneic T cells-treated unexpectedly exhibited rapid
B16 growth. This contrasted with previous experiments where the therapeutic efficacy of
TIL 1383I TCR transduced syngeneic T cells was usually better than untransduced
allogeneic T cells. In parallel to splenocyte transfers, we also tested the B16 and B16
A2/Kb tumor reactivity of donor splenocytes used for adoptive transfer by IFN-g
ELISPOT assay. In support of the results from the adoptive transfer pilot experiment,
the splenocytes from TIL 1383I TCR transduced allogeneic T cell-treated mice had a
significant frequency of IFN-g+ cells when co-cultured with B16 tumors in vitro compared
to splenocytes transferred from untreated mice (P=0.0412), untransduced allogeneic T
cell-treated mice (P=0.0035) and TIL 1383I TCR transduced syngeneic T cell-treated
mice (P=0.0047; Fig 66).Furthermore, we detected an increased frequency of B16
A2/Kb-reactive splenocytes following TIL 1383I TCR transduced allogeneic T cell
treatment compared to PBS (P=0.0931), untransduced allogeneic T cells (P=0.0773),
and TIL 1383I TCR transduced syngeneic T cells (P=0.0171). Splenocytes from mice
treated with TIL 1383I TCR transduced allogeneic T cells were significantly more
reactive against B16 and B16 A2/Kb cells compared to EL4 and EL4 A2 cells (P=0.0135
and P= 0.0056, respectively; Fig 66), confirming the tumor antigen-specificity of
treatment-induced endogenous T cells found in the tumor draining lymph nodes of mice.
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Figure 64. Adoptive Transfer of Splenocytes from TIL 1383I TCR Transduced
Allogeneic T Cell-Treated Mice Suppresses Growth of B16 Tumors in Individual
Mice. B16 tumor cells were inoculated into recipient mice, and seven days later,
recipient mice received 1 x 106 splenocytes i.v. from donor mice bearing B16 A2/Kb
tumors A) untreated or treated with B) untransduced allogeneic T cells C) TIL 1383I
TCR transduced syngeneic T cells D) TIL 1383I TCR transduced allogeneic T cells.
B16 tumors were measure 2-3 times per week. Mice were sacrificed when tumors
reached >150 mm2 or >10% body weight. Data represent one pilot experiment with
3-5 mice/group.
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Figure 65. Delayed B16 Tumor Progression Following Transfer of T Cells from
TIL 1383I TCR Transduced Allogeneic T Cell-Treated Mice. B16 tumor cells were
inoculated into recipient mice, and seven days later, recipient mice received 1 x 106
splenocytes i.v. from donor mice bearing B16 A2/Kb tumors treated with
untransduced allogeneic T cells, TIL 1383I TCR transduced syngeneic T cells, or TIL
1383I TCR transduced allogeneic T cells. Recipient mice were monitored for survival
and B16 tumor growth. Mice were sacrificed when tumors reached >150 mm2 or
>10% body weight. A) Average B16 tumor growth curves B) Slope determined by
linear regression analysis of group averages of B16 tumor growth. Data from A-B
represents one pilot experiment with 3-4 mice/group. C) B16 tumor growth after
receiving splenocytes from B16 A2/Kb tumor-bearing mice treated with TIL 1383I
TCR transduced allogeneic T cells or untreated mice. D) B16 slope. Data from C-D
represents two independent experiments with 7 (NT)- 8 (Td Allo) mice. Graph shows
mean ± SEM; Statistical analysis using one- way ANOVA with Tukey correction
[*P<0.05, **P<0.01]
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Figure 66. Tumor Reactivity of Donor Splenocytes Isolated from T Cell-Treated
Mice Used for Adoptive Transfer. Seven days after treating B16 A2/Kb tumorsbearing donor mice with TIL 1383I TCR transduced T cells, spleens were isolated
and 100,000 splenocytes were co-cultured with 100,000 B16, B16 A2/Kb, EL4, or EL4
A2 tumor targets in an IFN-g ELISPOT assay. Data represent one pilot experiment.
Graph shows mean ± SEM; Statistical analysis using 2way ANOVA with Tukey
correction [*P<0.05, **P<0.01]

These data further support our hypothesis that intratumoral treatment with TIL 1383I
TCR transduced allogeneic T cells induces cross-primed T cells that can transfer antitumor immunity to treat establish B16 tumors in naïve mice.

CHAPTER SEVEN
COMBINATION IMMUNOTHERAPIES TO ENHANCE THE EFFICACY OF
INTRATUMORAL TREATMENT WITH TIL 1383I TCR TRANSDUCED ALLOGENEIC
T CELLS
Rationale
Intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells
improved anti-tumor outcomes compared to TIL 1383I TCR transduced syngeneic T
cells. Although we observed protection against B16 tumors in approximately 50% of
mice treated with TIL 1383I TCR transduced allogeneic T cells, there remained room for
improvement. We next sought to improve upon anti-tumor responses using additional
immunomodulatory agents. In our studies, we explored three different approaches that
have been reported to modulate the tumor microenvironment and enhance T cell
responses: 1) Stimulating innate immune responses with the addition of the TLR3
agonist, poly I:C 2) Adding an immune-stimulating gene, LIGHT, to the retroviral vector
3) Activating T cell responses with the addition of checkpoint inhibitors, anti-PD-1 mAb
and anti-CTLA-4 mAb.
Addition of the TLR3 Agonist Poly I:C
Previous experiments demonstrated that intratumoral treatment with TIL 1383I
TCR transduced allogeneic T cells resulted in the induction of specialized antigen crosspresenting DC subsets and the promotion of T cell activation, which culminated in the
cross-priming of functional, endogenous tumor antigen-specific T cells that mediated
185
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protective and therapeutic effects. TLR stimulation has been demonstrated to induce
DC maturation, antigen presentation, and tumor-specific CTL487,488,157. For example,
administration of the TLR3 agonist, poly I:C, has been effective at inducing anti-tumor
responses in pre-clinical mouse studies and one pilot trial with two cancer
patients130,137,142. There have been additional reports demonstrating that poly I:C can be
effective at inducing immune responses against B16 tumors489. Therefore, we first
performed a series of small-scale pilot experiments to test if combination therapy with
poly I:C and TIL 1383I TCR transduced T cells could further suppress B16 A2/Kb tumor
growth and enhance cross-priming of T cells.
We intratumorally treated B16 A2/Kb tumors with TIL 1383I TCR transduced
syngeneic T cells, TIL 1383I TCR transduced allogeneic T cells or untransduced
allogeneic T cells and the following day, mice received 40 µg of poly I:C or saline
intratumorally (Fig 67). We measured B16 A2/Kb tumors every 2-3 days and sacrificed
mice seven days after intratumoral treatment with poly I:C (or PBS) to assess crosspriming by IFN-g ELISPOT assays. The addition of poly I:C did not appear to improve
upon B16 A2/Kb tumor suppression compared to intratumoral treatment with only
untransduced T cells, TIL 1383I TCR transduced syngeneic T cells, or TIL 1383I TCR
transduced allogeneic T cells (Fig 68 and Fig 69). When cells from the tumor draining
lymph nodes of treated mice were re-stimulated with irradiated B16 A2/Kb tumors ex
vivo for 5 days and then co-cultured with B16 and B16 A2/Kb tumors in an IFN-g
ELISPOT assay, we observed extremely robust reactivity accompanied with high
background and unfortunately could not interpret the results (Appendix Fig 103 and Fig
104).
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Figure 67. Experimental Design to Determine If the Combination of TIL 1383I
TCR Transduced Allogeneic T Cells and Poly I:C Improves Anti-Tumor
Responses. B16 A2/Kb tumor-bearing mice were intratumorally treated on day 10
post-tumor inoculation with TIL 1383I TCR transduced allogeneic T cells or
untransduced allogeneic T cells and one day later received an intratumoral injection
of 40 µg poly I:C or PBS. Tumor area was measured with a digital caliper 2-3x/week
and presented as the product of two opposing diameters. Mice were sacrificed 11
days after poly I:C treatment for further analysis.
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Figure 68. B16 A2/Kb Tumor Growth of Individual Mice Following Combination
Treatment with T Cells and Poly I:C. B16 A2/Kb tumor-bearing mice were
intratumorally treated on day 10 with A) PBS B) untransduced allogeneic T cells C-D)
TIL 1383I TCR transduced allogeneic T cells and one day later received an
intratumoral injection of B and D) poly I:C or C) PBS. Mice were sacrificed eleven
days later to examine T cell cross-priming by IFN-g ELISPOT assay. (i.t=
intratumoral). Graphs represent one pilot experiment.
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Figure 69. B16 A2/Kb Tumor Growth Following Combination Treatment with T
Cells and Poly I:C. B16 A2/Kb tumor-bearing mice were intratumorally treated on day
10 with untransduced allogeneic T cells, TIL 1383I TCR transduced syngeneic T cells,
or TIL 1383I TCR transduced allogeneic T cells. The next day, mice were intratumorally injected with PBS (solid line) or 40 µg poly I:C (dotted line) and sacrificed one
week later. A) Average B16 A2/Kb tumor growth. B) Slope derived from linear regression
analysis. C) Linear regression analysis. Graphs represent one pilot experiment with 5
mice per group. Statistical analysis was performed using one-way ANOVA (*P<0.05).
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We then performed a second pilot experiment using an adoptive transfer
experimental approach to determine if T cell cross-priming could be enhanced (Fig 70).
Ten days after intratumoral poly I:C treatment, we harvested the spleens of treated B16
A2/Kb tumor-bearing mice (donors, Group 1) to determine if treatment-induced T cells
could treat established B16 tumors (therapy, Group 2, Fig 70) or could prevent tumor
formation following challenge with B16 (protection, Group 3, Fig 70). We first examined
the effect of combination therapy on B16 A2/Kb tumors implanted in mice from Group 1
(Fig 71 and 72). The combination of poly I:C and untransduced allogeneic T cell
treatment slightly delayed the growth of B16 A2/Kb tumors compared to the combination
of no T cells and PBS (P=0.0473; Fig 71 and 72). When mice were treated with the
combination of TIL 1383I TCR transduced allogeneic T cell and poly I:C, we were
unable to detect a significant difference in the ability to suppress B16 A2/Kb tumor
growth compared to the combination of TIL 1383I TCR transduced T cells and PBS
(P=0.7023), consistent with the previous pilot experiment (Fig 68 and 69).
We adoptively transferred splenocytes from mice bearing B16 A2/Kb tumors that
had been treated with T cells (Group 1; Fig 70-72) into mice bearing seven-day-old
subcutaneous B16 tumors (Group 2) to test the therapeutic efficacy of the combination
of TIL 1383I TCR transduced allogeneic T cells and poly I:C. In this small-scale pilot
experiment, B16 tumor-bearing mice receiving splenocytes from mice treated with the
combination of TIL 1383I TCR transduced allogeneic T cells and PBS (Group 1) had
evidence of B16 tumor regression compared to B16 tumor-bearing mice receiving
splenocytes isolated from mice treated with the combination of untransduced allogeneic
T cells and poly I:C (P=0.0016), or no T cells and PBS (P<0.0001; Fig 73 and 74).
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Figure 70. Experimental Design to Determine if T Cell-Induced Splenocytes Can
Transfer Therapeutic or Prophylactic Immunity Against B16 Tumors in Naïve
Mice. B16 A2/Kb tumor-bearing mice were treated with TIL 1383I TCR transduced
allogeneic T cells or untransduced allogeneic T cells and the following day received
an intratumoral injection of poly I:C or PBS (Group 1). Ten days later, splenocytes
were isolated and transferred into a) Mice bearing 7-day-old B16 tumors (Group 2) or
b) Naïve mice that were then challenged with B16 two days post-T cell transfer
(Group 3). Mice were monitored for development of B16 tumors.
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Figure 71. B16 A2/Kb Tumor Growth of Individual Mice Following Combination
Treatment with T Cells and Poly I:C. Group 1 B16 A2/Kb tumor-bearing mice were
intratumorally treated on day 10 with A) PBS B) untransduced allogeneic T cells C-D)
TIL 1383I TCR transduced allogeneic T cells and one day later received an
intratumoral injection of D) poly I:C or C) PBS. Mice were sacrificed eleven days
later to examine T cell cross-priming by IFN-g ELISPOT assay. (i.t= intratumoral).
Graphs represent one pilot experiment with 3-6 mice per group.
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Figure 72. Average B16 A2/Kb Tumor Growth Following Intratumoral
Combination Therapy with T Cells and Poly I:C. B16 A2/Kb tumor-bearing mice
were intratumorally treated on day 10 post-B16 A2/Kb with PBS, untransduced
allogeneic T cells or TIL 1383I TCR transduced allogeneic T cells and one day later
received an intratumoral injection of poly I:C or PBS. A) Average B16 A2/Kb growth
following intratumoral treatment. B) Slope of B16 A2/Kb growth from group averages.
Data represent one pilot experiment with 3-6 mice per group. Graph shows mean ±
SEM; Statistical analysis performed using one-way ANOVA with Tukey correction
[*P<0.05, ***P<0.001, ****P<0.0001]
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Splenocytes transferred from mice intratumorally treated with the combination of TIL
1383I TCR transduced allogeneic T cells and poly I:C also significantly improved antiB16 tumor responses following adoptive transfer into B16 tumor-bearing mice compared
to the adoptive transfer of splenocytes isolated from mice intratumorally treated with
untransduced allogeneic T cells and poly I:C (P= 0.0013), or PBS (P<0.0001; Fig 73
and 74). The therapeutic effect observed following intratumoral treatment with TIL 1383I
TCR transduced allogeneic T cells was independent of the addition of TLR3 stimulation
(ns, P=0.9981). However, the addition of poly I:C to untransduced allogeneic T celltreated mice induced moderate therapeutic anti-B16 responses compared to PBStreated mice (P=0.0152). These preliminary data suggest that the addition of poly I:C
might improve the therapeutic efficacy of T cell responses, as demonstrated by the
slight improvement when added to untransduced allogeneic T cells treatment alone or in
comparison to PBS (Fig 69 and Fig 72) but the lack of improvement when combined
with transduced T cell treatment indicated that these experiments should be repeated in
order to reach conclusive findings.
The transfer of anti-tumor immunity to treat established B16 tumors is generally
more difficult than prevention experiments. Therefore, we performed a small-scale pilot
experiment to determine if splenocytes from mice with B16 A2/Kb tumors treated with
the combination of TIL 1383I TCR transduced allogeneic T cells and poly I:C (Group 1)
could transfer protection and prevent the development of B16 tumors in naïve mice
(Group 3; Fig 70). We adoptively transferred splenocytes from the T cell-treated mice in
Group 1 into naïve mice, allowed engraftment for two days, and then subcutaneously
inoculated mice with B16 tumor cells. The transfer of splenocytes from mice treated with
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Figure 73. B16 Tumor Growth in Individual Mice Following the Adoptive Transfer
of Splenocytes From Mice Treated with the Combination of TIL 1383I TCR
Transduced T Cells and Poly I:C. Mice were inoculated with 1.5x105 B16 tumor cells
and seven days later received adoptive transfer of splenocytes from B16 A2/Kb tumorbearing HLA-A2 transgenic mice treated with A) PBS B) untransduced allogeneic T
cells and poly I:C C) TIL 1383I TCR transduced allogeneic T cells and PBS, or D) TIL
1383I TCR transduced allogeneic T cells and poly I:C. Graphs represent one pilot
experiment with 3-5 mice per group.
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Figure 74. Average B16 Tumor Growth Following the Adoptive Transfer of
Splenocytes from Mice Treated with the Combination of TIL 1383I TCR
Transduced Allogeneic T cells and Poly I:C. Mice were inoculated with 1.5x105 B16
tumor cells and 7 days later received adoptive transfer of splenocytes from T celltreated, B16 A2/Kb tumor-bearing mice (Group 1). A) Average B16 tumor growth
following T cell transfer B) Slope of B16 tumor progression from group averages. Data
represent one pilot experiment. Graph shows mean ± SEM; C) Statistical analysis
using one-way ANOVA with Tukey correction [*P<0.05, **P<0.01, ****P<0.0001]
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TIL 1383I TCR transduced allogeneic T cells, regardless of poly I:C addition, did not
prevent the development of B16 tumors following transfer into recipient mice (Fig 75).
When we compared the slope of B16 tumor progression among treatment groups, we
observed a modest suppression of B16 tumor growth in mice that received splenocytes
isolated from B16 A2/Kb tumor-bearing mice that had been intratumorally treated with
the combination of TIL 1383I TCR transduced allogeneic T cells and poly I:C (slope:
2.450) compared to B16 tumor-bearing mice that had received splenocytes from B16
A2/Kb tumor-bearing mice treated with TIL 1383I TCR transduced allogeneic T cells and
PBS (slope: 3.092, P=0.0396), untransduced allogeneic T cells and poly I:C (slope:
3.384, P=0.0021) and no T cells and PBS (slope: 3.838, P<0.0001, Fig 76). The results
from these pilot experiments suggest that, in our model of using intratumoral delivery of
TCR gene-modified T cells, the combination of TIL 1383I TCR transduced allogeneic T
cells and subsequent poly I:C might possibly improve the suppression of primary B16
A2/Kb tumor growth or transfer anti-tumor immunity to mice bearing established B16
tumors. However, in these small scale experiments, we cannot draw a reliable
conclusion from the limited number of mice and limited treatment strategies Therefore,
the addition of poly I:C to TIL 1383I TCR transduced allogeneic T cell treatment might
enhance the induction of cross-primed T cells, which would have to be further verified in
replicate experiments.
Incorporation of the LIGHT Gene into the Retroviral Vector
The addition of a TLR agonist, such as poly I:C, to stimulate an innate immune
response is only one potential approach that one could use to modulate the tumor
microenvironment (TME) in order to facilitate DC activation and T cell cross-priming.
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Figure 75. Splenocytes from B16 A2/Kb Tumor-Bearing Mice Treated with the
Combination of TIL 1383I TCR Transduced Allogeneic T Cells and Poly I:C
Transferred into Naïve Mice Delay Progression of B16 Tumors. Naïve mice
received 1.0x106 splenocytes (black arrow) from B16 A2/Kb tumor-bearing mice
(Group 1) intratumorally treated with A) PBS, B) untransduced allogeneic T cells and
poly I:C, C) TIL 1383I TCR transduced allogeneic T cells and PBS, or D) TIL 1383I
TCR transduced allogeneic T cells and poly I:C. Two days later, mice were
subcutaneously inoculated with 1.0 x105 B16 tumor cells (pink arrow) and monitored
for the development of B16 tumors. Graphs represent one pilot experiment with 6
mice per group.
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Figure 76. Splenocytes From Mice Treated with the Combination of TIL 1383I
TCR Transduced Allogeneic T Cells and Poly I:C Transfer Anti-Tumor Immunity
to naïve mice. Naïve mice received 1 x106 splenocytes from T cell-treated donor
mice (Group 1) and two days later were inoculated with 1x105 B16 tumor cells
subcutaneously. A) Average B16 tumor growth following the transfer of T cells. B)
Slope of B16 tumor progression from group averages. Data represent one pilot
experiment with 6 mice per group. Graph shows mean ± SEM C) Statistical analysis
using one-way ANOVA with Tukey correction [* P<0.05, **P<0.01, ****P<0.0001]
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Another approach is to modify the retroviral vector used to express the TCR genes to
incorporate additional genes that encode for proteins that alter the TME and stimulate
immune responses. One candidate gene, LIGHT [TNFSF14 (homologous to
Lymphotoxins, shows Inducible expression, and competes with herpes simplex virus
Glycoprotein D for Herpesvirus entry mediator, a receptor expressed by T
lymphocytes)], is a TNF superfamily member and ligand for the lymphotoxin beta
receptor (LTbR)490. The LIGHT protein is expressed on activated T cells and dendritic
cells (DCs). Upon interaction with LTbR on stromal cells, LIGHT recruits and activates T
cells and DCs to form lymphoid-like tissue structures inside the tumor
microenvironment, which can result in the maturation of DCs and the induction of T cell
cross-priming, ultimately leading to an effective anti-tumor response491,492493.
Because our ultimate goal is to induce T cell cross-priming, we hypothesized that
engineering the TIL 1383I TCR-encoding retroviral vector to express the LIGHT gene
could further improve tumor antigen cross-presentation by DCs and anti-tumor T cell
responses. We cloned the extracellular domain of the LIGHT protein into the vector
containing the TIL 1383I TCR a and b chain genes (Fig 77A). We were able to detect
low surface levels of LIGHT expression following transduction and were able to identify
intracellular LIGHT protein after permeabilizing T cells and staining with anti-LIGHT
antibody (Fig 77B). These data confirmed the feasibility of generating TIL 1383I TCR
transduced T cells that co-express the LIGHT extracellular domain.
In a pilot study, we tested the efficacy of TIL 1383I TCR+LIGHT+ transduced T
cells in vivo. We transduced syngeneic and allogeneic T cells with a vector encoding the
TIL 1383I TCR only or a vector co-expressing the TIL 1383I TCR and LIGHT genes.
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Figure 77. Engineering T Cells to Express the TIL 1383I TCR and Extracellular
LIGHT Domain. Mouse T cells were activated for 48 hours with Dynabeads and then
transduced with retrovirus. Three days post-transduced, T cells were examined for
expression of CD3, CD4, CD8, Vb12 and LIGHT. A) Schematic of the retroviral vector
containing the TIL 1383I TCR a and b chain genes and extracellular LIGHT gene. B)
Expression of the TIL 1383I TCR and LIGHT protein following retroviral transduction.
Prior to flow cytometry, T cells were treated with brefeldin A (BfA) and monensin with
and without permeabilization.

On day 10 post-B16 A2/Kb injection, mice were intratumorally treated with TIL 1383I
TCR transduced syngeneic or allogeneic T cells with or without LIGHT. Surprisingly,
treatment with TIL 1383I TCR+LIGHT+ transduced allogeneic T cells (slope: 0.4847 ±
0.7920) was slightly less effective at suppressing B16 A2/Kb tumor growth than TIL
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1383I TCR transduced allogeneic T cells alone (slope: -0.6423 ± 0.3486, P= 0.7469; Fig
78 and 79). TIL 1383I TCR transduced syngeneic T cells co-expressing LIGHT (slope:
1.498 ± 0.5305) were equally effective at suppressing B16 A2/Kb tumor growth as TIL
1383I TCR transduced syngeneic T cells alone (slope: 1.666 ± 0.6916, P=0.9999).
From these pilot experiments, the co-expression of LIGHT and TIL 1383I TCR did not
appear to have an impact on anti-tumor responses. These results suggested that further
replicate experiments should be performed in order to determine if the addition of
LIGHT enhances the efficacy of TIL 1383I TCR transduced T cell treatment.
We entertained the possibility that LIGHT-expressing TIL 1383I TCR transduced
T cells might enhance T cell cross-priming without having a noticeable effect on the size
of primary B16 A2/Kb tumors. We, therefore, examined the tumor draining lymph nodes
after intratumoral treatment with TIL 1383I TCR+ LIGHT+ transduced T cells for
evidence of T cell cross-priming by IFN-g ELISPOT assays (Fig 80). The tumor draining
lymph nodes isolated from mice treated with TIL 1383I TCR transduced allogeneic T
cells contained a significant frequency of IFN-g+ cells in response to B16 tumors (spots:
178.75 ± 39.76) compared to the tumor draining lymph nodes of mice treated with TIL
1383I TCR transduced syngeneic T cells (31.667 ± 17.407, P<0.01), TIL 1383I
TCR+LIGHT+ transduced syngeneic T cells (15.0 ± 3.536, P<0.001), untreated mice
(13.33 ± 6.667, P<0.001) and naïve mice (13.33 ± 13.33, P<0.001; Fig 80A). However,
we were unable to detect a significant frequency of B16-reactive T cells from the lymph
nodes of mice treated with TIL 1383I TCR+LIGHT+ transduced allogeneic T cells (spots:
91.250 ± 57.387) compared to TIL 1383I TCR+ transduced allogeneic T cells only.
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Figure 78. B16 A2/Kb Tumor Growth in Individual Mice Following Intratumoral
Treatment with T Cells Transduced to Express the TIL 1383I TCR or Co-Express
the TIL 1383I TCR + LIGHT Protein. Syngeneic or allogeneic T cells were
transduced with retroviral vectors encoding the TIL 1383I TCR or TIL 1383I TCR +
LIGHT. On day 10 post-B16 A2/Kb tumor inoculation, mice were A) left untreated or
treated with B) TIL 1383I TCR Td Syn T cells C) TIL 1383I TCR + LIGHT Td Syn T
cells D) TIL 1383I TCR Td Allo T cells E) TIL 1383I TCR + LIGHT Td Allo T cells.
Tumors were measured 2-3 times/week and mice were sacrificed on day 7 post-T
cell treatment for ELISPOT assays. Graphs represent one pilot experiment with 3-6
mice per group.
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Figure 79. Linear Regression Analysis of B16 A2/Kb Tumor Growth Following
Treatment with T Cells Transduced to Co-Express the TIL 1383I TCR and LIGHT
Protein. Syngeneic or allogeneic T cells were transduced with retroviral vectors
encoding the TIL 1383I TCR or TIL 1383I TCR and LIGHT. On day 10 post-B16 A2/Kb
tumor inoculation, mice were left untreated or treated with TIL 1383I TCR Td Syn T
cells, TIL 1383I TCR + LIGHT Td Syn T cells, TIL 1383I TCR Td Allo T cells or TIL
1383I TCR + LIGHT Td Allo T cells. Tumors were measured 2-3 times/week and mice
were sacrificed on day 7 post-T cell treatment for ELISPOT assays. A) Average B16
A2/Kb tumor growth following T cell treatment B) Slope of B16 A2/Kb growth derived
from C) linear regression analysis of group averages. Data represent one pilot
experiment with 3-6 mice per group. Graph shows mean ± SEM; Statistical analysis
using one-way ANOVA with Tukey correction [**P<0.01, ***P<0.001, ****P<0.0001]
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Figure 80. Tumor-Specific IFN-g Production by Endogenous T Cells Following
Intratumoral Treatment with T Cells that Co-Express the TIL 1383I TCR and
LIGHT Protein. Seven days post-intratumoral T cell treatment, cells from the tumor
draining lymph nodes were isolated and co-cultured with A) Tumor targets or B)
gp100- or TRP-2-loaded RMA/S cells for 18 hours. Data represent one pilot
experiment with 3-6 mice per group. Graph shows mean ± SEM; Statistical analysis
using 2way ANOVA with Tukey correction [* P<0.05, **P<0.01, ***P<0.001,
****P<0.0001; #P<0.05 RMAS vs gp100]
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We observed a significant frequency of gp100-reactive T cells the tumor draining lymph
nodes of mice treated with TIL 1383I TCR transduced allogeneic T cells compared to
unpulsed RMA/S cells (P=0.0229; Fig 80B). None of the cells isolated from the tumor
draining lymph nodes of treated mice were reactive against gp100- or TRP-2-loaded
RMA/S cells (Fig 80B). The results from this pilot experiment suggested that coexpressing LIGHT with the TIL 1383I TCR may or may not enhance cross-primed T
cells reactive against B16 or B16 A2/Kb tumors, and further replicate experiments
should be performed.
It was possible that co-expressing the TIL 1383I TCR and LIGHT intrinsically
diminished the function of TIL 1383I TCR transduced T cells. We decided to perform
another pilot experiment to test whether the administration of recombinant LIGHT
protein could improve the anti-tumor efficacy following treatment with TIL 1383I TCR
transduced T cells. Interestingly, intratumoral administration of recombinant LIGHT
protein concurrent with TIL 1383I TCR transduced allogeneic T cells (slope: 2.125) did
not delay B16 A2/Kb tumor growth compared to TIL 1383I TCR transduced allogeneic T
cells alone (slope: 2.871, P=0.9993; Fig 81 and 82). Similarly, TIL 1383I TCR
transduced syngeneic T cells with recombinant LIGHT (slope: 4.684) did not improve
tumor suppression compared to TIL 1383I TCR transduced syngeneic T cells alone
(slope: 4.589, P>0.9999). The lack of improved anti-tumor responses following
intratumoral treatment with the recombinant LIGHT protein was not limited to mice
treated with TIL 1383I TCR transduced T cell treatment, as we did not observe a
significant anti-tumor response in mice treated with recombinant LIGHT alone (slope:
6.615) compared to mice treated with PBS (slope: 8.053, P=0.9854; Fig 81 and 82).
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Figure 81. B16 A2/Kb Tumor Growth in Individual Mice Following Intratumoral
Treatment with TIL 1383I TCR Transduced T Cells +/- Recombinant LIGHT
Protein. B16 A2/Kb tumor-bearing mice were A) left untreated or B) treated with
rLIGHT C) TIL 1383I TCR transduced syngeneic T cells D) TIL 1383I TCR transduced
syngeneic T cells + rLIGHT E) TIL 1383I TCR transduced allogeneic T cells F) TIL
1383I TCR transduced allogeneic T cells + LIGHT. Tumors were measured 2-3 times
per week. Graphs represent one pilot experiment with 3 mice per group.
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Figure 82. Linear Regression Analysis of B16 A2/Kb Tumor Growth Following
Treatment with TIL 1383I TCR Transduced T Cells and Recombinant LIGHT
Protein. A) Group averages of B16 A2/Kb tumors following intratumoral treatment. B)
Slope of B16 A2/Kb growth from group averages. Graph shows mean ± SEM; No
statistical significance was observed using one-way ANOVA with Tukey correction.
Graph represent one pilot experiment with 3 mice per group.
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From these pilot studies, we concluded that co-expressing LIGHT with the TIL 1383I
TCR on transduced T cells may improve responses against B16 A2/Kb primary tumors
and enhance T cell cross-priming. Furthermore, the addition of intratumoral recombinant
LIGHT protein to TIL 1383I TCR transduced T cells might mediate improved anti-tumor
responses compared to TIL 1383I TCR transduced T cell treatment. Future replicate
experiments should be performed to address these treatments.
Combination Therapy with Anti-PD-1 and Anti-CTLA-4 Monoclonal Antibodies
There has been rising success in the use of checkpoint inhibitors to treat various
malignancies. We wanted to determine if the addition of checkpoint inhibitors could
enhance the therapeutic efficacy of TIL 1383I TCR transduced allogeneic T cells. We
observed an increase in PD-1 expression on CD8+ T cells in the tumor
microenvironment following treatment with TIL 1383I TCR transduced allogeneic T cells
compared to treatment with TIL 1383I TCR transduced syngeneic T cells (P<0.0001)
and PBS (P=0.0006; Fig 83). We first investigated whether the addition of anti-PD-1
monoclonal antibodies (mAb) could improve anti-tumor responses in a pilot study. Mice
were intratumorally treated with TIL 1383I TCR transduced T cells and intraperitoneally
injected with 200 µg of anti-PD-1 mAb. Seven days post-treatment, mice were
challenged with B16 on the contralateral flank (Fig 84). We monitored survival and the
development of B16 tumors. For overall survival, the addition of anti-PD- 1 mAb did not
significantly increase median survival post-treatment (Fig 85, Table 2). Additionally,
when mice were monitored for B16 tumor development, we observed a delay in B16
tumors in mice treated with TIL 1383I TCR transduced allogeneic T cellsHowever, the
addition of anti-PD-1 mAb did not improve anti-tumor responses (Fig 86, Table 3).
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Figure 83. Expression of Immune Checkpoints on T Cells in the Tumor
Microenvironment Following TIL 1383I TCR Transduced T Cell Treatment.
Seven days after intratumoral treatment with TIL 1383I TCR syngeneic T cells, TIL
1383I TCR transduced allogeneic T cells, untransduced allogeneic T cells, or PBS,
B16 A2/Kb tumors were harvested and cells were analyzed for expression of CD3,
CD4, CD8, CTLA-4, PD-1, and TIM-3 by flow cytometry. A) CD3+CD4+ T cells B)
CD3+CD8+ T cells. Symbols (circles and squares) represent two independent
experiments with 4-5 mice/group. Cells were gating on live, single cells. Graph shows
mean ± SEM; Statistical analysis using one-way ANOVA with Tukey correction [*
P<0.05, ***P<0.001, ****P<0.0001]
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Figure 84. Experimental Design to Determine if the Combination of Anti-PD-1
Monoclonal Antibody and TIL 1383I TCR Transduced T Cell Treatment
Enhances Anti-Tumor Responses. Mice were subcutaneously inoculated with
2.5x105 B16 A2/Kb tumor cells and ten days later, were treated i.p with anti-PD-1
mAb or control mAb and intratumoral injections of TIL 1383I TCR transduced
allogeneic T cells, TIL 1383I TCR transduced syngeneic T cells, untransduced
allogeneic T cells, or PBS. Administration of anti-PD-1 mAb continued 2x/week.
Seven days post-T cell treatment, mice were challenged with 1.0 x105 B16 tumor
cells on the left contralateral flank. Mice were monitored for survival and the
appearance of B16 tumors. Mice were sacrificed when one tumor or the sum of both
tumors exceeded >150 mm2 or >10% body weight.

212

Survival
100

Percent survival

80

60

40

20

0

0

5

10

15

20

25

30

Day post-treatment

Figure 85. Survival of B16 A2/Kb Tumor Bearing Mice Following Treatment with
TIL 1383I TCR Transduced T cells and Anti-PD-1 Monoclonal Antibody. B16
A2/Kb tumor-bearing mice were intratumorally treated with TIL 1383I TCR transduced
syngeneic T cells, TCR transduced allogeneic T cells, untransduced allogeneic T
cells or PBS and treated i,p with anti-PD-1 mAb (solid lines) or isotype (dotted lines).
Mice were sacrificed when tumors reached >150 mm2 or >10% body weight. Data
represent one pilot experiment with 4-5 mice/group. Statistics performed using the
Log Rank (Mantel-Cox) test. [* P<0.05, **P<0.01]
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**
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*
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Table 2. Log Rank (Mantel-Cox) Test of Survival Following Combination
Treatment with TIL 1383I TCR Transduced T Cells and Anti-PD-1 Monoclonal
Antibody. Mice were intratumorally treated with PBS, untransduced allogeneic T
cells, TIL 1383I TCR transduced syngeneic T cells, or TIL 1383I TCR transduced
allogeneic T cells alone or in combination with 200 µg of anti-PD-1 and anti-CTLA-4
in 100 µl volume intraperitoneally. Tumors were measured with a digital caliper 2-3
time per week. Mice were sacrificed when tumors reached >150 mm2 or >10% body
weight. Data represent one pilot experiment with 4-5 mice/group. Statistics performed
using the Log Rank (Mantel-Cox) test. [* p<0.05, **p<0.01]
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Figure 86. Percentage of Mice Protected from Contralateral B16 Following
Treatment of Primary B16 A2/Kb Tumors with TIL 1383I TCR Transduced T Cells
and Treatment with Anti-PD-1 Monoclonal Antibody. B16 A2/Kb tumor-bearing
mice were intratumorally treated with TIL 1383I TCR transduced syngeneic T cells,
TCR transduced allogeneic T cells, untransduced allogeneic T cells or PBS and
treated i,p with A) control mAb or B) anti-PD-1 mAb. Mice were sacrificed when one
tumor or the sum of both tumors reached >150 mm2 or >10% body weight. Data
represent one pilot experiment with 4-5 mice/group.
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Table 3. Log-Rank (Mantel-Cox) Test of B16 Tumor-Free Mice Following
Treatment with TIL 1383I TCR Transduced T Cells and Anti-PD-1 Monoclonal
Antibody. Mice were intratumorally treated with PBS, untransduced allogeneic T
cells, TIL 1383I TCR transduced syngeneic T cells, or TIL 1383I TCR transduced
allogeneic T cells alone or in combination with 200 µg of anti-PD-1 and anti-CTLA-4
in 100 µl volume intraperitoneally. Tumors were measured with a digital caliper 2-3
time per week. Mice were sacrificed when tumors reached >150 mm2 or >10% body
weight. Data represent one pilot experiment with 4-5 mice/group. Statistics performed
using the Log Rank (Mantel-Cox) test.
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These data are consistent with previous reports examining the therapeutic effects and
anti-tumor effects of systemic administration of anti-PD-1 mAb in the B16 mouse model
of melanoma352. These results indicate that anti-PD-1 mAb alone does not improve antitumor responses following intratumoral treatment with TIL 1383I TCR transduced
allogeneic T cells.
The addition of anti-CTLA-4 mAb to anti-PD-1 mAb treatment has been
demonstrated to improve responses in pre-clinical and clinical studies360,494–496. Seven
days post-T cell treatment, we observed similar expression of CTLA-4 on T cells
isolated from the tumor draining lymph nodes of mice from all treatment groups, with
about 25-35% CTLA-4+CD4+ T cells and 4-8% CTLA-4+ CD8+ T cells in the tumor
microenvironment (Fig 83). We then tested whether anti-CTLA-4 mAb, in combination
with anti-PD-1 mAb, could enhance the efficacy of intratumoral treatment with TIL 1383I
TCR transduced allogeneic T cells (Fig 87). Mice were inoculated with B16 A2/Kb tumor
cells on the right flank and ten days later were intratumorally injected with TIL 1383I
TCR transduced T cells only or in combination with i.p anti-PD-1 mAb (200 µg) and antiCTLA-4 mAb (200 µg). We continued administering the checkpoint inhibitors twice
weekly. The addition of dual anti-PD-1 mAb/anti-CTLA-4 mAb significantly extended the
median survival of mice treated with TIL 1383I TCR transduced allogeneic T cells
(median survival: 39 days post-treatment vs 27 days post-treatment, P<0.001; Fig 88,
Table 4). The addition of anti-CTLA-4 mAb and anti-PD-1 mAb also significantly
extended survival compared to PBS alone (median survival: 29 vs. 13 days, P=0.01).
These results demonstrated that the combination of anti-PD-1 mAb and anti-CTLA-4
mAb with TIL 1383I TCR transduced allogeneic T cell treatment can improve survival.
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Figure 87. Experimental Design to Determine If the Addition of Checkpoint
Inhibitors Enhances the Efficacy of Intratumoral Treatment with TIL 1383I TCR
Transduced Allogeneic T Cells. B16 A2/Kb tumor-bearing mice were intratumorally
treated with PBS, untransduced allogeneic T cells, TIL 1383I TCR transduced
syngeneic T cells, or TIL 1383I TCR transduced allogeneic T cells. On the same day,
mice were given 200 µg of anti-PD-1 and anti-CTLA-4 in 100 µl volume
intraperitoneally and twice weekly thereafter. Tumors were measured with a digital
caliper 2-3 time per week. Mice were sacrificed when tumors reached >150 mm2 or
>10% body weight.
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Figure 88. The Combination of TIL 1383I TCR Transduced Allogeneic T Cells
and Checkpoint Inhibitors Improves Survival of B16 A2/Kb Tumor-Bearing Mice.
Mice were intratumorally treated with A) PBS, untransduced allogeneic T cells, TIL
1383I TCR transduced syngeneic T cells, or TIL 1383I TCR transduced allogeneic T
cells alone (solid lines) or in combination with 200 µg of anti-PD-1 and anti-CTLA-4 in
100 µl volume intraperitoneally (dotted lines). Tumors were measured with a digital
caliper 2-3 time per week. Mice were sacrificed when tumors reached >150 mm2 or
>10% body weight. Data represent one independent experiment with 4-5 mice/group.
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Table 4 Log Rank (Mantel-Cox) Test of Survival Following Treatment with TIL
1383I TCR Transduced T Cells and Anti-PD-1/Anti-CTLA-4 Monoclonal
Antibodies. On day 10 post- B16 A2/Kb tumor inoculation, mice were treated with
intratumoral T cells only intratumoral T cells and i.p anti-anti-PD-1, intratumoral T
cells and i.p anti-CTLA-4, intratumoral T cells and i.p anti-PD-1/anti-CTLA-4. A)
Comparison of checkpoint inhibitor treatment groups B) Comparison of T cell
treatment groups. Data represent one experiment with 4-5 mice/group. Statistics
performed using the Log Rank (Mantel-Cox) test. [* P<0.05, **P<0.01]
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In these experiments, we only examined survival and protection against B16 tumors, but
it would be interesting to determine if combination therapy with checkpoint inhibitors and
TIL 1383I TCR transduced allogeneic T cells also resulted in enhanced CD80 and
CD86 expression on intratumoral or lymph node-resident DCs.
Linear regression analysis of B16 A2/Kb tumors indicated that the addition of antiPD-1 mAb and anti-CTLA-4 mAb also affected tumor progression (Fig 89 and Table
5). Comparing the slopes of B16 A2/Kb tumor growth curves, we did not observe a
significant difference between B16 A2/Kb tumor growth after the combination of anti-PD1 mAb and anti-CTLA-4 mAb with TIL 1383I TCR transduced allogeneic T cells;
however, the addition of anti-PD-1 mAb and anti-CTLA-4 mAb to PBS treated mice
significantly suppressed B16 A2/Kb tumor growth (P=0.0001; Fig 89, Table 5). There
was a moderate difference in B16 A2/Kb tumor suppression with TIL 1383I TCR
transduced syngeneic T cells and anti-PD-1 mAb and anti-CTLA-4 mAb (P=0.0603).
These results suggested that the addition of anti-CTLA-4 mAb was improving anti-tumor
responses following intratumoral T cell treatment.
To confirm that the addition of anti-CTLA-4 mAb was responsible for mediating
the observed enhanced anti-tumor responses, we intratumorally treated mice with PBS,
untransduced allogeneic T cells, TIL 1383I TCR transduced syngeneic T cells, and TIL
1383I TCR transduced allogeneic T cells alone or in combination with intraperitoneal
administration of 1) anti-PD-1 mAb monotherapy, 2) anti-CTLA-4 mAb monotherapy, or
3) anti-PD-1 mAb/anti-CTLA-4 mAb dual therapy (Fig 90). We continued to administer
checkpoint inhibitors twice weekly. We additionally wanted to determine if the
combination of checkpoint inhibitors further improved systemic anti-tumor responses.
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Figure 89. Intratumoral Treatment with TIL 1383I TCR Transduced T Cells and
Anti-PD-1/Anti-CTLA-4 Monoclonal Antibodies Suppresses B16 A2/Kb Tumor
Growth. B16 A2/Kb tumor-bearing mice were treated with A) intratumoral T cells only
or B) intratumoral T cells and intraperitoneal anti-PD-1 mAb (200 µg) and anti-CTLA4 mAb (200 µg) in 100 µl volume. C) Slope obtained through linear regression
analysis of B16 A2/Kb tumor growth averaged from one experiment with 4-5
mice/group. Graph shows mean ± SEM; Statistical analysis performed using oneway ANOVA with Tukey correction [*P<0.05, ***P<0.001, ****P<0.0001]
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0.1912
0.0297
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T cells only

T cells only
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UnTd Allo
anti-PD-1 mAb/anti-CTLA4 mAb
Td Syn
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Td Allo
anti-PD-1 mAb/anti-CTLA4 mAb

Table 5. Log-Rank (Mantel-Cox) Test of B16 Tumor-Free Mice Following
Treatment with TIL 1383I TCR Transduced T Cells and Anti-PD-1/Anti-CTLA-4
Monoclonal Antibodies. On day 10 post- B16 A2/Kb tumor inoculation, mice were
treated with intratumoral T cells and i.p anti-CTLA-4/anti-PD-1 monoclonal
antibodies. A) Comparison of checkpoint inhibitor treatment groups B) Comparison of
T cell treatment groups. Data represent one experiment with 4-5 mice/group.
Statistics performed using the Log Rank (Mantel-Cox) test. [*P<0.05, ***P<0.001,
****P<0.0001]
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Anti-PD-1 mAb
Anti-CTLA-4 mAb
Anti-PD-1/Anti-CTLA-4 mAb
intraperitoneally
2X/week

Figure 90. Experimental Design to Determine If the Combination of Anti-PD-1
and Anti-CTLA-4 Monoclonal Antibodies and TIL 1383I TCR Transduced T Cell
Treatment Enhances Anti-Tumor Responses. Mice were subcutaneously
inoculated with 2.5x105 B16 A2/Kb tumor cells and ten days later, were treated i.p
with PBS, anti-PD-1 mAb, anti-CTLA-4 mAb, or dual anti-PD-1 mAb/anti-CTLA-4
mAb, and intratumoral injections of TIL 1383I TCR transduced allogeneic T cells, TIL
1383I TCR transduced syngeneic T cells, untransduced allogeneic T cells, or PBS.
Administration of anti-PD-1 mAb and anti-CTLA-4 mAb continued 2x/week. Seven
days post-T cell treatment, mice were challenged with 1.0x105 B16 tumor cells on the
left contralateral flank. Mice were monitored for survival and the appearance of B16
tumors. Mice were sacrificed when one tumor or the sum of both tumors exceeded
150 mm2 or >10% of body weight.

Therefore, seven days after intratumoral treatment, mice were challenged with B16 on
the contralateral flank and monitored for survival and development of B16. The addition
of anti-PD-1 mAb and anti-CTLA-4 mAb to all intratumoral treatment groups significantly
improved the survival of B16 A2/Kb tumor-bearing mice (Fig 91, Table 6).Additionally,
the median survival of mice treated with the combination of systemic anti-PD-1
mAb/anti-CTLA-4 mAb and intratumoral TIL 1383I TCR transduced T cells was 55 days
post-T cell treatment compared to a median survival of 30 days following intratumoral
treatment with TIL 1383I TCR transduced allogeneic T cells only (P=0.0002). The
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addition of anti-CTLA-4 mAb monotherapy significantly improved the survival of tumorbearing mice compared to the addition of anti-PD-1 mAb monotherapy (P=0.0003; Fig
91, Table 6), indicating that anti-CTLA-4 mAb was predominantly mediating the
improved survival in the dual therapy-treated mice. Even with the addition of anti-CTLA4 mAb and anti-PD-1 mAb, treatment with TIL 1383I TCR transduced allogeneic T cells
significantly improved survival compared to TIL 1383I TCR transduced syngeneic T
cells (median survival: 55 vs. 42.5 days; P=0.0266). These results supported our
hypothesis that anti-CTLA-4 mAb monotherapy or anti-CTLA-4 mAb/anti-PD-1 mAb
dual therapy significantly prolonged survival of B16 A2/Kb tumor-bearing mice.
The addition of anti-CTLA-4 mAb monotherapy or anti-PD-1 mAb and anti-CTLA4 mAb dual therapy induced significant regression of B16 A2/Kb tumors compared to
intratumoral T cells only or in combination with anti-PD-1 monotherapy (Fig 92 and 93,
Table 7). The combination of intratumoral TIL 1383I TCR transduced allogeneic T cells
and dual checkpoint therapy often resulted in complete regression of B16 A2/Kb primary
tumors (P<0.0001 compared to TIL 1383I TCR transduced allogeneic T cells only). Dual
anti-PD-1 mAb/ anti-CTLA-4 mAb or anti-CTLA-4 mAb monotherapy significantly
attenuated B16 A2/Kb tumor progression compared to intratumoral treatment with PBS
(P=0.0002), untransduced allogeneic T cells (P<0.0001), and TIL 1383I TCR
transduced allogeneic T cells only (P<0.0001). These results demonstrated that antiCTLA-4 mAb or anti-PD-1 mAb/anti-CTLA-4 mAb dual therapy can promote complete
regression of B16 A2/Kb tumors following treatment with TIL 1383I TCR transduced
allogeneic T cells.
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Figure 91. The Combination of TIL 1383I TCR Transduced Allogeneic T Cells
and Anti-PD-1/Anti-CTLA-4 Improves Survival of B16 A2/Kb Tumor-Bearing
Mice. On day 10 post-B16 A2/Kb tumor inoculation, mice were treated with (A)
intratumoral T cells only (B) intratumoral T cells and i.p anti-PD-1 mAb C)
intratumoral T cells and i.p anti-CTLA-4 mAb (D) intratumoral T cells and i.p anti-PD1/anti-CTLA-4mAbs. Tumors were measured with a digital caliper 2-3 times per
week. Mice were sacrificed when tumor reached >150 mm2 or >10% body weight.
Data represent two independent experiments with 4-5 mice/group.
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Table 6. Log-Rank (Mantel-Cox) Test of Survival Following Combination
Treatment with TIL 1383I TCR Transduced T Cells and Anti-PD-1/Anti-CTLA-4
Monoclonal Antibodies. A) Comparing the efficacy of PBS, untransduced allogeneic
T cells, TIL 1383I TCR transduced syngeneic T cells and TIL 1383I TCR transduced
allogeneic T cells within checkpoint inhibitor treatment groups B) Comparing the
efficacy of anti-PD-1, anti-CTLA-4, and anti-PD-1/CTLA-4 within T cell treatment
groups. Results represent two independent experiments with 4-5 mice/group.
Statistical analysis using the Log Rank (Mantel-Cox) test. [* P<0.05, **P<0.01,
***P<0.001, ****P<0.0001]
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Intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells in
combination with systemic anti-PD-1 mAb/anti-CTLA-4 mAb dual therapy resulted in
nearly 100% protection from developing B16 tumors in comparison to TIL 1383I TCR
transduced allogeneic T cells alone (P=0.0051; Fig 94 and Table 8). Intratumoral
treatment with TIL 1383I TCR transduced allogeneic T cells in combination with antiCTLA-4 mAb monotherapy resulted in B16 protection in approximately 80% of mice
(P=0.0056 compared to TIL 1383I TCR transduced allogeneic T cells only). Consistent
with previous experiments, intratumoral treatment with TIL 1383I TCR transduced
allogeneic T cells alone or in combination with anti-PD-1 mAb monotherapy protected
approximately 30-40% of mice from B16 development.
In mice that were intratumorally treated with TIL 1383I TCR transduced
syngeneic T cells, the addition of anti-PD-1 mAb /anti-CTLA-4 mAb dual therapy
resulted in approximately 80% protection from developing B16 tumors (P= 0.0003
compared to TIL 1383I TCR transduced syngeneic T cells only) and the addition of antiCTLA-4 mAb monotherapy resulted in approximately 40% of mice that were B16 tumorfree (P=0.5445 compared to TIL 1383I TCR transduced syngeneic T cells only). The
addition of anti-CTLA-4 monotherapy or anti-PD-1 mAb/anti-CTLA-4 mAb dual therapy
to PBS- or untransduced allogeneic T cell- treated mice resulted in the protection of 5%
and 10% of mice, respectively, from developing B16 tumors. In some cases, there were
mice that were protected from developing B16 tumors but succumbed to B16 A2/Kb
tumor burden. These mice are reflected in Fig 94 as a black mark on the curve. The
final number of B16 tumor-free mice is indicated at the end of each line. Furthermore,
we observed a substantially higher number of mice developing vitiligo after treatment
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with TIL 1383I TCR transduced allogeneic T cells and dual anti-PD-1 mAb/anti-CTLA-4
mAb or mono-anti-CTLA-4 mAb checkpoint inhibitor therapy (Fig 95). Interestingly,
vitiligo was present at the primary B16 A2/Kb tumor site or at the contralateral flank
where B16 was inoculated. One mouse developed evidence of vitiligo under the belly.
These data provide evidence that the combination of intratumoral treatment with TIL
1383I TCR transduced allogeneic T cells and anti-PD-1 mAb/anti-CTLA-4 mAb dual
therapy can mediate complete regression of primary B16 A2/Kb tumors and provide
durable immunity to prevent the development of distant, untreated B16 tumors on the
contralateral flank.
Summary
In this section, we investigated whether combination therapies might augment
the efficacy of intratumoral delivery of TIL 1383I TCR transduced T cells. We targeted
the innate immune components by stimulating TLR3 with poly I:C in combination with
intratumoral T cells. However, we were unable to observe a substantial difference in
primary B16 A2/Kb tumor growth and T cells cross-priming when intratumoral poly I:C
was given the day after T cell treatment. In the second method, we engineered the
retroviral vector used to express the TIL 1383I TCR to include the extracellular domain
of the LIGHT protein. Treatment with T cells co-expressing the TIL 1383I TCR and
LIGHT protein resulted in equal or worse anti-tumor responses compared to TIL 1383I
TCR transduced T cells alone. We observed similar results when recombinant LIGHT
protein was administered with TIL 1383I TCR transduced T cell treatment. The best
anti-tumor responses were observed in mice following the combination of TIL 1383I
TCR transduced allogeneic T cells and anti-CTLA-4 mAb monotherapy or anti-CTLA-
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4/anti-PD-1 dual therapy, which resulted in protection from developing contralateral B16
tumors in nearly all treated mice.
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Figure 92. The Combination of TIL 1383I TCR Transduced T Cells and Anti-PD1/Anti-CTLA-4 Suppresses B16 A2/Kb Tumor Growth. On day 10 post-B16 A2/Kb
tumor inoculation, mice were treated with (A) intratumoral T cells only (B) intratumoral
T cells and i.p anti-PD-1 mAb C) intratumoral T cells and i.p anti-CTLA-4 mAb (D)
intratumoral T cells and i.p anti-PD-1/anti-CTLA-4 mAbs. Tumors were measured with
a digital caliper 2-3 times per week. Mice were sacrificed when one tumor or the sum
of both tumors reached >150 mm2 or >10% body weight. Data represent two
independent experiments with 4-5 mice/group. [i.p: intraperitoneal)
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Figure 93. The Impact of Combination Therapy with TIL 1383I TCR Transduced
T Cells and Anti-PD-1/Anti-CTLA-4 on the Slope of B16 A2/Kb Progression
Following Treatment. On day 10 post-B16 A2/Kb tumor inoculation, mice were
treated with intratumoral T cells only; intratumoral T cells and i.p anti-PD-1;
intratumoral T cells and i.p anti-CTLA-4; intratumoral T cells and i.p anti-PD-1/antiCTLA-4. Tumors were measured with a digital caliper 2-3 time per week. Mice were
sacrificed when one tumor or the sum of both tumors reached >150 mm2 or >10%
body weight. Slopes were obtained through linear regression analysis of B16 A2/Kb
tumor growth from group averages shown in Fig 88. Data represent two independent
experiments with 4-5 mice/group.
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Table 7. Statistical Analysis of the Slope of B16 A2/Kb Tumors Following
Treatment with TIL 1383I TCR Transduced T Cells and Anti-PD-1/Anti-CTLA-4
Monoclonal Antibodies. A) Comparing the efficacy of PBS, untransduced allogeneic
T cells, TIL 1383I TCR transduced syngeneic T cells and TIL 1383I TCR transduced
allogeneic T cells within checkpoint inhibitor treatment groups B) Comparing the
efficacy of anti-PD-1 mAb, anti-CTLA-4 mAb, and anti-PD-1/CTLA-4 mAbs within T cell
treatment groups. Results represent two independent experiments with 4-5
mice/group. Statistical analysis using the Log Rank (Mantel-Cox) test. [* P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001]
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Figure 94. The Combination of TIL 1383I TCR Transduced T Cells and Anti-PD1/Anti-CTLA-4 Monoclonal Antibodies Mediates Complete Protection Against
the Development of Contralateral B16 Tumors. On day 10 post-B16 A2/Kb tumor
inoculation, mice were treated with (A) intratumoral T cells only (B) intratumoral T cells
and i.p anti-anti-PD-1 C) intratumoral T cells and i.p anti-CTLA-4 (D) intratumoral T
cells and i.p anti-PD-1/anti-CTLA-4. Tumors were measured with a digital caliper 2-3
times per week. Mice were sacrificed when tumor reached >150 mm2 or >10% body
weight. Data represent two independent experiments with 4-5 mice/group. Number of
B16 tumor-free mice shown at the end of each line.
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Table 8. Log-Rank (Mantel-Cox) Test of B16 Tumor-Free Mice Following
Treatment with TIL 1383I TCR Transduced T Cells and Anti-PD-1/Anti-CTLA-4
Monoclonal Antibodies. A) Comparing the efficacy of PBS, untransduced
allogeneic T cells, TIL 1383I TCR transduced syngeneic T cells and TIL 1383I TCR
transduced allogeneic T cells within checkpoint inhibitor treatment groups B)
Comparing the efficacy of anti-PD-1, anti-CTLA-4, and anti-PD-1/CTLA-4 within T cell
treatment groups. Results represent two independent experiments with 4-5
mice/group. Statistical analysis using the Log Rank (Mantel-Cox) test. [* P<0.05,
**P<0.01, ***P<0.001]

235
A)

C)

B)

D)

E)

Figure 95. Increased Incidence of Vitiligo with the Combination of TIL 1383I
TCR Transduced Allogeneic T Cells and Anti-PD-1/Anti-CTLA-4 Monoclonal
Antibodies. Development of vitiligo following intratumoral treatment with TIL 1383I
TCR transduced allogeneic T cells in combination with A-B) anti-CTLA mAb or C-E)
anti-PD-1 mAb/anti-CTLA-4 mAb. Red arrow indicates site of B16 A2/Kb primary
tumor and green arrow indicates site of B16 inoculation.

CHAPTER EIGHT
DISCUSSION
Introduction
Adoptive cell transfer (ACT) of autologous TCR gene-modified T cells targeting
tumor antigens is a promising therapeutic strategy currently in clinical trials for patients
with advanced malignancies. We have seen clinical and biologic responses treating
patients with autologous TIL 1383I TCR transduced T cells administered intravenously,
as well as treating patients with allogeneic MART-1- specific TCR transduced T cells
administered intratumorally1,2. However, only a small subset of patients achieved longterm and durable responses. Some of the factors that influence the outcome of
immunotherapy are the immunosuppressive tumor microenvironment (TME),
heterogeneity of solid tumors, and evasion of immune cell detection. Patients presenting
with cold tumors, which are characterized by a lack of CD8+ T cells and interferonstimulatory genes, often have poor prognoses. Conversely, patients presenting with hot,
or T cell-inflamed, tumors are more likely to respond to immunotherapies. Therefore, it
would be advantageous to engineer TCR gene-modified T cells capable of converting
cold tumors into hot tumors to counteract the immunosuppressive TME.
The goal of this dissertation was to utilize intratumoral injections of TCR genemodified allogeneic T cells to mediate direct interactions for tumor-specific killing and
induce local inflammatory immune responses. We developed an animal model utilizing
subcutaneous B16 A2/Kb mouse melanoma tumors that express the tyrosinase antigen
236
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in the context of HLA-A2, which permits recognition by TIL 1383I TCR transduced T
cells. This mouse model also allowed us to assess the capacity of TIL 1383I TCR
transduced T cell treatment to generate B16-reactive endogenous T cells, thus
broadening the anti-tumor T cell response beyond the TCR specificity conferred by the
adoptively transferred cells. We conclude that the tumor-specific response,
characterized by TIL 1383I TCR-mediated tumor destruction leading to the release of
tumor antigens, and the allogeneic response, mediated by the host recognition of
foreign donor T cells, synergize to improve responses against injected B16 A2/Kb
tumors and to promote systemic, endogenous tumor-specific T cell responses that can
protect against distant, uninjected B16 tumors.
Intratumoral Delivery of TIL 1383I TCR Transduced T Cells Extends Survival and
Suppresses B16 A2/Kb Tumor Growth
Mouse T cells transduced to express the TIL 1383I TCR recognize B16 A2/Kb
tumor cells, but not B16 tumor cells, in a CD8-independent manner. We observed a
significant frequency of TIL 1383I TCR transduced T cells expressing CD107a, IFN-g
and TNF-a in response to B16 A2/Kb tumors in vitro, indicating the potential for
therapeutic efficacy in vivo497. Intratumoral treatment of B16 A2/Kb tumors with TIL
1383I TCR transduced allogeneic T cells improved survival and suppressed B16 A2/Kb
tumor growth compared to intratumoral treatment of B16 A2/Kb tumors with TIL 1383I
TCR transduced syngeneic T cells or untransduced allogeneic T cells. After one
intratumoral injection, we observed differences in B16 A2/Kb progression between TIL
1383I TCR transduced syngeneic and TIL 1383I TCR transduced allogeneic T celltreated mice that remained consistent among independent experiments. Translationally,
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current clinical trials testing intratumoral delivery of TCR gene-modified T cells have
demonstrated the feasibility of multiple injections into metastatic lesions2,111,498.
Therefore, while our studies performed one intratumoral injection for the purposes of
reproducibility and consistency in measuring tumor development, we expect that
multiple intratumoral injections would likely lead to more effective regression of injected
lesions in patients with cancer.
We observed additional factors that influenced the robustness and breadth of the
anti-tumor response following T cell treatment. One factor that affected anti-tumor
responses was the transduction efficiency of transferred TIL 1383I TCR transduced T
cells. The transduction efficiency, measured by expression of GFP and Vb12, averaged
51.2 ± 3.5% GFP+Vb12+ T cells for syngeneic HLA-A2 transgenic mice and 49.5 ± 3.5%
GFP+Vb12+ T cells for allogeneic BALB/c mice. In earlier experiments, we obtained 3040% TIL1383I TCR transduced T cells, with later experiments reaching ³ 60-70%
GFP+Vb12+ T cells. Experiments performed with T cells that were transduced at
efficiencies ³ 60% tended to result in better regression of B16 A2/Kb tumors and more
robust anti-tumor immunity upon characterization of the tumor and tumor draining lymph
nodes. These findings suggest that the maximum frequency of TCR gene-modified T
cells within the infused T cell product should be used.
Our lab has developed a novel approach to enrich for T cells expressing the
tumor-specific TCR following transduction. The retroviral vector includes a truncated
CD34 molecule (CD34t) to serve as a transgene selection marker. Using a CliniMacs,
TIL 1383I TCR transduced T cells are purified through CD34t selection and expanded to
large quantities. We would anticipate that intratumoral injection with a high dose of pure
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TIL 1383I TCR transduced allogeneic T cells would lead to more efficient killing of
primary, injected tumors leading to either complete regression of injected lesions or to
prolonged progression-free survival.
The second factor that influenced the outcome of treatment with TIL 1383I TCR
transduced T cells was the size of the primary tumor at the time of treatment. As
expected, larger tumors (>30mm2) were typically more difficult to control following
intratumoral T cell treatment compared to smaller tumors. Generally, this problem
mostly affects mouse studies, as patient tumors are often much smaller in relative size
to their body. Additionally, the final size of T cell-treated B16 A2/Kb tumors correlated
with the extent of T cell cross-priming. Therefore, smaller tumors at the time of T cell
injection, which correlated with tumor regression, might also increase systemic antitumor T cell responses. Taken together, the frequency of tumor-specific transduced T
cells and size of the tumor lesion used for injection can influence the anti-tumor
responses following intratumoral T cell treatment.
The Recipient Immune Recognition of Foreign Allogeneic Donor Cells
Enhances the Efficacy of Intratumoral Treatment with TIL 1383I TCR Transduced
Allogeneic T Cell Treatment
Syngeneic and allogeneic donor T cells transduced to express the TIL 1383I
TCR exhibited similar polyfunctional phenotypes against B16 A2/Kb tumors cells in vitro.
TIL 1383I TCR transduced allogeneic T cells were more effective than TIL 1383I TCR
transduced syngeneic T cells at suppressing the growth of B16 A2/Kb tumors. Using
recipient NSG A2 mice, which are defective in myeloid and lymphoid lineage-derived
cells, we observed that the injection of B16 A2/Kb tumors with TIL 1383I TCR
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transduced allogeneic T cells resulted in strikingly similar survival outcomes and ability
to suppress tumor growth compared to TIL 1383I TCR transduced syngeneic T celltreated mice. We also detected TIL 1383I TCR transduced T cells in the tumors of NSG
A2 recipient mice up to twenty days post-T cell treatment. In comparison, TIL 1383I
TCR transduced T cells were undetectable in the tumors implanted in
immunocompetent HLA-A2 transgenic mice by day 7 post-T cell treatment. Although not
directly tested, we speculated that the host T cells eliminated the donor T cells, which is
why they were undetectable in the tumor by day 7 post-T cell treatment in the
immunocompetent recipient mice.
The differences in T cell persistence raises the question of whether the persisting
TIL1383I TCR transduced T cells within the tumors of NSG A2 mice continued to
mediate tumor killing and cytokine production. If so, the prolonged presence of TIL
1383I TCR transduced T cells could further improve upon the suppression of primary
B16 A2/Kb tumors. However, the persistence of intratumoral tumor-specific T cells
required an immunodeficient recipient, which would prevent the induction of DC
activation and cross-priming of endogenous T cells. Although the lack of systemic T cell
responses would fail to prevent escape of tumor immune variants, the persistence of
functional TIL 1383I TCR transduced T cells in the tumors of immunodeficient recipients
could potentially induce complete regression of primary tumors. It is unknown whether
an immunodeficient recipient, with T cell persistence, would be more advantageous
than an immunocompetent recipient, with cross-primed T cells but the transient
presence of TIL 1383I TCR transduced T cells.
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We retrospectively compared the slopes of B16 A2/Kb growth following TIL 1383I
TCR transduced T cell treatment of HLA-A2 transgenic mice compared to NSG A2
mice. The slope of B16 A2/Kb growth in NSG A2 mice treated with TIL 1383I TCR
transduced syngeneic and TIL 1383I TCR transduced allogeneic T cells was 2.205 and
1.866, respectively. In immunocompetent HLA-A2 transgenic recipient mice, the slope
of B16 A2/Kb tumor progression (within the same time frame as NSG A2 mice) was
3.447 and 1.364 following treatment with TIL 1383I TCR transduced syngeneic T cells
and TIL 1383I TCR transduced allogeneic T cells, respectively. This retrospective
analysis suggests that the induction of endogenous host T cell cross-priming, which
resulted in the induction of epitope spreading (Fig 52 and 56), is more advantageous
than the persistence of TIL 1383I TCR transduced allogeneic T cells in the tumor.
Interestingly, we observed the opposite findings during treatment with TIL 1383I TCR
transduced syngeneic T cells. We observed a lower slope, indicating better tumor
suppression, in NSG A2 mice (2.205) compared to slope in HLA-A2 transgenic mice
(3.447). This would suggest that in the absence of adequate host T cell cross-priming,
as observed in the mice treated with TIL 1383I TCR transduced syngeneic T cells, the
persistence of tumor-specific T cells in the tumor might provide additional benefits. NSG
A2 mice are defective in both innate and adaptive immunity and it is most likely that the
best anti-tumor responses require both components. In our studies, we have
demonstrated that the host immune system can contribute to altering the TME to drive
the process of T cell cross-priming, which results epitope spreading (the induction of T
cells specific to gp100 and TRP-2, Fig 52 and 56), ultimately leading to effective,
durable anti-tumor immunity.
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TIL 1383I TCR Transduced Allogeneic T Cells Induce an
Immune-Active Tumor Microenvironment
Our results indicated that the recipient immune system had the capacity to alter
the tumor microenvironment and contribute to the anti-tumor response. Additionally, TIL
1383I TCR transduced T cells produced IFN-g and TNF-a and mediated lytic responses
(CD107a+) against B16 A2/Kb tumor targets within 24 hours in vitro. This prompted us to
investigate the immune components within the tumor. The cytokines IFN-g and TNF-a
can promote maturation of dendritic cells. At two days post-T cell treatment, the
frequency of CD11c+MHCII+ DCs was 10% of total cells in the tumors of all treatment
groups. This is consistent with previous literature indicating that the syngeneic
implantable B16 tumor model, in the absence of treatment, contains variable
percentages of tumor-infiltrating DCs depending on the size of the tumor517. Two days
post-T cell treatment, the size of tumors from mice treated with T cells are still relatively
similar to the size of tumors from untreated mice, supporting the similar percentages of
DCs observed. We observed an increased frequency of CD11c+MHCII+ DCs expressing
the co-stimulatory molecule CD80 in the tumors treated with TIL 1383I TCR transduced
allogeneic T cells.
Consistent with previous reports, untreated B16 A2/Kb tumors contained a small
subset of CD103+ and CD205+CD11c+MHCII+ DCs499. We detected an increase in
CD205+CD11c+MHCII+, but not CD103+, DCs in tumors from untransduced allogeneic
or TIL 1383I TCR transduced syngeneic mice. However, intratumoral treatment with TIL
1383I TCR transduced allogeneic T cells resulted in a significant increase in CD8a+ DC,
CD103+ DC, and CD205+ cross-presenting DC subsets in the tumor two days post-T cell
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treatment. There are two possible explanations: 1) the enhanced pro-inflammatory
response, due to the allogeneic T cells, was capable of recruiting additional crosspresenting DC subsets to the tumor; however, without the release of tumor antigens,
which requires the TIL 1383I TCR, these cross-presenting DC subsets don’t acquire
tumor antigen and therefore don’t migrate to a tumor draining lymph node. 2) in the
presence of only antigen release but without the additional inflammatory response, as in
the case of TIL 1383I TCR transduced syngeneic T cells, the cross-presenting DCs are
not recruited to the tumor and therefore, these mice are unable to generate tumor
draining lymph node-activated cross-primed T cells. These results suggested that the
allogeneic response, through producing inflammatory cytokines, and tumor-specific
responses, through production of inflammatory cytokines, alone can promote the
accumulation of DCs expressing CD205 in the tumor; however, the synergy of the two
responses, enhanced cytokine production with antigen release, manifested in TCR
gene-modified allogeneic T cells, can further promote the accumulation of additional
cross-presenting DC subsets.
We also observed increased frequencies of T cells expressing activation markers
CD25, CD44, and CD69, and increased frequencies of IFN-g+ or TNFa+ CD8+ T cells in
the tumor microenvironment of mice treated with TIL 1383I TCR transduced allogeneic
T cells. In support of these findings, we also observed an increase in PD-L1 expression,
which has been demonstrated to occur in response to IFN-g, on CD11b+CD11c+ cells.
The impact of IFN-g+ T cells within the tumor microenvironment remains controversial.
While IFN-g+ CD8+ T cells in the tumor microenvironment can correlate with positive
outcomes, IFN-g production also induces PD-L1 expression on tumors which can inhibit
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T cell responses and promote angiogenesis. We did not look at the production of IL-12
by DCs, but it is possible that IL-12 could play a role in stimulating T cell responses.
Tumors treated with TIL 1383I TCR transduced syngeneic T cells unexpectedly
had the highest frequency of T regulatory (Treg) cells, whereas tumors treated with TIL
1383I TCR transduced allogeneic T cells had the lowest frequency of Tregs. We
examined tumors for the presence of Treg seven days post-intratumoral T cells
treatment. At this time, we were unable to detect any T cells expressing GFP or H-2d,
suggesting that the observed Tregs were derived from the host and not the donor T
cells. Interestingly, in a small scale experiments, the tumors from NSG A2 recipient
mice, where donor T cells had been detected for up to 3 weeks post-T cell treatment,
we observed an increased ratio of CD4:CD8 transduced T cells in the tumors of mice
treated with TIL 1383I TCR transduced allogeneic T cells. This contrasted to the initial
population of transduced T cells that were used for treatment, which was predominantly
CD8+ transduced T cells. Although we did not pursue the observation of increased
CD4:CD8 transduced T cells, i.e. whether there was an expansion of CD4+ Tregs or if
the CD8+ transduced T cells underwent apoptosis, this would be a feasible and
interesting future direction.
The Tregs present in the tumors of treated mice could have been induced
(iTregs) in the microenvironment or, alternatively, thymic-derived Tregs (nTregs) can be
recruited to tumors or expand in tumors522. In these experiments, Tregs could have a
role in two different ongoing immune responses, anti-tumor and allogeneic, adding
another level of complexity. One study demonstrated that 15-40% of CD4+ T cells in
B16 tumors express Foxp3 and indirectly argued in favor of a preferential accumulation
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of intratumoral nTregs524. One future direction could examine the treated tumors for
differences in CCR4, CCL22, or CXCR4, which promote nTreg migration to the
tumors523, or TGF-β which can promote proliferation of Treg in vivo524.
Tregs are induced in the presence of antigen and TGF-β and in the absence of
inflammatory stimuli500. It is possible that the absence of the potent alloresponse in the
tumors treated with TIL 1383I TCR transduced syngeneic T cells promoted the induction
of Treg. cells Alloantigen-specific Treg preferentially reside in the spleen, less in the
lymph nodes, and not in the thymus or bone marrow501. In the context of transplantation
tolerance, studies have demonstrated that Treg cells use mainly the indirect antigen
recognition pathway to control alloreactive responses502. Results from our experiments
suggest that direct alloreactive responses are contributing to enhanced anti-tumor
immunity. Therefore, Treg cells might not be induced in response to allogeneic T cells
within the time frame of the B16 melanoma mouse model. For these experiments, we
only examined the tumors for the presence of Tregs, and therefore we cannot determine
if there were any treatment related changes in the frequency of Tregs in the spleens or
tumor draining lymph nodes of mice.
Tumor-specific and allogeneic responses occur quite rapidly, and therefore it is
difficult to determine if the secretion of cytokines by TIL 1383I TCR transduced T cells
precedes maturation of DCs. Alternatively, mature, cytokine-producing DCs could be
promoting sustained cytokine production by T cells. It is most likely that these immune
responses overlap, and the combination of alloreactivity and tumor reactivity extend that
activation window leading to more effective DC responses. Collectively, we have
demonstrated that intratumoral treatment with TIL 1383I TCR transduced allogeneic T
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cells induces DC maturation and T cell activation and cytokine production in the tumor
two days post-T cell treatment.
Induction of Immune Responses in the Tumor Draining Lymph Nodes
Following TIL 1383I TCR Transduced Allogeneic T Cell Treatment
Intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells
promoted higher numbers and frequencies of CD11c+ MHC II+ conventional DCs in the
tumor draining lymph nodes. In contrast to the tumor, we observed more CD86+ DCs in
the tumor draining lymph nodes of T cell-treated mice.
Studies have demonstrated that CD86 is rapidly and abundantly expressed,
while CD80 is slowly expressed but has a higher affinity to CD28 and CTLA-4 and, thus,
the more potent ligand503.504 Expression of CD80 and CD86 is upregulated in response
to the cytokines IFN-a, IFN-g, and GM-CSF505. It is possible that the stronger stimulation
from the combination of tumor antigen-specific reactivity and alloresponse promoted the
increased CD80 expression in the tumor. CD80/CD86 and CD28/CTLA-4 interactions
also play a role in the induction and function of T regulatory (Treg) cells. Zheng et al.
demonstrated that allogeneic mature DCs expressing high levels of CD86 were
resistant to Treg suppression506. The increased expression of CD80 and CD86 on DCs
from the tumors treated with TIL 1383I TCR allogeneic T cells could also prevent Treg
suppression. Furthermore, during alloresponses, tolerogenic DCs can promote the
induction of Treg cells507. The allogeneic response is characterized by the production of
inflammatory cytokines, which might overcome the microenvironment-induced tumor
suppression. It is possible that the tumor-specific response alone is not enough to
overcome tumor resistance mechanisms. The untransduced allogeneic T cell-treated
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tumors have the contribution of the alloresponse, which resulted in the activation of DCs
and T cells, however without the released tumor antigens from lysed tumors cells
mediated by the transduced TCR, these mice are unable to mount a tumor antigenspecific response. Our data suggest that TIL 1383I TCR transduced allogeneic T cell
treatment induced mature, conventional DCs that would not promote the induction of
Treg cells.
We also observed an accumulation of CD205+ DCs in the tumor draining lymph
nodes of mice treated with TIL 1383I TCR transduced allogeneic T cells. The tumor
draining lymph nodes of mice treated with TIL 1383I TCR transduced allogeneic T cells
also contained significantly higher frequencies and absolute numbers of mature CD8a+
and CD205+CD11c+MHCII+ DCs. We also observed an increase in the migratory
CD103+ DCs in the mice treated with TIL 1383I TCR transduced allogeneic T cells.
Interestingly, the mice treated with untransduced allogeneic T cells failed to promote
these cross-presenting DC subsets. It is possible that the lack of tumor antigens in the
microenvironment resulted in the inability to induce cross-presenting DC subsets. These
data suggest that the combination of tumor-specificity and alloreactivity can promote
cross-presenting DC subsets compared to either response alone.
Previous studies have demonstrated that targeting tumor antigens to CD205+
DCs enhances tumor-specific CTL responses. Wu and colleagues observed the priming
of autologous tumor-specific T cells upon stimulation with allogeneic CD205+ DCs
engineered to express hTERT antigen508. Additionally, CD205 expression increases as
DC maturation occurs, with peak upregulation occurring at 48 hours509. CD11c+MHCII+
DCs extracted from the tumors of TIL 1383I TCR transduced allogeneic T cell-treated
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mice expressed the highest levels of CD205, measured by mean fluorescence intensity
(MFI), confirming the induction of mature cross-presenting DC subsets in the tumor
draining lymph nodes. In support of previous reports, we also observed the most
significant differences in mature CD205+ DCs two days post-intratumoral T cell
treatment.
The tumor draining lymph nodes isolated from B16 A2/Kb tumor-bearing mice
seven days after treatment with TIL 1383I TCR transduced allogeneic T cells exhibited
increased frequencies of activated CD4+ and CD8+ T cells. As demonstrated by
ELISPOT assays, these endogenous cells produced IFN-g in response to B16 and B16
A2/Kb tumor targets, as well as in response to gp10025-33 - and TRP-2181-188 peptidepulsed RMA/S cells. TRP-2 and gp100 are melanocyte differentiation antigens (MDAs),
the most common group of antigens, compared to mutated antigens and cancer/testis
antigens, recognized by CTL in human melanomas. We chose the TRP-2 peptide
because the literature has reported that naïve mice have relatively high numbers of
TRP-2-specific CTL precursors and therefore, this self-antigen is relatively easy to
generate low-affinity CD8+ T cells510. Additionally, it has been demonstrated that T cells
specific to the TRP-2 antigen predominate in mice vaccinated with irradiated B16
tumors511.
Endogenous T cells induced after treatment with TIL 1383I TCR transduced
allogeneic T cells were also capable of mediating tumor antigen-specific killing, as
demonstrated by the in vivo CTL assay. As mentioned in the literature review, different
types of antigens are more efficiently cross-presented than other types of antigens159164

. This may explain why we more frequently observed the induction of gp100-specific
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reactivity and killing in comparison to TRP-2-specific reactivity and killing. Even though
we observed increased gp100-specific T cells compared to TRP-2-specific T cells, mice
treated with TIL 1383I TCR transduced allogeneic T cells commonly generated T cell
responses against both B16-associated tumor antigens. In a previous report, the
immunization of mice with plasmids that encoded either gp100 or TRP-2 proteins
resulted in only partial protection against B16 melanoma challenge. In contrast, when
mice were immunized with both antigens, they observed complete protection in 100% of
the mice512. It would be interesting to retrospectively compare anti-tumor responses in
mice that generated endogenous T cell responses against gp100 or TRP-2 only versus
responses against both antigens. These results suggest that treatment with TIL 1383I
TCR transduced allogeneic T cells promoted more robust tumor antigen-specific T cell
responses and increased epitope spreading compared to TIL 1383I TCR transduced
syngeneic T cells.
Intratumoral treatment with TIL 1383I TCR Transduced Allogeneic T Cells
Induces Cross-Priming of Endogenous, Tumor-Specific T Cells
We tested if the endogenous recipient T cells induced after treatment with TIL
1383I TCR transduced allogeneic T cells protected against B16 development on the
contralateral flank. Following intratumoral treatment of primary B16 A2/Kb tumors with
TIL 1383I TCR transduced allogeneic T cells, approximately half of the mice were
protected from B16 following inoculation on the contralateral flank. In contrast,
approximately 20% of mice with primary B16 A2/Kb tumors treated with TIL 1383I TCR
transduced syngeneic T cells were protected from developing B16. These results were
consistent with the increased DC and T cell activation in the tumor and tumor draining
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lymph nodes. Although intratumoral treatment with TIL 1383I TCR transduced
syngeneic T cells prevented the development of contralateral B16 tumors in a small
fraction of mice, it is clear that TIL 1383I TCR transduced allogeneic T cells provided an
enhanced protective benefit.
While the observation that treatment with TIL 1383I TCR transduced allogeneic T
cells had impressive protective effects, we wanted to determine if intratumoral T cell
treatment could also provide therapeutic benefits. Transferring the splenocytes from
tumor-bearing mice intratumorally treated with TIL 1383I TCR transduced allogeneic T
cells into mice with established B16 tumors can suppress tumor growth. In these
experiments we only transferred 1 x106 splenocytes and therefore it is possible that
transferring more cells or selecting for T cells could provide an enhanced therapeutic
response. It is notoriously more difficult to achieve in vivo responses when utilizing
transfer experiments and therefore the impact of TIL 1383I TCR transduced allogeneic
T cell treatment against B16 tumors is very impressive.
Treatment with TIL 1383I TCR transduced allogeneic T cells induced significant
epitope spreading compared to the other treatments. The extent of cross-priming in
these experiments may be underestimated due to two factors. We initially began
interrogating the ability of TIL 1383I TCR transduced T cell treatment to generate T cells
specific to MHC class I-restricted melanoma antigens, which are better characterized
and more commonly generated in vivo compared to MHC class II-restricted tumorspecific T cells. It is possible that TIL 1383I TCR transduced T cells induced tumorspecific CD4+ T cells with specificities to mouse H-2 I-Ab I-Eb- restricted peptides.
Recent mapping of non-synonymous mutations in B16 tumors by next-generation
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sequencing and subsequent vaccination with synthetic peptides harboring the mutated
epitope lead to the observation that responses against neo-epitopes were nearly all
CD4+ T cell-mediated. Therefore, it would be highly beneficial for future experiments to
investigate the contribution of MHC class II-restricted tumor antigen-specific CD4 T cells
to anti-tumor immunity following intratumoral treatment with TIL 1383I TCR transduced
allogeneic T cells.
Immunotherapy-Associated Adverse Events
One must take into consideration the possibility of immunotherapy-associated
adverse events that can occur using TCR gene-modified T cells. TCR mispairing
between the introduced and endogenous TCR chains could result in the generation of
self-reactive T cells (off-target). The cross-reactivity against antigens expressed on
normal tissue can limit the efficacy and impact safety. We did not anticipate this to be a
problem, as the targeting of melanoma/melanocyte shared antigens is relatively safe
and the TIL 1383I TCR used in these experiments has already been tested pre-clinically
in mice and used to treat patients. Both human and mouse studies have demonstrated
the safety of the TIL 1383I TCR with minimal toxicity. In patients, these have included
lymphopenia, neutropenia, thrombocytopenia, and rash, which can be a consequence
of non-myeloablative lymphodepletion. Toxicity related to the administration of
melanoma/melanocyte-specific T cells seen in our clinical trial included vitiligo, but
others have observed uveitis or hearing loss2,470.
We have demonstrated that intratumoral injections of TCR gene-modified
allogeneic T cells is an effective and safe approach to mediate tumor regression.
However, adverse events have been reported in other studies using intravenous (i.v)
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infusions of TCRs that turned out to be dangerous or cross-reactive. Severe
inflammatory colitis was observed in patients with colorectal cancer that received i.v
infusions of T cells transduced to express an affinity-enhanced TCR specific to the
carcinoembryonic antigen (CEA). Later, they discovered that low levels of CEA were
present in the colonic epithelium428. On-target toxicity events have also been reported
with CAR T cell therapy. In one study using CAR T cells that targeted the carbonic
anhydrase IX (CAIX) antigen, lethal liver toxicity was reported in two patients with
metastatic renal cell carcinoma. Upon further examination, they detected low expression
of the CAIX antigen on normal bile duct epithelial tissue407. Our strategy using
intratumoral delivery of TCR gene-modified T cells can potentially prevent the systemic
on-target effects against normal tissue. We have demonstrated that intratumorallyinjected allogeneic TCR gene-modified T cells do not migrate out of the tumor and are
eliminated within seven days after injection.
In our experiments, we observed only one case of vitiligo when mice were
treated with TIL 1383I TCR transduced allogeneic T cells only. In contrast, we observed
the development of vitiligo in 6/20 mice following treatment with TIL 1383I TCR
transduced allogeneic T cells and anti-CTLA-4 mAb monotherapy or anti-CTLA-4
mAb/anti-PD-1 mAb dual therapy. Therefore, caution should be used when attempting
to achieve epitope spreading depending on the expression of target antigen on normal
tissue. The advantage to our approach is the ability to confine robust immune
responses to the microenvironment by intratumoral delivery of the TIL 1383I TCR genemodified T cells. An additional safety measure that could be taken is irradiating the TIL
1383I TCR transduced allogeneic T cells before delivery. We chose not to irradiate the
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TIL 1383I TCR transduced allogeneic T cells in our experiments, but the clinical trial
testing MART-1-specific TCR transduced allogeneic T cells irradiated the cells prior to
intratumoral delivery. They noted that the irradiated T cells maintained lytic function and
produced cytokines in response to tumor targets for up to 48 hours after radiation. We
concluded that intratumoral delivery of TIL 1383I TCR transduced allogeneic T cells was
safe, with vitiligo as the only TCR-specific toxicity to our knowledge.
We were also aware of the possible induction of graft-versus-host disease
(GVHD) mediated by complete MHC-mismatched allogeneic T cells. GVHD can be
acute or chronic and can be life-threatening in patients receiving a hematopoietic stem
cell transplant513. In mouse models, GVHD can induce severe disease; however, in our
model using intratumoral delivery of allogeneic T cells, we did not observe severe or
lethal GVHD following intratumoral injection of TIL 1383I TCR transduced allogeneic T
cells or untransduced allogeneic T cells. We demonstrated that TIL 1383I TCR
transduced allogeneic T cells and untransduced allogeneic T cells do not egress from
the tumor microenvironment, as they were undetected in the spleens or tumor draining
lymph nodes and are eliminated by seven days post-intratumoral injection. This is one
hypothesis explaining the lack of severe GVHD.
A second potential explanation for the lack of severe GVHD could be the
phenotype of the TIL 1383I TCR transduced T cells used for treatment. Beilhack and
colleagues performed an extensive characterization of the events mediating GVHD95.
Through in vivo bioluminescence imaging, they observed the proliferation of donor CD4+
T cells, followed by CD8+ T cells, that initiated GVHD in secondary lymphoid organs
when transplants contained pure naïve donor T cells. In contrast, grafts containing CD4+
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effector memory T cells did not proliferate in vivo, despite their alloreactivity in vitro. In
our experiments, T cells used for therapy are activated with anti-CD3/anti-CD28 beads
prior to transduction, and presumably more closely resemble effector memory T cells
when delivered intratumorally. The effector memory phenotype of TIL 1383I TCR
transduced allogeneic T cells or untransduced allogeneic T cells could limit the extent of
alloreactivity induced. Future experiments purifying different T cell subsets either before
or after transduction could further elucidate the impact of T cell phenotypes on the
alloreactive response and anti-tumor immunity.
Combination Immunotherapy to Enhance the Efficacy of
TIL 1383I TCR Transduced T Cell Treatment
We observed significant improvements in anti-tumor responses in B16 A2/Kb
tumor-bearing mice treated with TIL 1383I TCR transduced allogeneic T cells compared
to TIL 1383I TCR transduced syngeneic T cells or untransduced allogeneic T cells. We
sought to further improve T cell cross-priming and systemic anti-tumor immunity using
additional immunotherapies that have been reported to modulate anti-tumor immune
responses. In a series of pilot experiments, we investigated three different approaches
that varied in therapeutic targets and route of delivery. We targeted innate immunity, the
tumor microenvironment, or adaptive T cell responses through intratumoral delivery,
modification of transduced T cells, and systemic infusion, respectively.
The first pilot experiments we performed tested if the combination of intratumoral
treatment with TIL 1383I TCR transduced T cells and TLR3 stimulation using poly I:C
could improve suppression of B16 A2/Kb tumor progression or T cell cross-priming. The
timing of poly I:C delivery to the tumor microenvironment could also affect the outcome
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of therapy. It would have been interesting to test if intratumoral delivery of poly I:C and
TIL 1383I TCR transduced T cells on the same day affected B16 A2/Kb tumor growth or
cross-priming. However, technical difficulties prevented us from addressing this
question. First, two separate intratumoral injections on the same day is not feasible
because the therapeutic agent in the second injection would leak out of the injection site
from the first therapeutic agent. The alternative option would require pre-mixing the T
cells and poly I:C prior to intratumoral injection. However, TLR3 is expressed on CD4
and CD8 T cells from C57Bl/6 and BALB/c mice and the magnitude of TLR3 expression
is strain-dependent. Therefore, it would be almost impossible to control for the effect of
poly I:C on TIL 1383I TCR transduced T cells isolated from HLA-A2 transgenic mice,
which are on a C57Bl/6 background, compared to BALB/c mice.
We were unable to achieve better anti-tumor responses, using the retroviral
vector as delivery method, upon co-expression of the TIL 1383I TCR and the LIGHT
protein to the tumor in a single exploratory experiment. Additionally, injecting tumors
with the combination of TIL 1383I TCR transduced allogeneic T cells and poly I:C were
inconclusive. There remains the question, can too much immune stimulation within the
tumor microenvironment, in the context of cancer immunotherapy, cause harm? In two
of the three combination strategies employed, the addition of poly I:C and incorporation
of the LIGHT gene into the vector, the anti-tumor responses were either equal to or
worse than intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells. In
some reports, TLR-mediated chronic inflammation induced tumorigenesis58,514. In
contrast, when intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells
was combined with systemic administration of immune checkpoint inhibitors anti-CTLA-
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4 mAb or anti-CTLA4/anti-PD-1 mAb, we observed a substantial improvement in antitumor responses. The route of delivery is one difference that distinguishes the former
strategies from the latter approach. It is possible that administering poly I:C or
expressing the LIGHT protein in the tumor microenvironment, in which immune cells
were already stimulated via alloreactivity and the tumor-specific TCR, resulted in
activation-induced death or quiescence.
Intratumoral treatment with TIL 1383I TCR transduced allogeneic T cells in
combination with systemic administration of anti-PD-1 mAb and anti-CTLA-4 mAb
further enhanced anti-tumor responses, protecting nearly 100% of mice from the
development of B16 tumors when challenged on the contralateral flank. We also
observed increased incidences of the development of vitiligo in mice intratumorally
treated with TIL 1383I TCR transduced allogeneic T cells and anti-CTLA-4 mAb
monotherapy or anti-CTLA-4 mAb/anti-PD-1 mAb dual therapy. The addition of antiCTLA-4 mAb presumably induced robust autoreactive T cell responses that would
otherwise be maintained through peripheral tolerance. The mechanisms governing
tumor immunity versus autoimmunity have yet to be clearly defined. In one study, CD8+
T cells required perforin to mediate the induction of autoimmunity whereas perforin was
dispensable for tumor immunity515. Because TIL 1383I TCR transduced syngeneic T
cell-treated mice did not develop vitiligo, it is possible that TIL 1383I TCR transduced
allogeneic T cell treatment with anti-CTLA-4 mAb induces a more potent cytotoxic CD8+
T cell response. This hypothesis is further supported by previous reports demonstrating
that CD4+ T cells were not required for vitiligo development following whole tumor cell
vaccination with anti-CTLA-4 mAb37.

257
A moderate number of mice treated with TIL 1383I TCR transduced allogeneic T
cells and anti-CTLA-4 mAb developed vitiligo at the site of the primary B16 A2/Kb tumor
and, in some cases, the contralateral B16 tumor. These findings are further evidence
that TIL 1383I TCR transduced allogeneic T cells in combination with anti-CTLA-4 mAb
induced systemic cross-primed T cells.
The addition of the allogeneic component to TIL 1383I TCR transduced T cells
can also be considered a combination therapy. The contribution of allogeneic response
clearly improved outcomes; however, one factor that has yet to be explicitly tested is the
level or threshold of alloreactivity that is sufficient to promote superior anti-tumor
immunity. The frequency of alloreactive T cells in mice varies 30-fold (0.71+/-0.31% to
21.05+/- 3.62%), which could influence immune activation. Presumably, TCR
transduced T cells that generate the highest frequency of alloreactive T cells would be
preferable over transduced T cells that minimally induce alloreactivity.
About one-third of minor histocompatibility antigens are generated from the Y
chromosome516. Does this make a difference in the impact of alloreactivity to enhance
anti-tumor responses? We did not observe notably different outcomes that correlated
with the sex of the donor T cells or recipient mice. We used a mixture of female and
male mice as recipients for B16 A2/Kb throughout every experiment. For the donor T
cells, we used the same sex (male or female) of HLA-A2 transgenic and BALB/c mice
for donor T cells within each experiment, but among independent experiments, we used
both male and female mice. In this manner, we can conclude that major
histocompatibility protein mismatch is sufficient to engage the recipient immune
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response to contribute to enhanced anti-tumor responses, but the extent to which minor
histocompatibility proteins can contribute to these responses remains to be elucidated.
The allogeneic response is primarily T cell-mediated and is characterized by the
production of IL-2, IFN-g, and TNF-a. As described in the literature review, these
cytokines are also critical components in generating anti-tumor immunity. TNF-a was
initially defined as the mediator of hemorrhagic necrosis of tumors and contributing to
tumor regression497. Clinical and biologic responses have been observed in patients
following the administration of high-dose IL-2. The presence of interferon-stimulating
genes and IFN-producing T cells can correlate with positive anti-tumor responses.
Supplementing immunotherapies with adjuvants, agonists, and vaccines aim for the
induction of these cytokines. Direct or indirect administration of IL-2, IFN-g, and TNF-a
induce potent immune responses, but the critical missing component is tumor antigenspecificity. With our strategy, intratumoral delivery of TIL 1383I TCR transduced
allogeneic T cells elicited the robust immune responses described above but provided
tumor antigen-specific killing directly in the tumor microenvironment.
The experiments described in this dissertation have centered around a unique
tumor-specific TCR in the setting of a mouse melanoma model. While MHC-restriction
and lack of suitable tumor-specific TCR limit the experimental scope of this dissertation,
the overall conclusions that, in the setting of tumor immunology, an allogeneic donor cell
can provide additional advantageous qualities, such as combating the
immunosuppressive tumor microenvironment. The underlying principles of allogeneic
immune responses remain constant among species and in between individuals.
Additionally, expression and function of antigen cross-presenting CD205 DC and
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CD103 DC subsets are maintained across humans and mice. Therefore, we believe that
our approach of utilizing intratumoral delivery of allogeneic TCR gene-modified T cells is
feasible and more effective immunotherapeutic strategy that can induce protective,
therapeutic systemic anti-tumor immunity.
Concluding Remarks
Cancer immunotherapies have shown great promise in the treatment of various
malignancies. A vast majority of immunotherapies aim to improve T cell function or
induce anti-tumor T cell responses. The ACT of TCR gene-modified T cells has been a
rapidly developing and promising strategy to treat various tumor types. Clinical and
biologic responses have been observed following the ACT of autologous TCR genemodified T cells, but there is still a need to improve the frequency and durability of
responses. In patients receiving monospecific immunotherapy, poor response rates or
high relapse rates are commonly observed. Contributing factors include immune-escape
tumor variants that can arise through target antigen downregulation or MHC allele loss.
Additionally, the tumor microenvironment is highly suppressive, and adept at excluding
effector T cells or inhibiting effector functions. As a result, designing T cell-based
immunotherapies that induce a broad T cell response (epitope spreading) or improve
the persistence and function of the transferred T cells within the suppressive
microenvironment is critical to improving clinical and biologic responses in cancer
patients.
In this dissertation, we explored the mechanisms underlying the improved antitumor responses mediated by TIL 1383I TCR-transduced allogeneic T cells. We report
that intratumoral treatment with TIL 1383I TCR-transduced allogeneic T cells resulted in
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enhanced T cell activation and dendritic cell maturation-locally within the tumor
microenvironment and in the tumor draining lymph nodes. Furthermore, TIL 1383I TCR
transduced allogeneic T cells generated protective and therapeutic endogenous tumorspecific T cells through dendritic cell cross-presentation. The effective tumor control by
intratumoral delivery of allogeneic TIL 1383I TCR-transduced T cell was further
improved upon with the addition of anti-PD-1 mAb and anti-CTLA-4 mAb immune
checkpoint inhibitors. We concluded that tumor specificity via the transduced TCR and
alloreactivity synergized to enhance anti-tumor immune responses. By understanding
mechanisms that enhance T cell function in the tumor microenvironment and generate
systemic anti-tumor immunity, we can improve upon the therapeutic efficacy and safety
of T cell-based immunotherapies.
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Figure 96. Intratumoral Treatment with TIL 1383I TCR Transduced C3H T Cells
Promotes B16 A2/Kb Tumor Suppression. B16 A2/Kb tumors were intratumorally
treated on day 10 with A) untransduced BALB/c T cells B) untransduced C3H T cells
C) TIL 1383I TCR transduced BALB/c T cells and D) TIL 1383I TCR transduced C3H
T cells. Two opposing diameters were measured with a digital caliper every 2-3 days
per week. Mice were sacrificed when tumors reached >150 mm2 or >10% of body
weight. Data represent one pilot experiment with 3-4 mice per group.
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weight. Data represent one pilot experiment with 3-4 mice per group.
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Figure 98. Intratumoral Treatment with TIL 1383I TCR Transduced C3H T Cells
Promotes Tumor-Specific IFN-g+ Cells in the Tumor Draining Lymph Nodes.
Eight days post-T cell treatment, tumor draining lymph nodes were isolated and restimulated with irradiated B16 tumor cells for 5 days. 100,000 effector cells and
100,000 target cells were co-cultured for 18 hours. Spots were automatically
enumerated using an ELISPOT plate reader. Data represent the average of
duplicates from individual mice, with 3 mice per group from one pilot experiment.
Statistical analysis performed using 2way ANOVA with Tukey’s correction. [**P<0.01,
***P<0.001, ****P<0.0001]
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Figure 99. Intratumoral Treatment with TIL 1383I TCR Transduced C3H T Cells
Promotes Tumor Antigen-Specific IFN-g+ Cells in the Tumor Draining Lymph
Nodes Eight days post-T cell treatment, tumor draining lymph nodes were isolated
and re-stimulated with irradiated B16 tumor cells for 5 days. 100,000 effector cells
and 100,000 target cells were co-cultured for 18 hours. Spots were automatically
enumerated using an ELISPOT plate reader. Data represent the average of
duplicates from individual mice, 3 mice per group, from one pilot experiment. No
statistically significant differences were observed using 2way ANOVA with Tukey’s
correction.
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Figure 100. CD11c+ MHC II+ Dendritic Cells in the Tumor Draining Lymph Nodes
Three- and Five- Days Post-T Cell Treatment. Tumor draining lymph nodes from
B16 A2/Kb tumor-bearing mice were isolated A) three and B) five days post-T cell
treatment. Expression of CD11c, MHC II, CD80, CD86, and CD205 was assessed by
flow cytometry. Frequency (left panel) and total number (right panel) of
CD11c+MHCII+ cells. One pilot experiment with 2-3 mice/group. Graph shows mean
± SEM; statistical analysis by one-way ANOVA with Tukey’s correction [*P<0.05]
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Figure 101. Expression of Co-Stimulatory Molecules on CD11c+ MHC II+
Dendritic Cells in the Tumor Draining Lymph Nodes Three- and Five- Days
Post-T Cell Treatment. Tumor draining lymph nodes from B16 A2/Kb tumor-bearing
mice were isolated A) three and B) five days post-T cell treatment. Expression of
CD11c, MHC II, CD80, CD86, and CD205 was assessed by flow cytometry.
Frequency (left panel) and total number (right panel) of positive cells gated on
CD11c+MHCII+ cells. One pilot experiment with 2-3 mice/group. Graph shows mean
± SEM; Statistics performed using one-way ANOVA with Tukey’s correction
(*P<0.05)
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Figure 102. CD205+ DCs in the Tumor Draining Lymph Nodes Three- and FiveDays Post-T Cell Treatment. Tumor draining lymph nodes from B16 A2/Kb tumorbearing mice were isolated A) three and B) five days post-T cell treatment.
Expression of CD11c, MHC II, CD80, CD86, and CD205 was assessed by flow
cytometry. Frequency (left panel) and total number (right panel) of CD205+ cells
gated on CD11c+MHCII+ cells. One pilot experiment with 2-3 mice/group. Graph
shows mean ± SEM; No statistical significance was detected by one-way ANOVA
with Tukey’s correction.
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Figure 103. Tumor Antigen-Specific IFN-g+ Cells in the Tumor Draining Lymph
Nodes of Mice Treated with the Combination of Intratumoral TIL 1383I TCR
Transduced Syngeneic T Cells and Poly I:C. B16 A2/Kb tumor-bearing mice were
intratumorally treated on day 10 post-tumor inoculation with TIL 1383I TCR
transduced syngeneic T cells and one day later received an intratumoral injection of
A) PBS or B) 40 µg poly I:C. Mice were sacrificed 11 days after poly I:C treatment.
Cells from the tumor draining lymph nodes were re-stimulated with irradiated B16
A2/Kb tumor cells for 5 days and then co-cultured with B16, B16 A2/Kb, EL4, and EL4
A2 tumor targets in an IFN-g ELISPOT assay. Wells are presented in duplicate with 3
mice per group from one pilot experiment. Yellow indicates high background and
spots could not be enumerated.
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Figure 104. Tumor Antigen-Specific IFN-g+ Cells in the Tumor Draining Lymph
Nodes of Mice Treated with the Combination of Intratumoral TIL 1383I TCR
Transduced Allogeneic T Cells and Poly I:C. B16 A2/Kb tumor-bearing mice were
intratumorally treated on day 10 post-tumor inoculation with TIL 1383I TCR
transduced allogeneic T cells and one day later received an intratumoral injection of
A) ) PBS or B) 40 µg poly I:C. Mice were sacrificed 11 days after poly I:C treatment.
Cells from the tumor draining lymph nodes were re-stimulated with irradiated B16
A2/Kb tumor cells for 5 days and then co-cultured with B16, B16 A2/Kb, EL4, and EL4
A2 tumor targets in an IFN-g ELISPOT assay. Wells are presented in duplicate with 3
mice per group from one pilot experiment. Yellow indicates high background and
spots could not be enumerated.
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Figure 105. Average Growth of Contralateral B16 Tumors in Mice with PreExisting B16 A2/Kb Tumors Treated with TIL 1383I TCR Transduced Allogeneic
T Cells. Primary B16 A2/Kb tumors, implanted on the right flank of mice, were treated
with TIL 1383I TCR transduced allogeneic T cells (red), untransduced allogeneic T
cells (green), or PBS (black) and seven days later were inoculated with 1.0 x105 B16
tumor cells on the left, contralateral flank. Mice were monitored for survival and
development of B16 tumors. NT/NT (Purple): no primary B16 A2/Kb tumor/No
Treatment. Mice were sacrificed when one tumor or the sum of both tumors reached
>150 mm2 or >10% body weight. Data represent one pilot experiment with 1-10
mice/group.
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Figure 106. Average Growth of B16 A2/Kb Tumors Following Intratumoral
Treatment with TIL 1383I TCR Transduced Allogeneic T Cells and B16 Tumor
Challenge Seven Days Later. Primary B16 A2/Kb tumors, implanted on the right
flank of mice, were treated with TIL 1383I TCR transduced allogeneic T cells (red),
untransduced allogeneic T cells (green), or PBS (black) and seven days later were
inoculated with 1.0 x105 B16 tumor cells on the left, contralateral flank. Mice were
monitored for survival and development of B16 tumors. Mice were sacrificed when
one tumor or the sum of both tumors reached >150 mm2 or >10% body weight. Data
represent one pilot experiment with 7-10 mice/group.
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Figure 107. Expression of HLA-A2 on B16 A2/Kb Tumor Cells 10 Days PostIntratumoral Treatment. B16 A2/Kb tumor-bearing mice were intratumorally treated
with untransduced allogeneic T cells, TIL 1383I TCR transduced syngeneic T cells, or
TIL 1383I TCR transduced allogeneic T cells. Ten days later, tumors were harvested
and cells were analyzed for expression of HLA-A2 by flow cytometry. One pilot
experiment A) MFI B) Frequency C) Representative histograms
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